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ABSTRACT 
Afghanistan has one of the highest infant mortalities in the world, and pneumonia is one of 
the main killers. Moreover, Dietary intake of vitamin D is low and exposure to sunlight is 
limited due to widespread use of Burqa by women. Two studies in Ethiopia and India 
suggest that vitamin D deficiency may substantially increase the risk of severe pneumonia 
among children under-5. Thus a randomized controlled trial was conducted to assess effects 
ofvitamin Don the incidence of pneumonia. 
The study was conducted on 3046 children aged 1-11 months (approximately 1500 per 
arm), in Kabul, Afghanistan. Intervention group was given quarterly 100.000 IU vitamin D 
(6 doses in total), and control arm received placebo (olive oil). Active and passive 
surveillance of pneumonia was done for 18 months. 
Time to the first episode in the Vitamin D group was compared to that in the placebo group 
using log rank tests and proportional hazards models. The incidence rate ratio for the 
episodes of pneumonia was calculated using Cox proportional hazard models. 
Vitamin D had no effect on the incidence of first or only episode of x-ray confirmed 
pneumonia (RR= 1.06, 95% CI: 0.89- 1.27; p=0.47). The incidence of repeat episodes of x-
ray confirmed pneumonia was higher in the vitamin D group (RR=1.68; 95% CI: 1.28 -
2.21; p <0.00 1 ). Infants 6-12 months old had a higher incidence of pneumonia compared to 
those <6 months old (RR=2.01; 95% CI: 1.12- 3.63). Children of fathers without any 
formal education had a higher incidence of repeat episodes of pneumonia compared to 
children of fathers having any formal education (RR=1.67, 95% CI: 1.20- 2.29). 
Vitamin D supplementation is not useful to reduce the incidence of pneumonia in children. 
The effective implementation of measles, OPT, Hib, and pneumococcal vaccines, and IMCI 
guidelines remain the key strategy to reduce the burden of pneumonia in Afghanistan. 
5 
ACKNOWLEDGEMENT 
I would like to extend my thanks to all families who kindly took part in this trial. Thanks to 
head of municipalities for keeping their support for this project's field works. I am grateful 
to Wakils, Mullahs and security in-charges for their endless assistance during field data 
collection. 
I am very thankful to my supervisor, Professor Daniel Chandramohan, Dr Semira Manaseki 
Holland, and Jane Bruce for their kind assistance and support in all aspects of this study. 
My special thanks to Jane Bruce for her endless support in data analysis. I am thankful to 
the entire study staffs, including field supervisors and clinical pediatricians, who patiently 
performed their daily responsibilities. 
I thank Pakistan Institute of Medical Sciences (PIMS), ARI Unit for assisting in 
interpretation of chest x-rays and thanks to the pharmacy of Aga Khan University (AKU) 
for their special support in providing this study with vitamin D and placebo syringes. 
Many thanks to Francesco Checchi for his technical advice on some parts of my PhD work, 
and I am very thankful to Asad Rehman from lTD computing, who provided IT support 
during my PhD work at LSHTM. My special thanks to Annemarie Ter Veen for all her 
support when I first came to London, and many thanks to Silke Lutzelschwab, who came to 
Kabul for teaching me Stata. 
I would like to thank USAID, Afghanistan and Washington States University for providing 
me with scholarship to come to London and complete my PhD. I also thank all sponsors of 
this trial, such as The Welcome Trust, British Council, UNICEF, Roshan, AKHS, and 
International Association ofNational Public Health Institution. 
Finally, I would love to thank my honorable family, specially my mother, my father, my 
wife, my lovely two years old son (Ahmad Mutahar Maroot), my brother, and my sisters, 
who took over all home responsibilities and made it possible for me to come to London and 
complete my PhD. 
6 
TABLE OF CONTENTS 
DECLARATION .................................................................................................................. 2 
SCOPE OF WORK OF THE CANDIDATE FOR THE PHD ........................................ 3 
WORKS THE CANDIDATE WAS NOT INVOLVED ................................................... 4 
REGISTRATION ................................................................................................................. 4 
PUBLICATION ................................................................................................................... 4 
ABSTRACT .......................................................................................................................... 5 
ACKN'OWLEDGEMENT ................................................................................................... 6 
TABLE OF CONTENTS ..................................................................................................... 7 
LIST OF FIGURES ........................................................................................................... 11 
LIST OF TABLES ............................................................................................................. 13 
LIST OF ANNEXES .......................................................................................................... 16 
ACRONYMS ...................................................................................................................... 17 
CHAPTER 1: INTRODUCTION ..................................................................................... 18 
1.1 BURDEN OF PNEUMONIA ............................................................................................. 18 
1.2 VITAMIN 0 DEFICIENCY - A RISK FACTOR FOR PNEUMONIA 19 
1.3 PREVALENCE OF VITAMIN DDEFICIENCY .................................................................... 19 
1.4 THE STUDY QUESTIONS ................................................................................................ 20 
1.4.1 Primary question ................................................................................................. 20 
1.4.2. Secondary questions ........................................................................................... 20 
1.5 OUTLINE OF THE REPORT ........................................................................................... 20 
CHAPTER 2: LITERATURE REVIEW ......................................................................... 22 
2.1 BURDEN OF PNEUMONIA IN CHILDREN ....................................................................... 22 
2.2 RISK FACTORS FOR PNEUMONIA IN CHILDREN ............................................................. 23 
2.3 PROTECTIVE FACTORS AGAINST PNEUMONIA ............................................................... 25 
2.4 SOURCES OF VITAMIN 0 AND ITS KEY ROLES ............................................................... 27 
2.5. EPIDEMIOLOGY OF VITAMIN 0 DEFICIENCY ............................................................... 29 
7 
2.6. IMMUNOLOGICAL ROLES OF VITAMIN D ..................................................................... 31 
2.7. VITAMIN D DEFICIENCY AND RISK OF TUBERCULOSIS ................................................ 32 
2.8. ASSOCIATION BETWEEN VITAMIN D DEFICIENCY AND PNEUMONIA ............................ 33 
2.9 POTENTIAL ADVERSE EFFECTS OF VITAMIN D SUPPLEMENTATION ............................... 35 
2.10 RATIONALE FOR THE STUDY ...................................................................................... 36 
CHAPTER 3: METHODS ................................................................................................ 37 
3.1 STUDY COUNTRY ........................................................................................................ 37 
3.2 STUDY AREA ................................................................................................................ 38 
3.3 STUDY DESIGN ............................................................................................................ 39 
3.4 STUDY POPULATION .................................................................................................... 39 
3.5 INCLUSION AND EXCLUSION CRITERIA ......................................................................... 39 
3. 5.1 Inclusion criteria ................................................................................................. 3 9 
3.5.2 Exclusion criteria ................................................................................................ 39 
3.5.3 Temporary exclusion criteria .............................................................................. 39 
3.6 PRIMARY END POINT ................................................................................................... 39 
3.7 SECONDARY END POINTS ............................................................................................ 40 
3.8 SAMPLE SIZE .............................................................................................................. 40 
BOX 1: DEFINITION OF OUTCOMES ......................................................................... 41 
3. 9 COMMUNITY SENSITIZATION ....................................................................................... 41 
3.10 ETHICS CONSIDERATION ........................................................................................... 42 
3.11 TRAINING OF STUDY STAFF ........................................................................................ 44 
3.11.1 Assessment of clinical parameters by field workers ......................................... 44 
3.11.2 Consenting and completing study forms ........................................................... 44 
3.11. 3 Clinical assessment of children at the study hospital ....................................... 45 
3.11. 4 Radiography ...................................................................................................... 45 
3.11.5 Collecting venous blood samples ...................................................................... 45 
3.11.6 Refresher Training ............................................................................................ 45 
3.12 SCREENING, CONSENTING AND RECRUITMENT .......................................................... 46 
3.13 RANDOMIZATION AND CONCEALMENT ...................................................................... 47 
3.14 ACTIVE SURVEILLANCE ............................................................................................. 48 
3.15 PASSIVE SURVEILLANCE ............................................................................................ 49 
8 
3.16 VITAMIN DIPLACEBO ADMINISTRATION ................................................................... 50 
3.17 VITAMIN D ADVERSE EFFECTS ................................................................................. 51 
3.18 READING OF CHEST X-RAYS ....................................................................................... 51 
3.19 BLOOD SAMPLING AND ASSESSMENT OF SERUM VITAMIN D LEVELS .......................... 52 
3.20 ASSESSMENT OF CONTEXTUAL AND POTENTIAL RISK FACTORS OF PNEUMONIA ......... 53 
3.21 DATA ENTRY AND DATA PROCESSING ...................................................................... 54 
3.22 STUDY TIMELINE ....................................................................................................... 54 
3.23 ANALYTICAL METHODS ........................................................................................... 55 
3.23.1 Baseline characteristics .................................................................................... 55 
3.23.2 Potential Risk Factors for Pneumonia .............................................................. 55 
3.23.3 Person Time At risk and End points .................................................................. 57 
3.23.4 Per Protocol Analysis ..................................................................................... 58 
CHAPTER 4: RESULTS ................................................................................................... 60 
4.1 TRIAL PROFILE ............................................................................................................ 60 
4.2 SOCIO-DEMOGRAPHIC CHARACTERISTICS OF STUDY CHILDREN ................................... 61 
4.3 BASELINE POTENTIAL RISK FACTORS ......................................................................... 61 
4.4 CHARACTERISTICS OF CHILDREN IN COMPARISON TO EPISODE OF PNEUMONIA ............ 62 
4.5 PRIMARY ENDPOINT .................................................................................................... 63 
4.6 SECONDARY ENDPOINTS ............................................................................................. 64 
4.6.1 Repeat Episodes of X-Ray Confirmed Pneumonia .............................................. 64 
4.6.2 First or only Episode of clinical Pneumonia ...................................................... 64 
4.6.3 Repeat Episodes of Clinical Pneumonia ............................................................. 65 
4. 6.4 All Episodes of X-ray confirmed Pneumonia .................................................... 65 
4. 6. 5 All Episodes of Clinical Pneumonia ................................................................. 65 
4.6.6 Time to repeat episodes of pneumonia after vitamin D/Placebo administration 
...................................................................................................................................... 66 
4.6. 7 All Cause and Pneumonia specific Mortality .................................................... 66 
4.6.8 Hospitalization for any diseases ....................................................................... 67 
4.7 PER PROTOCOL ANALYSIS BASED ON INITIAL PROTOCOL: ............................................ 67 
4. 7.1 First or only Episode of X-Ray confirmed Pneumonia ....................................... 68 
4. 7.2 Repeat Episodes of X-Ray Confirmed Pneumonia .............................................. 68 
4. 7.3 First or only Episode of clinical Pneumonia ...................................................... 68 
9 
4. 7.4 Repeat Episodes ofClinical Pneumonia ............................................................. 69 
4.8 PER PROTOCOL ANALYSIS WITH AT LEAST 4 CONSECUTIVE DOSES OF VITAMIN 
D/PLACEBO ....................................................................................................................... 69 
4.8.1 First or only Episode of X-Ray confirmed Pneumonia ....................................... 69 
4.8.2 Repeat Episodes of X-Ray Confirmed Pneumonia .............................................. 70 
4.8.3 First or only Episode of clinical Pneumonia ...................................................... 70 
4.8.4 Repeat Episodes of Clinical Pneumonia ............................................................. 71 
4.9 PER PROTOCOL ANALYSIS WITH AT LEAST 5 CONSECUTIVE DOSES OF VITAMIN 
D/PLACEBO ....................................................................................................................... 71 
4. 9.1 First or only Episode of X-Ray confirmed Pneumonia ....................................... 71 
4. 9.2 Repeat Episodes of X-Ray Confirmed Pneumonia .............................................. 72 
4.9.3 First or only Episode of clinical Pneumonia ...................................................... 72 
4.9.4 Repeat Episodes of Clinical Pneumonia ............................................................. 72 
4.10 EFFECT OF RISK FACTORS ON THE INCIDENCE OF PNEUMONIA ................................... 73 
4.11 EPISODES OF BRONCHIOLITIS .................................................................................... 74 
4.12 EFFECT OF VITAMIN D SUPPLEMENTATION ON SERUM VITAMIN D LEVEL .................. 74 
CHAPTER 5: DISCUSSION ............................................................................................ 76 
5.1 PRIMARY AND SECONDARY END POINTS ..................................................................... 76 
5.2 RISK FACTORS OF PNEUMONIA ..................................................................................... 82 
5.3 SERUM VITAMIN D LEVELS ........................................................................................ 85 
5.4 PERCEPTIONS OF HEALTH CARE PROVIDERS ................................................................ 86 
5.5 IMMUNOLOGICAL ROLE OF VITAMIN 0 ........................................................................ 86 
5.6 DOSE OF VITAMIN 0 SUPPLEMENTATION ..................................................................... 88 
5. 7 GENERALISABILITY OF THE FINDINGS .......................................................................... 89 
5.8 ALTERNATIVE INTERVENTIONS FOR CONTROL OF PNEUMONIA IN CHILDREN IN 
AFGHANISTAN ................................................................................................................... 90 
5.9 CONCLUSION ............................................................................................................... 92 
REFERENCES ................................................................................................................... 95 
FIGURES·························································································································· 105 
TABLES ............................................................................................................................ 117 
ANNEXES ......................................................................................................................... 157 
10 
LIST OF FIGURES 
FIGURE I: ESTIMATES OF INCIDENCE OF CLINICAL PNEUMONIA IN DIFFERENT REGIONS OF 
THE WORLD BY EPISODES PER CHILD-YEAR ........................................................................ 105 
FIGURE 2: GLOBAL CAUSES OF CHILD DEATHS, 2008 .................................................................. 105 
FIGURE 3: TRIAL PROFILE .................................................................................................................... 106 
FIGURE 4: STUDY DESIGN AND PROJECT TIMELINE FOR INTERVENTION AND DATA 
COLLECTION POINTS ................................................................................................................... 1 07 
FIGURE 5: TIMELINE FOR STUDY INTERVENTIONS, AND DATA COLLECTION POINTS ........ 108 
FIGURE 6: CHEST X-RAYS FROM STUDY CHILDREN DIAGNOSED WITH SIGNIFICANT 
PATHOLOGY FOR PNEUMONIA ................................................................................................. 109 
FIGURE 7: CHEST X-RAYS FROM STUDY CHILDREN, WHERE ONE OF THE TWO READERS 
DISAGREED TO DIAGNOSE THEM AS PNEUMONIA, AND WERE CONFIRMED AS 
PNEUMONIA AFTER 3RD READER'S OPINION ....................................................................... 110 
FIGURE 8: CHILDREN WITH X-RAY CONFIRMED PNEUMONIA EPISODES IN VITAMIN D AND 
PLACEBO GROUPS (N=3046) ........................................................................................................ 111 
FIGURE 9: INCIDENCE OF OF X-RAY CONFIRMED PNEUMONIA BY SEASON IN VITAMIN D 
AND PLACEBO GROUPS ............................................................................................................... 111 
FIGURE I 0: PROPORTION OF CHILDREN WITHOUT FIRST OR ONLY EPISODE OF X-RAY 
CONFIRMED SEVERE AND NON-SEVERE PNEUMONIA DURING 18 MONTHS ................ 112 
FIGURE 11: PROPORTION OF CHILDREN WITHOUT FIRST OR ONLY HOSPITAL ADMISSION 
DURING 18 MONTHS ..................................................................................................................... I12 
FIGURE 12: COMPARISON OF FIRST OR ONLY EPISODES OF SEVERE AND NON-SEVERE X-
RAY CONFIRMED PNEUMONIA IN VITAMIN D AND PLACEBO GROUPS ......................... 113 
FIGURE 13: COMPARISON OF REPEAT EPISODES OF SEVERE AND NON-SEVERE X-RAY 
CONFIRMED PNEUMONIA IN VITAMIN D AND PLACEBO GROUPS .................................. 113 
11 
FIGURE 14: COMPARISON OF FIRST OR ONLY EPISODES OF SEVERE AND NON-SEVERE 
CLINICAL PNEUMONIA IN VITAMIN D AND PLACEBO GROUPS ....................................... 114 
FIGURE 15: COMPARISON OF REPEAT EPISODES OF SEVERE AND NON-SEVERE CLINICAL 
PNEUMONIA IN VITAMIN D AND PLACEBO GROUPS ........................................................... 114 
FIGURE 16: INCIDENCE OF BRONCHIOLITIS BY SEASON IN VITAMIN D AND PLACEBO 
GROUPS ........................................................................................................................................... 115 
FIGURE 17: MEAN SERUM VITAMIN D LEVELS (NMOLIL) IN VITAMIN D AND PLACEBO OVER 
STUDY PERIOD (NOV 2007- JULY 2099) (N=636) .................................................................... 115 
FIGURE 18: LOCAL HEATING DEVICE (CHARI & BOKHARI) USED DURING WINTER IN KABUL 
CITY .................................................................................................................................................. 116 
12 
LIST OF TABLES 
TABLE 1: ESTIMATES OF INCIDENCE AND NUMBER OF NEW CASES PER YEAR OF CLINICAL 
PNEUMONIA IN CHILDREN AGED LESS THAN 5 YEARS, BY WHO REGIONS ................. 117 
TABLE 2: RISK FACTORS RELATED TO THE HOST AND THE ENVIRONMENT THAT AFFECTS 
INCIDENCE OF CHILDHOOD PNEUMONIA IN THE COMMUNITIES IN DEVELOPING 
COUNTRIES ..................................................................................................................................... 117 
TABLE 3: TRIALS EVALUATED THE ROLE OF VITAMIN DIN TREATMENT OR PREVENTION OF 
INFECTIONS .................................................................................................................................... 118 
TABLE 4: TOTAL POPULATION IN DISTRICTS 2, 3 AND 8 WITH THEIR CATEGORIES ............ 119 
TABLE 5: STUDY TIMELINE .................................................................................................................. 120 
TABLE 6: INDOOR AIR-POLLUTION SCORE MATRIX ..................................................................... 120 
TABLE 7: BASELINE SOCIO-DEMOGRAPHIC CHARACTERISTICS OF CHILDREN, MOTHERS, 
AND FATHERS ................................................................................................................................ 121 
TABLE 8: PNEUMONIA RISK FACTORS IN VITAMIN D AND PLACEBO GROUPS ..................... 123 
TABLE 9: BACKGROUND CHARACTERISTICS OF CHILDREN WITH NUMBER OF X-RAY 
CONFIRMED SEVERE AND NON SEVERE PNEUMONIA EPISODES .................................... 125 
TABLE 10: PREDICTORS OF SINGLE AND MULTIPLE EPISODES OF X-RAY CONFIRMED SEVERE 
AND NON SEVERE PNEUMONIA ................................................................................................ 128 
TABLE 11: COMPARISON OF FIRST/ONLY EPISODE OF SEVERE AND NON-SEVERE 
PNEUMONIA IN VITAMIN D AND PLACEBO GROUPS (INTENTION TO TREAT ANALYSIS) 
........................................................................................................................................................... 130 
TABLE 12: COMPARISON OF REPEAT EPISODES OF SEVERE AND NON-SEVERE PNEUMONIA IN 
VITAMIN D AND PLACEBO GROUPS (INTENTION TO TREAT ANALYSIS) ....................... 131 
TABLE 13: COMPARISON OF ALL EPISODES OF SEVERE AND NON-SEVERE PNEUMONIA IN 
VITAMIN D AND PLACEBO GROUPS (INTENTION TO TREAT ANALYSIS) ....................... 132 
13 
TABLE 14: TIME TO REPEAT EPISODES OF X-RAY CONFIRMED SEVERE AND NON-SEVERE 
PNEUMONIA AFTER LATEST VITAMIN DIPLACEBO DOSE ................................................. 132 
TABLE 15: COMPARISON OF FIRST/ONLY EPISODE OF SEVERE AND NON-SEVERE 
PNEUMONIA IN VITAMIN D AND PLACEBO GROUPS (INTENTION-TO-TREAT ANALYSIS 
15 DAYS GAP FOR NEW EPISODE) ............................................................................................. 133 
TABLE 16: COMPARISON OF REPEAT EPISODES OF SEVERE AND NON-SEVERE PNEUMONIA IN 
VITAMIN D AND PLACEBO GROUPS (INTENTION-TO-TREAT ANALYSIS 15 DAYS GAP FOR 
NEW EPISODE) ............................................................................................................................... 134 
TABLE 17: DISTRIBUTION AND CAUSES OF DEATHS ACCORDING TO WHO IDD-1 0 CODES 
BETWEEN VITAMIN D AND PLACEBO GROUPS ..................................................................... 135 
TABLE 18: COMPARISON OF HOSPITAL ADMISSIONS IN VITAMIN & PLACEBO GROUPS .... 137 
TABLE 19: COMMON CAUSES AND LENGTH OF HOSPITAL ADMISSIONS BETWEEN VITAMIN D 
AND PLACEBO GROUPS ............................................................................................................... 137 
TABLE 20: COMPARISON OF FIRST/ONLY EPISODE OF SEVERE AND NON-SEVERE 
PNEUMONIA IN VITAMIN D AND PLACEBO GROUPS (PER-PROTOCOL ANALYSIS) ..... 138 
TABLE 21: COMPARISON OF REPEAT EPISODES OF SEVERE AND NON-SEVERE PNEUMONIA IN 
VITAMIN D AND PLACEBO GROUPS (PER-PROTOCOL ANALYSIS) ................................... 139 
TABLE 22: COMPARISON OF FIRST/ONLY EPISODE OF SEVERE AND NON-SEVERE 
PNEUMONIA IN VITAMIN D AND PLACEBO GROUPS (PER-PROTOCOL ANALYSIS WITH 
AT LEAST 4 CONSECUTIVE DOSES OF VITAMIN DIPLACEBO ............................................ 140 
TABLE 23: COMPARISON OF REPEAT EPISODES OF SEVERE AND NON-SEVERE PNEUMONIA IN 
VITAMIN D AND PLACEBO GROUPS (PER-PROTOCOL ANALYSIS WITH AT LEAST 4 
CONSECUTIVE DOSES OF VITAMIN 0/PLACEBO ................................................................... 141 
TABLE 24: COMPARISON OF FIRST/ONLY EPISODE OF SEVERE AND NON-SEVERE 
PNEUMONIA IN VITAMIN D AND PLACEBO GROUPS (PER-PROTOCOL ANALYSIS WITH 
AT LEAST 5 CONSECUTIVE DOSES OF VITAMIN DIPLACEBO ............................................ 142 
TABLE 25: COMPARISON OF REPEAT EPISODES OF SEVERE AND NON-SEVERE PNEUMONIA IN 
VITAMIN D AND PLACEBO GROUPS (PER-PROTOCOL ANALYSIS WITH AT LEAST 5 
CONSECUTIVE DOSES OF VITAMIN DIPLACEB0 ................................................................... 143 
14 
TABLE 26: EFFECT OF DIFFERENT RISK FACTORS ON THE INCIDENCE RATE OF FIRST OR 
ONLY EPISODE OF X-RAY CONFIRMED SEVERE AND NON-SEVERE PNEUMONIA .... 144 
TABLE 27: EFFECT OF DIFFERENT RISK FACTORS ON THE INCIDENCE RATE OF REPEAT 
EPISODE OF X-RAY CONFIRMED SEVERE AND NON-SEVERE PNEUMONIA .................. 146 
TABLE 28: EFFECT OF DIFFERENT RISK FACTORS ON THE INCIDENCE RATE OF FIRST OR 
ONLY EPISODE OF X-RAY CONFIRMED SEVERE PNEUMONIA ........................................ 148 
TABLE 29: EFFECT OF DIFFERENT RISK FACTORS ON THE INCIDENCE RATE OF FIRST OR 
ONLY EPISODE OF X-RAY CONFIRMED SIMPLE PNEUMONIA ........................................... l50 
TABLE 30: EFFECT OF DIFFERENT RISK FACTORS ON THE INCIDENCE RATE OF FIRST OR 
ONLY EPISODE OF X-RAY CONFIRMED VERY SEVERE DISEASES ................................... 152 
TABLE 31: LEVEL OF AGREEMENT BETWEEN TWO READERS FOR CHEST X-RAYS ............. 154 
TABLE 32: COMPARISON OF ALL BRONCHIOLITIS EPISODES IN VITAMIN D AND PLACEBO 
GROUPS (INTENTION TO TREAT ANALYSIS) .......................................................................... 154 
TABLE 33: VITAMIN D LEVEL IN BLOOD SAMPLES OF INTERVENTION AND NON-
INTERVENTION GROUPS AFTER EACH 3-MONTLY DOSE ADMINISTRATION ................ I 55 
TABLE 34: VITAMIN D SERUM LEVELS MEASURED AT DIFFERENT STAGES IN SAMPLES OF 
STUDY CHILDREN ......................................................................................................................... 156 
15 
LIST OF ANNEXES 
ANNEX 1: ERB APPLICATION FOR ETHICS COMMITTEE OF MOPH, AFGHANISTAN .............. 157 
ANNEX 2: STUDY APPROVAL LETTER BY ETHIC COMMITTEE, MOPH, AFGHANISTAN ...... 174 
ANNEX 3: STUDY APPROVAL LETTER BY ETHICS COMMITTEE, LSHTM ................................. 175 
ANNEX 4: CONSENT FORM ................................................................................................................... 176 
ANNEX 5: RECRUITMENT QUESTIONNAIRES (FORM A AND F) ................................................... 180 
ANNEX 6: CHILD'S ID CARD ................................................................................................................. 186 
ANNEX 7: PICTORIAL SIGNS AND SYMPTOMS CARD .................................................................... I90 
ANNEX 8: STANDARD OPERATING PROCEDURE (SOP) FOR VITAMIN D ADMINISTRATIONI91 
ANNEX 9: VITAMIN D ADMINISTRATION FORM ............................................................................. I93 
ANNEX 10: TWO-WEEKLY HOME VISIT FORM ................................................................................ 194 
ANNEX 11: ABSENT FORM .................................................................................................................... 197 
ANNEX 12: OUTPATIENT (OPD) FORM ............................................................................................... 198 
ANNEX 13: STUDY PROTOCOL (1) ....................................................................................................... 203 
ANNEX 14: INPATIENT (IPD) FORM ..................................................................................................... 206 
ANNEX 15: X-RAY FORM ....................................................................................................................... 212 
ANNEX 16: BREASTFEEDING AND LIVING STATUS FORM ........................................................... 213 
ANNEX 17: SUN-EXPOSURE AND INDOOR AIR POLLUTION FORM ............................................ 216 



























Aga Khan Health Service, Afghanistan 
Aga Khan University Hospital 
Acute Lower Respiratory Tract Infection 
Acute Respiratory Tract Infection 
Consolidated Standards of Reporting Trials 
Chronic Obstructive Pulmonary Disease 
Central Statistics Office, Afghanistan 
Health Management Information System 
Integrated Management of Childhood Illness 
Inpatient Department 
Kabul Medical University 
London School ofHygiene and Tropical Medicine 
Multi Indicator Cluster Survey 
Ministry of Higher Education 
Ministry of Public Health 
Outpatient Department 
Doctor of Philosophy 
Pakistan Institute of Medical Sciences 
Randomized Controlled Trial 
Respiratory Syncytial Virus 
Toll-like Receptors 
United Arab Emirates 
United Nations Children's Fund 
World Health Organization 
17 
CHAPTER 1: INTRODUCTION 
1.1 Burden of Pneumonia 
Each year 10.5 million children <5 years of age die worldwide, of which 98% occurs in 
developing countries (2). Afghanistan has the 3 rd highest under-5 mortality in the world 
(257 /1000 Live births) after Sierra Leone and Angola (3).The infant mortality rate was 
165/1000 live births in 2005 (3). However a recently published report by Ministry of 
Public Health (MoPH), Afghanistan showed a marked reduction in under-5 and infant 
mortalities in 2006 (19111000 live births and 129/1000 live births respectively) (4). The 
under-5 mortality rate in district 1 of Kabul city was estimated 0.02 (95% CI: 0.01 - 0.02) 
per child year in 2008 (5). One of the global Millennium Development Goals is to reduce 
child mortality by two-third by 2015 compared to 1990 (6). Afghanistan aims a 50% 
reduction in under-5 mortality by 2015 and a 66% reduction in infant mortality by 2020 
compared to the levels observed in 2003. (7). 
The number of deaths attributable to childhood pneumonia globally was estimated 1.9 
millions in the year 2000 (8). Around 19% of under-5 mortality globally is attributable to 
pneumonia (9). The incidence of pneumonia in children under-5 years of age has been 
estimated 0.29 episodes per child-year in developing countries and 0.05 episodes per child-
year in developed countries (8). The global annual new episodes of pneumonia is estimated 
156 million of which 151 millions episodes occur in developing world (8). Another 
estimate suggests that the mean annual number of new cases of pneumonia is 146.5 
millions in developing countries (1 0). South-east Asia has the highest incidence of 
pneumonia in children under-5 (0.36 episodes per child-year) followed by Africa (0.33 
episodes per child-year) (8). A multi-indicator cluster survey (MICS) conducted by 
UNICEF in 2003 in Afghanistan showed that the prevalence of pneumonia in a two week 
period in children under-5 was 19% (11). 
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1.2 Vitamin D deficiency - a risk factor for pneumonia 
Vitamin D is an essential micronutrient. Its role in regulating bone mineralization is well 
understood (12). Vitamin D is essential for skeletal development and cellular functions due 
to its effects on Calcium homeostasis and promoting absorption of calcium from intestine 
(13). Vitamin Dis mainly produced in the skin after exposure to ultraviolet Brays (13). If 
sun exposure is limited due to different reasons, it can be maintained through the intake of 
foods and supplements rich in Vitamin D (13). 
Recently the function of vitamin D as a key link between Toll-Like receptors activation 
and antimicrobial responses in innate immunity has been shown (12). Two hospital-based 
case-control studies from Ethiopia (14) and India (15) suggest that vitamin D deficiency 
may substantially increase the risk of severe pneumonia among children. 
1.3 Prevalence of vitamin D deficiency 
Vitamin D deficiency is defined as 25-hydroxyvitamin D level :::; 20 ng/mL (16). It has 
been estimated that overall 1 billion people have vitamin D deficiency (16). Nutritional 
rickets is the main manifestation of Vitamin D deficiency (17), and rickets remains a 
common disease around the world (18). The prevalence of Vitamin D deficiency rickets, a 
common problem in many developing countries, ranges from 5 to 45% in children under-
5, even where there is abundant sunlight: Turkey (19), Iran (20), Saudi Arabia (21 ), India 
(15), (22), China (23), (24), Mongolia (25), Algeria (26), and Nigeria (27), (28). The 
disease remains an endemic problem in many developing countries and has re-emerged in 
some developed countries (29). The main risk factors for rickets during infancy include 
exclusive breastfeeding without vitamin supplementations, dark skin pigmentation, 
decreased sunlight exposure, winter season, increased latitude, and maternal vitamin D 
deficiency ( 18), (3 0), (3 1 ). 
In Afghanistan, dietary intake of vitamin D is low and exposure of pregnant women to 
sunlight is also limited due to the widespread use of Burqa. A small proportion of 
population with better socio-economic status can afford quality food rich in vitamins and 
micronutrients. Therefore, foods rich in vitamin D, such as fish and liver, are not 
19 
affordable. Moreover, because Afghanistan is a land-locked country with little water 
resources, fish products are not commonly found in the market. Fortified formulas with 
vitamin D are not produced in the county, and fortified milk imported from other countries 
is very expensive. Other dietary sources of vitamin D, such as eggs, are commonly found 
and consumed by majority of the families. Swaddling of infants that reduces exposure to 
sunlight is also a common practice (32). Thus young children are at a high risk of vitamin D 
deficiency. 
1.4 The study questions 
1.4.1 Primary question 
Will 3-monthly vitamin D supplementation reduce the incidence of radiological confirmed 
pneumonia among <24 month old children living in a socio-economically deprived 
community of Kabul? 
1.4.2. Secondary questions 
• Will 3-monthly vitamin D supplementation reduce the incidence of clinical 
moderate or severe ALRI (IMCI criteria) among <24 month old children living in a 
socio-economically deprived community of Kabul, Afghanistan? 
• Will vitamin D supplementation reduce the incidence of hospital admissions for any 
severe illness? 
• Will Vitamin D supplementation reduce all cause mortality and pneumonia specific 
mortality in children? 
• What are the risk factors for pneumonia in children living m deprived areas of 
Kabul? 
1.5 Outline of the report 
In chapter 2 an extensive literature revtew of epidemiology of pneumonia in children 
globally and in developing countries specifically, global prevalence of vitamin D deficiency 
and rickets, the association between Vitamin D deficiency and respiratory diseases, and 
immunological functions of Vitamin D are presented. The methods of the randomized 
controlled trial that investigated the protective efficacy of vitamin D against pneumonia, 
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and the analysis plan are described in chapter 3. The study findings are described in chapter 
4. The interpretations and implications of the findings are discussed in chapter 5 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Burden of pneumonia in children 
WHO estimates that the annual episodes of clinical pneumonia are 156 million, of which 
only 4 million occur in developed countries (8) while 115 million (74%) occurs in 15 
developing countries (Table 1; Figure 1) (8). WHO also estimates that up to 20 million new 
cases of pneumonia are severe and require hospitalization (33). Each year, about 10.5 
million children die in the world (6) and 19% of these deaths are attributable to pneumonia 
(6). In 2008, the annual global under-5 deaths was estimated 8.8 million, of which, 18% 
was attributable to pneumonia (Figure 2) (34). Afghanistan has a high under-5 mortality 
rate and high mortality from pneumonia. UNICEF best Estimates 1 suggest that 23% of 
under-5 mortality in Afghanistan in 2005 was attributable to pneumonia. 
There is very limited data on the burden of pneumonia in Afghanistan. However there is 
extensive literature on the epidemiology of pneumonia in the neighbouring country 
Pakistan. Pneumonia has been the second leading cause of under-5 mortality in Pakistan 
(35). One in 4 deaths in children under-5 years of age in Pakistan is due of pneumonia 
(36). In north western of Pakistan that lies 1525m above sea level, the annual pneumonia 
specific mortality has been estimated 14 deaths per 1000 under-5 children (3 5). A 
community based surveillance of mortality using verbal autopsy in an area in Karachi 
found that 33% of deaths in infants and 3 7% of deaths in children 1-4 years were due to 
pneumonia(35). 
A household surveillance in a low-income area of Karachi from 2007 to 2008 found that 
the incidence of pneumonia was 0.26 (95% CI: 0.25 - 0.28) episodes per child year (36) .. 
1 The best estimates report was prepared by the ministry of Economy/Central Statistics Office of Afghanistan, 
and UNICEF Afghanistan Country Office during 2005. The indicator in this report has come from a 
comprehensive search of all available information in Afghanistan related to women and children. The data has 
been analyzed and indicators generated are from adjusted survey results and use of models and indirect 
deductive estimates. The report has been delivered from reanalysis of the Multiple Indicator Cluster Survey 
(MICS) 2003 by UNICEF and the Government of Afghanistan in addition to information from MICS surveys 
in 1997 and 2000. The main problems in 2003 survey were problems in sampling frame, unknown total 
population, less Access to rural remote areas due to security problems, and problems in accuracy of responses 
due to high illiteracy. In the surveys ARI was measured by asking if any of the children had ARI problems in 
the two weeks period before the survey day. 
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A cohort study of 1476 infants in Lahore in 1984 found the incidence of pneumonia to be 
22 per 100 child years (3 5). In 1990, the incidence of pneumonia in children under-5 was 
found 30 per 100 child years near Gilgit in northern Pakistan (35). A cohort study of 5204 
children aged 2-35months living at high altitudes in Himalayan parts of Pakistan found that 
the annual incidence of non-severe pneumonia was 29.9 per 100 child years and the annual 
incidence of severe pneumonia was 8.1 per 100 child year (35). 
2.2 Risk factors for pneumonia in children 
Various risk factors for pneumonia have been indentified, related to the host, the 
environment and infections (Table 2) in developing countries (8). Children aged 4 months 
have higher risk of pneumonia compared to older children. In a cohort study conducted in 
Northern Pakistan the incidence rate ratio adjusted for altitude, number of children less than 
36 month of age at home, and child's sex was 4.33 (95% Cl: 3.53- 5.32) in 2-5 month old 
infants compared to children aged 24-35 months(35). 
Around 3 billion people use solid fuel as a principle household fuel which is linked to 
poverty (37). Exposure to extreme level of indoor pollution mainly from burning of 
biomass fuels for cooking and heating is common in developing countries (6). Use of 
wood, crop residues and animal dung for heating and cooking (38), which are sources of 
smoke in the homes that expose children to the high risk of acute respiratory infections, is 
common in developing countries (38). In 1995, Kirkwood et all found that indoor air 
pollution from household use of solid fuels such as wood, animal dung, crop wastes and 
coal is a risk factor for pneumonia in children (3 7). A critical review of the studies of 
association between indoor air pollution from use of biomass fuels and acute respiratory 
infections showed a significant increase in the risk of acute respiratory infections for 
children exposed to household biomass smoke compared to those using cleaner fuels. Nine 
case control studies (n=4311) conducted in South Africa, Zimbabwe, Nigeria, Tanzania, 
Gambia Brazil, India and Argentina showed that the odds of exposure to biomass smoke 
was higher in children with pneumonia than healthy controls (odds ratio ranged from 2.2 to 
9.9). Four cohort studies conducted in Nepal, Kenya, and Gambia (n=910) also showed a 
high risk of pneumonia in children exposed to biomass smoke (odds ration ranged from 2.2 
to 6.0). A cohort study in Nepal showed a close relationship between hours/day children 
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under-2 spent near the stove, and episodes of life threatening acute respiratory infections. 
Two cohort studies involving 780 and 455 children aged 0-23 months respectively, found 
that children spending more than 1 hours per day near the fireplace had higher risk of 
developing ARI grades 1 to 4 compared to those spending less time (OR=2.2, 95% CI: 1.6 
-3.0) (38). 
Lack of exclusive breastfeeding during the first 6 months of age is also a risk factor for 
developing Acute Lower Respiratory Infections (ALRI) and mortality from ALRI (39), 
( 40), ( 41 ). A meta-analysis of studies focusing on cause-specific morbidity due to 
patterns of breastfeeding in children under 6 months old, found that the incidence of 
pneumonia was 1. 79 (95% CI: 1.29- 2.48) in exclusive breastfed children, 2.48 (95% CI: 
0.23 - 27.15) in partially breastfed and 2.07 (95% CI: 0.19 - 22.64) in not breastfed 
children (40). A review of 6 studies conducted in China, Argentina, Brazil and America 
focusing on relationship between pneumonia and nutritional factors, found that lack of 
breastfeeding was a risk factor for pneumonia ( 41 ). 
A large cohort study of 5204 children 2-36 months old in Himalayan parts of Pakistan 
found that male gender, high altitude and younger ages were the main risk factors for 
pneumonia(35). The incidence rate ratio (IRR) of pneumonia for Children living in 
altitudes of 1980 - 2285 m was higher compared to those living in altitudes of 1675 - 1980 
m (IRR= 1.66 and 95% CI: 1.45 - 1.90). Male children had higher incidence of pneumonia 
compared to that of females (IRR= 1.14 and 95% CI: 1.01 - 1.29). Children 2-5 months 
had highest IRR of pneumonia (IRR= 4.33 and 95%CI: 3.53 - 5.32) compared to 24- 35 
month old children. (35). 
A case-control study of 1300 children under-2 years old from July 1989 to June 1990 in 
Fortaleza city of Brazil found that malnutrition was the most important risk factor for 
childhood pneumonia. The odds of weight-for-height Z-score<-3 was 6.75 higher (95% CI: 
1.88- 24.27), and the odds of weight-for-age Z-score<-3 was 4.57 higher (95%CI: 2.93-
7 .13) in pneumonia cases compared to healthy controls ( 42). Moreover, no breastfeeding 
(OR=1.69; 95% CI: 1.02- 2.80) and crowding (total household size of2:8 persons and the 
number of children at home if 2:7 children) were also significant risk factors for the 
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incidence of pneumonia. In this study, there was no association between the risk of 
pne':lmonia and the number of persons sleeping in the same room as the index child ( 42). 
High altitude is known to be a risk factor for pneumonia and other lung disease ( 43). At 
high altitudes where the oxygen supply is lower, the ability of lungs for getting oxygen to 
the blood is impaired ( 43). A retrospective cohort study examining the effect of residential 
altitude on hospitalization for respiratory syncytial virus infection in Colorado from 1998 
through 2002 revealed that children 1-4 years old who resided at high altitude (>2500 m) 
had a 62% increase in rate of hospitalization compared to those living at low altitude 
(<1500m) (RR=l.62, P= 0.004). The study concluded that high altitude above 2500 m is 
a modest predictor ofRSV- associated hospitalization (43). 
Afghanistan is a poor country with cold winters. Using solid fuel such as wood, crop 
residue and animal dung is common as in other developing countries for heating and 
cooking. Additionally, tobacco smoking indoor in the presence of children, low maternal 
education, and malnutrition of children are also common. Though no formal studies have 
been conducted yet to explore the role of these factors on pneumonia and other infectious 
diseases in children, it is plausible that these factors would impact the incidence of 
pneumonia in children in Afghanistan. 
2.3 Protective factors against pneumonia 
Zinc supplementation has been shown to have some protective effect against pneumonia in 
some settings. A meta-analysis of 4 randomized controlled trials conducted in South Asia 
showed that administration of oral zinc supplementation daily or weekly significantly 
reduced the incidence of ALRI in children (RR= 0.80, 95% CI: 0.70- 0.92) (39). The first 
study was conducted in 2482 children aged 6 to 30 months in a slum community in New 
Delhi. Infants were given 1 Omg and older children were given 20 mg elemental zinc per 
day for 4 months. Children in both groups got a single high dose of vitamin A (1 00,000 IU 
for infant and 200,000 for children). The incidence of pneumonia was lower in zinc 
supplemented group compared to that in placebo group (OR=0.74, 95% CI: 0.56- 0.99) 
(44). The second study was done in children aged 1-6 months in urban slums in Dhaka, 
Bangladesh. The intervention group (n=152) was given 5mg elemental zinc daily till 24 
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weeks of age and the placebo group (n=149) was given a liquid containing sucrose, flavors 
and preservatives. In this study there was no difference in the risk of respiratory diseases in 
infants with normal baseline zinc concentration. However, among infants with zinc 
deficiency at baseline, fewer ALRI case were observed in intervention group compared to 
that in the placebo group (RR=0.30, 95% CI: 0.10- 0.92) (45). 
The third study was also conducted in Bangladesh in 1665 children 2 to 12 months of age. 
Intervention group was given 70mg zinc weekly for 12 months and the placebo group was 
give a non-nutritious and vitamin free liquid .The relative risk of pneumonia was 0.83 (95% 
CI: 0.73- 0.95) in the zinc group compared to that in the placebo group (46). The last study 
was done in an urban setting in India in 609 children 6-35 months old. The intervention 
group was given a daily liquid containing 1 Omg elemental zinc plus some other elements 
such as vitamins A, Bl, 82, 86, 03, E, and niacinamide for 6 months. Placebo group was 
given same liquid without zinc. The incidence of ALRI was lower in the zinc supplemented 
group compared to that in the placebo group (OR= 0.55, 95% CI: 0.33- 0.90, p=0.02) (47). 
The protective effect of Vitamin A against pneumonia has been explored in several studies. 
In Ecuador, from July 1996 to April 1997, a randomized controlled trial was carried out 
about effects of low dose vitamin A supplementation on the incidence of ALRI and 
diarrhea in 400 children aged 6-36 months old. The intervention group received a weekly 
100 000 IU vitamin A and the placebo group received weekly syrup with anise flavouring. 
After 40 weeks, there was no significant difference in the incidence of ALRI between 
vitamin A supplemented and placebo groups (RR=1.21, 95% CI: 0.81 - 1.82, p=0.35). 
However, among children underweight at baseline (weight-for-age z-score< - 2 SD), 
vitamin A supplementation significantly decreased the incidence of ALRI (RR=0.38, 95% 
CI: 0.17- 0.85, p=O.Ol). The incidence of ALRI in children with normal weight-for-age z-
score at baseline was higher in vitamin A supplemented group compared to that in placebo 
group (RR=2.21, 95% CI: 1.24- 3.93, p=0.005) (48). 
The effect of large dose vitamin A on the severity of respiratory diseases was studied in 687 
children aged 6 to 60 months old in Tanzania between April 1993 and March 1997. 
Children admitted to the hospital with non-measles pneumonia were randomly assigned to 
vitamin A and placebo groups and followed during hospital stay. The intervention group 
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received one dose of 200 000 vitamin A (half the dose for infants) on the admission day 
and the second dose on the following day. The placebo group received corn oil. There was 
no significant difference between vitamin A and Placebo groups in clinical course of 
pneumonia. Vitamin A supplementation had no significant effect on duration of hospital 
stay (RR=0.96, 95% CI: 0.82 - 1.12, p=0.58) and number of deaths (RR=l.63, 95% CI: 
0.67 -3.97, p=0.28) between the two groups (49). 
In India 1520 children less than 10 years old were randomly assigned to vitamin A and 
placebo to explore effect of vitamin A on mortality and morbidities such as pneumonia, 
diarrhea and measles. Half the children was given vitamin A (200 000 IU for children over 
1 year old, 100 000 IU for 6-12 month-olds, and 50 000 IU for Jess than 6 month olds) and 
half was given placebo (arachis oil) every 4 to 6 months for 15 months. The study showed 
that vitamin A supplementation did not have a statistically significant effect on reducing 
incidence of pneumonia (RR=0.69, 95% CI: 0.43- 1.11, p=O.l3). However, children in 
intervention groups had a significant lower incidence of measles (RR=0.46, 95% CI: 0.29-
0.74, p<O.OOI) and diarrhea (RR=0.62, 95% CI: 0.58- 0.66, p<O.OOl) (50). 
2.4 Sources of vitamin D and its key roles 
Vitamin D, also called a pro-hormone or sunlight hormone, is a fat soluble vitamin. Its 
major biological function is in the formation and maintenance of bones (51), (52).There are 
two sources of Vitamin D for humans: foods and supplements, and the endogenous 
synthesis (18). Vitamin D is available mainly in oily fish and to a lesser extent in eggs and 
liver; breast milk is a poor source (53). Other dietary sources of vitamin D include foods 
fortified with vitamin D2 (ergocalciferol produced by the ultraviolet irradiation of 
ergosterol from yeast) or D3 (cholecalciferol produced by ultraviolet irradiation of 7-
dehydrocholesterol from lanolin) (30) such as fortified dairy products, infant formula, and 
breakfast cereals (18) (30). Only Less than 10% of vitamin D is derived from dietary 
sources. The rest of vitamin Dis derived by endogenous mechanism (54). 
Endogenous synthesis of vitamin D takes place in several steps. The first important step is 
absorption of Ultraviolet B radiations (wave lengths 290-310 nm) by 7 -dehydrocholestterol 
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in the skin to form pro-vitamin D3. The pro-vitamin D3 rapidly transforms to vitamin D3 
(30). Ultraviolet rays trigger synthesis in the skin, which is reduced in darker skins (53), 
(55), (56). Vitamin D3 is stored in the body fat to be released when there is limited natural 
production of Vitamin D3 due to the sun irradiation such as winter season (30). Once 
produced whether vitamin 03 or vitamin 02 will pass the liver for hydroxylation to 
produce 25-hydroxyvitamin D. This will be hydroxylated further in the first position in 
kidneys to produce 1, 25 dihydorxyvitamin D, the biological active metabolite of vitamin 
D. In practice circulatory level of intermediate metabolite of vitamin D (25 hydorxyvitamin 
D) is used as best indicator of vitamin D sufficiency (57) (58) (30) (59). The half life of 
25(0H)D is 2-3 weeks compared to very short half life of its active metabolite, 1 ,25(0H)2-
D, which is only 4 hours (54). 
Penetration of the ultraviolet radiations into the skin can be reduced by factors such as dark 
skin pigmentations, sunscreen, winter season, high latitude (northern latitude), air pollution, 
confinement indoors, skin covered by clothes, and skin diseases such as ichthyosis (18) 
(30). The required UV light reduces with distance from the equator to zero at latitudes 
above 50° in winter (60). 
Intestinal absorption of vitamin D is reduced by mal-absorption diseases such as cystic 
fibrosis and hepatic disorders (30). Taking into account the variation in skin pigmentation 
between individuals, as well as, the level of sunlight exposure in various latitudes, twice 
weekly exposure of arms and legs to 5-30 minutes mid-day sunlight in older children, and 
twice weekly exposure of head and shoulder in infants are probably enough for stimulating 
adequate production ofvitamin D3 (30). 
Vitamin D plays important role in maintaining calcium homeostasis (59). Vitamin 03 
enhances the intestinal absorption of calcium and phosphorus. The absorption takes place 
through binding of 1, 25-Dihydroxyvitamin D to vitamin D receptors in small intestine to 
stimulate trans-cellular absorption of calcium and phosphorus (59) (30). It has also been 
known that calcium deprivation increases the need of a child to vitamin D, and makes 
children susceptible to mild vitamin D deficiency (30). Studies have shown that low 
calcium intake enhances the catabolism of 25(0H) vitamin D through the activation of 24-
hydorxylase as a result of elevated 1.25-Dihydroxy vitamin D concentration (61 ).Vitamin 
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D is also necessary for mineralization and development of skeleton (59). Genetic factors 
can affect production of vitamin D in the body. Its main role has been described as 
polymorphism of enzyme 7-dehydrocholestrol reductase in the skin, cytochrome p450 25-
hyroxylase in the liver, and vitamin D binding protein in the circulation. These factors can 
affect functionality of vitamin D either by interrupting with uptake of 25(0H)D by target 
cells, or by affecting efficiency of la-hyroxylation to produce the active metabolite of 
vitamin 0{ 1 ,25(0H)2D} (62). 
2.5. Epidemiology of Vitamin D Deficiency 
The Institute of Medicine (I OM) and American Academy of Pediatrics (AAP) has defined 
vitamin D deficiency in infants and children as a serum level of 25(0H)vitamin D below 
11 ng/mL(27 .5 nmol/L) (18) and Vitamin D insufficiency as 25(0H)D <30 ng/mL(75 
nmol/L) (18). 
A recent review of literatures classifies the vitamin D deficiency status in children based on 
level of serum 25(0H)D in ng/mL2 as follow (54): 
a. Severe deficiency: 25(0H)D :::;5ng/mL 
b. Deficiency: 25(0H)D 6- ::Sl4ng/mL 
c. Insufficiency: 25(0H)D 15-20ng/mL 
d. Sufficiency: 25(0H)D 21-1 OOng/mL (50-250nmol/L) 
e. Excess: > 1 OOng/mL 
f. Intoxication:> 150ng/mL (>250nmol/L) 
More than one billion people in the world have insufficient circulatory level of vitamin D 
(30). Dietary insufficiency of calcium is common in developing countries (30). 
Approximately half of the children in the North America are vitamin D insufficient and 
children in the European countries also seem at risk despite ongoing supplementary efforts 
(30). Neonatal vitamin D deficiency due to insufficient level of vitamin D in pregnant 
women is very common (30). Breast milk has lower level of vitamin D as compared to 
2 To convert ng/mL to nmol/L, multiply by 2.496 62. Thacher TD, Clarke BL. Vitamin D insufficiency. 
Mayo Clin Proc. Jan;86( 1 ):50-60. 
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cow's milk. Therefore, prolonged breastfeeding in some settings has been associated with 
vitamin D insufficiency in infants (30). In a newborn baby, concentration of 25(0H) 
vitamin D is approximately 2/3 of the maternal values (57). The half life of 25(0H) D is 
around 3 weeks. Therefore, newborns will need exogenous supply of vitamin D after few 
weeks of the life (57). It has been proposed that high dose vitamin D supplementation for 
lactating mothers may increase the level of vitamin D in breast milk sufficient to prevent 
rickets in breast feeding infants (30). 
The prevalence of vitamin D deficiency is high in developing countries. In Tehran in a 
small pilot study during March 1966 in Shahrazad Children's Hospital admitting children 
from lowest income groups, it was found that 15% of children under 5 years of age (n=82) 
had evidence of rickets in wrist x-rays (20). In the UAE, Pakistan, and China the prevalence 
of vitamin D deficiency( serum 250HD<1 Ong/ml) in exclusive breastfeeding infants has 
been reported 82% (n=78), 55% (n=62), and 20% (n=42) respectively (31). 
In a case control study of risk factors for pneumonia in a rural community of Bangladesh 
during the winter season, the mean 25(0H) D level was 36.7nmoi/L (95% CI: 30.2- 43.2) 
among 29 healthy controls aged 1-6 month. Among these children 28% (95% CI: 10- 45) 
had 25(0H)D <25nmol/L, and 50% (95% Cl: 40- 78) had 25(0H)D < 40nmol/L (63). 
A study during the winter of 2005 in Afghanistan showed very high levels of vitamin D 
deficiency in a poor district in Kabul. The median concentration of 25- hydroxyl vitamin D 
was 5ng/ml (range 2-25ng/ml) among 108 children aged 6-48 months. Of total, 104 
(96.2%) had concentrations below 15ng/ml, the minimum level considered to be sufficient, 
and 79 (73%) had concentrations below 8ng/ml, a level considered to be significantly 
deficient (32). 
Vitamin D deficiency rickets is associated with 25(0H) vitamin D below 5ng/ml (12.5 
nmol/L) (58). It results from impaired bone mineralization in children particularly due to 
inadequate calcium and phosphorus in the growth palate. (58) Inadequate calcium can 
cause nutritional rickets in spite of adequate vitamin D status (58). Infants are generally 
protected from vitamin D deficiency rickets during the first few months of life because 
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vitamin D metabolites crosses the placenta (57). The peak age for rickets is 3-18 months 
(57). 
The burden of nutritional rickets is greatest in developing countries where it is either 
underreported or ignored. Cultural practices limit sun exposure in pregnant women and 
children in spite of abundant sunlight and rickets is common in the middle east particularly 
in Saudi Arabia (58). In Muslim countries due to cultural beliefs, women wear concealing 
clothing which minimizes sunlight exposure to them and their children (64). A study done 
in an urban hospital in Saudi Arabia, revealed that 59% of women (n= 1 00) delivering and 
70% oftheir newborns had vitamin D deficiency below 25 nmol/L (58). 
A study of infants 9-24 months old in India with similar socio-economic conditions and no 
vitamin D supplementation showed that children (n=26) living in the areas with intensive 
air pollution had lower serum 25-(0H)D than children (n=31) living in the areas with no air 
pollution. The mean 25(0H)D in children living in polluted areas was 12.4 ng/ml compared 
to 27.1 ng/ml in low polluted areas (p<0.001) (65). 
In Kuwait, among 858 infants born in a hospital over a period of 2 years, 75 infants (9%) 
were diagnosed with rachitic rosary by a pediatrician within 24 hours after birth (66) (58). 
In Turkey, a review of medical records of 42 infants seen in the pediatric endocrinology 
clinic over a period of 2 years (May 2001 - May 2003) found that children had rickets 
mainly due to limited sun exposure and low maternal and infantile level of vitamin D (67). 
In 1999, in a large cross-sectional study for rapid assessment of prevalence of lower limb 
clinical rickets in Bangladesh, 25891 people 1-20 years old were studied in Cox's Bazaar. 
The prevalence of lower limb clinical rickets was found 931 per 100 000 (95% CI 795 -
1067) (68). The monthly incidence of rickets among 1476 infants born between 1984-
1987 and followed from birth to 24 months of age in Lahore, Pakistan was reported 0.10% 
(95% CI: 0.06- 0.14) in a morbidity study (69) (58). 
2.6. Immunological roles ofVitamin D 
The evidence for profound effects of vitamin D on innate immunity is rapidly growing (70). 
The increased expression of anti microbial cathelicidin by macrophages and epithelial cells 
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in response to exposure to microbes depends upon presence of vitamin 0 (70). In vitro 
studies have shown that 1 ,25-dihydroxyvitamine03, the active metabolite of vitamin D. is 
important for promoting and regulating immune responses (51), (71 ), (52). 1 ,25(0H)203 is 
an immune system modulator and induces expression of the TLR co-receptor CD14 (72), 
(73). Wang et al showed that 1 ,25(0H)203 directly induced antimicrobial gene expression 
(camp and deficin 82 expression) and highlighted the potential uses of vitamin 0 in 
treatment of opportunistic and some antibiotic resistant infections (7 4 ). 
Sub-clinical vitamin D deficiency is associated with an increased risk of tuberculosis in 
adults through modification of polymorphisms in the vitamin 0 receptor (75). Rook and 
colleagues using cultured human macrophages showed that 1, 25(0H)2 0 inhibits the 
growth of Mycobacterium tuberculosis (76). A study by Lui et al revealed the crucial role 
of endogenous 1 ,25(0H)2 D3 produced by macrophages for its anti-mycobacterial 
capacity (77), (39). 
Recent studies have shown that vitamin D activated by expressed enzyme 1-oo-hydorxylase 
from some tissues has important immune-modulatory effects (78). The enzyme 1-oo-
hydorxylase expressed from lung epithelial cells converts inactive 25-(0H)2 vitamin 03 to 
the active 1 ,25-dihydroxyvitamin03. The active vitamin03 increases the expression of 
vitamin 0-regulated genes with important innate immune functions (78). These genes 
include the cathelicidin antimicrobial peptide and the TLR co-receptor CD14 (78). The 
regulatory effects of vitamin D on innate immunity in the epidermis was detected from 
expression of cathelicidin in human epidermal keratinocytes induced by 1,25(0H)203 (77). 
2.7. Vitamin D deficiency and risk of tuberculosis 
Recently, an association between vitamin 0 deficiency and higher risk of tuberculosis has 
been observed. In a hospital based matched case control study of adult Vietnamese (166 
cases and 219 controls), the prevalence of vitamin 0 insufficiency (25(0H)D<30ng/mL) 
was higher in TB positive men compared to that in men in the control group (35.45% vs 
19.5%; p=O.O 1) . The difference in the prevalence of vitamin D deficiency between female 
TB cases and controls was not statistically significant (45.3% vs 47.6%; p=0.91) (79). A 
matched case control study of 72 pairs aged 8-74 years in Greenland found that both high 
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and low level of serum vitamin D were associated with risk of tuberculosis. After adjusting 
for alcohol intake and ethnicity, lower level of serum vitamin D {25(0H) D<75nmol/l} was 
highly associated with TB (adjusted OR=6.5; 95% CI: 1.8 - 23.5). Paradoxically higher 
level of serum vitamin D {25(0H) D>140nmol/l} was also associated with risk ofTB 
(adjusted OR=6.5; 95% CI: 1.9- 22.2). Cases and controls were matched on the basis of 
age and sex (80). 
Recently, a multi-center randomized controlled trial of vitamin Din 146 adults with sputum 
smear-positive tuberculosis was conducted in London. Half of the patients received 4 doses 
of 2.5 mg vitamin 03 on days 7, 14, 28 and 42 along with anti TB treatment. The study 
found that vitamin D significantly hastened sputum culture conversion in patients with tt 
genotypes of the Taql vitamin D receptor polymorphism(HR=8.09; 95% Cl: 1.36- 48.01; 
p=0.02) (81). 
A double-blind randomized controlled trial was conducted among 192 healthy adult TB 
contacts in London to determine the effect of vitamin D on enhancing immunity to 
tuberculosis. Participants were given a single dose of 2.5mg vitamin D and followed for 6 
weeks. The primary outcome was measured by assessing ability of whole blood count to 
restrict luminescence and as a result, growth of mycobacterium in vitro. The trial found that 
the single dose of vitamin D significantly enhanced ability of participants' whole blood 
count to restrict BCG-Iux luminescence compared to that in the placebo group. The mean 
luminescence ratio for intervention group was 0.57 versus 0.71 for placebo group (95% CI: 
0.01 - 0.25; p=0.03) (82). 
2.8. Association between vitamin D deficiency and pneumonia 
High rates of vitamin D deficiency rickets have been found among children admitted to 
hospital for pneumonia ranging from 43% in Tehran (20), (14) and Kuwait (83), (14) to 
50% in Yemen (84). Two hospital-based case-control studies from Ethiopia (14) and India 
(15) suggested that vitamin D deficiency may substantially increase the risk of severe 
pneumonia among children aged less than 5 years. The study in Ethiopia which included 
1021 children under-5 (521 cases and 500 controls) , showed that the prevalence of rickets 
among children with pneumonia was higher than that of among controls (14); 42% of 
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pneumonia cases had rickets, compared to 4% of controls (children admitted for other 
reasons)( OR=22.1; 95% CI: 11.3- 43.1, P<0.001). After adjusting for several potential 
confounders (family size, birth order, crowding, and months of exclusive breastfeeding), 
the OR was still extremely high (adjusted OR=13.4; 95% CI: 8.1- 24.2, P<O.OOl) (14). 
The role of other possible confounding factors not adjusted for, such as zinc deficiency and 
severe malnutrition, could not be ruled out in this study. 
The Indian study which was conducted in 150 children under-5 years of age (80 cases and 
70 controls) to determine whether sub-clinical vitamin D deficiency is a risk factor for 
ALRI, found that sub-clinical vitamin D deficiency and non-exclusive breastfeeding in the 
first 4 months of life were significant risk factors for ALRI (15). In this study serum 
25(0H) D3 > 22.5nmol/L (sufficient level) had a protective effect for ALRI compared to 
that in controls (OR=0.09, 95% CI: 0.03- 0.24; P<0.001). Small sample size and a lower 
cut off point (>22.5nmol/L) compared to commonly used cut off point (> 50 nm/L) for a 
sufficient level of serum vitamin D in this study were the main technical limitations 
limiting its internal and external validity. 
In a cohort of 800 young Finnish men serving in a military base, men with a serum 
25(0H)D level <40nmol/L (n=24) had more number of absent days due to respiratory 
infections than those had higher levels of 25(0H)D (RR=1.63, 95% CI: 1.15 - 2.24, 
p=0.004) (12). 
The cytokines released during influenza episode could disrupt the epithelial layer of the 
lung, leading invasion of streptococcus pneumonia and streptococcus pyogenes to grow and 
cause pneumonia (85). A randomized controlled trial of vitamin D supplementation 
conducted among 334 school children in Japan in 2008-2009, found that the relative risk 
of influenza A infection for school children taking 1200 IU/day vitamin D3 compared to 
placebo group was 0.58 (95% CI: 0.34- 0.99; p=0.04) (86). 
In 2007, a hospital based study of the effect of a single dose 100,000 IU vitamin D3 
supplementation along with antibiotic treatment for pneumonia in 453 children 1-36 
months old in Kabul found that the risk of having a repeat episode of pneumonia within 90 
days after treatment was lower in the vitamin D supplementation group compared to that in 
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placebo (RR=0.78; 95% CI: 0.64- 0.94, p=O.Ol) (87). In this study although children were 
recruited by experienced pediatricians, cases were not confirmed radiographically. Thus 
possible misclassification of pneumonia initially, as well as, during the follow up visits 
could not be ruled out. 
2.9 Potential adverse effects of vitamin D supplementation 
Vitamin 0 can cause acute and chronic intoxication mainly due to its hypercalcemic 
effects. Acute intoxication is associated with nausea, vomiting, dehydration, anorexia, 
apathy, polyuria, polydipsia, hypotonia, constipation, corneal clouding, hypercalcemia and 
hypercalcemia (88),(89) ,(90) , (91) , (92). Prolonged vitamin 0 intoxication affects 
kidneys resulting in nephrocalcinosis, renal colic, renal failure, and neurological disorders 
(93), (94), (92). Studies focused on adverse effects of vitamin D are limited; however, 
cases of acute and chronic vitamin D intoxication in adults and children have been 
documented through case reports from different countries (95). A review of 21 clinical 
trials comparing the risk of vitamin D from a low daily dose (3800 IU/day) to a very high 
daily dose (1 00,000 IU/day) in adults, concluded that prolonged intake of 10,000 IU/day of 
vitamin 03 as upper limit is less likely to increase the risk of adverse effects in the general 
population; however, the capacity of circulating vitamin 0-binding protein might affect the 
safety of vitamin 0 intake (96) (94). 
Three-monthly oral doses of 100,000 IU of vitamin 0 have been proven to be safe and 
effective in alleviating vitamin D deficiency in high risk normal or ricketic children. In a 
randomized controlled trial in Istanbul, Turkey to compared the effect of oral calcium, high 
dose vitamin 0, and combination of these two in treatment of nutritional rickets in 42 
children 6-30 months in a hospital, it was found that a single high dose of intramuscular 
vitamin 0 (300 000 IU) together with oral calcium was a safe and effective regimen (97). In 
France the circulating level of 25(0H)O was measured in 70 neonates given 500 - 1000 IU 
oral vitamin 02 per day for 3 months. It was found that daily administration of 500-1000 
IU oral vitamin 02 did not induce any risk of vitamin D over load during the first 3 months 
of life (98). In Paris, 30 neonates were assigned either to single 5mg (200 000 IU) 
cholecalciferol at birth or to 2.5mg cholecalciferol at birth, 3 months and 6 months after 
birth. Venous blood were collected from all after administration of each dose and at various 
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times to measure serum vitamin 25(0H) D. Both regimens provided similar protection 
against vitamin D deficiency without any risk of vitamin D overload (99). In another 
study, 80 full-term neonates born in a maternity hospital in Paris from April to July 1994 
were assigned either to 500 IU/day or 1000 IU/day of oral ergocalciferol to compare the 
effectiveness of these two regimens in correction of subclinical vitamin D deficiency. Both 
regimens were found to be effective in raising serum vitamin D level in a desired level 
without posing any sign of vitamin D overload.(! 00). The dosage of vitamin D used in 
different trials along with main end points, study outcomes and references are summarized 
in table 3. 
2.10 Rationale for the study 
Afghanistan has very high under-5 and infant mortality rates (19111 000 live births and 
129/1000 live births respectively) and probably pneumonia contributes to a significant 
proportion of these deaths. The incidence of pneumonia (0.29 episodes per child-year) (8) 
and the prevalence of vitamin D deficiency rickets (5 to 45%) are also high in children 
under-5 in developing countries. It is plausible that vitamin D deficiency is a risk factor for 
pneumonia in some settings and therefore Vitamin D supplementation may reduce the risk 
of pneumonia in children. Although studies in India and Ethiopia have revealed an 
association between sub-clinical vitamin D deficiency and lower respiratory tract infections 
in children, these observations from case control studies are not robust enough to causal 
inference and to make policy recommendation for routine vitamin D supplementation for 
children in developing world. Thus a randomized controlled trial of vitamin D 
supplementation was needed to assess the potential beneficial effects of this intervention on 
the incidence of pneumonia. If it is shown that vitamin D supplementation can reduce the 
incidence of pneumonia, it can be incorporated into child health schemes. 
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CHAPTER 3: METHODS 
3.1 Study Country 
Afghanistan is a land-locked country situated in southern Central Asia, surround by 
Pakistan in the south, south-east and partly in the north-east, Iran in the West, and 
Turkmenistan, Uzbekistan, and Tajikistan in the North (1 01 ). The total land area of 
Afghanistan is estimated 251,700 square mile (around 647,500 sq km), and is composed of 
34 provinces. The country has extreme climatic conditions- very cold winters and very hot 
summers. The climate varies from one area to another area according to altitude. 
The total population of Afghanistan is estimated 29,863,000 (3). Fifty two percent of the 
population is aged :'S 17 years old (1 02). The average number of persons in a household is 
7 .4. Only 28% of people aged >5 years can read(l 02). Only 31% of the population has 
access to safe drinking water in the whole country but it is 71% in the capital, Kabul (1 02). 
National access to electricity from different sources is 23%, and access to different sources 
of electricity in the capital is 61%. During the summer, animal dung and bushes are the 
common source of energy for cooking in the country (23%), while during the winter the 
common source is firewood (35%). (1 02). Firewood is also the main fuel for heating 
during the cold season in the country (39%). Agriculture is the main source of income in 
Afghanistan - 4 7% of households are engaged in agriculture (1 02 ). 
The main exports of the country are opium, nuts, hand-woven carpets, wool, cotton, pelts 
and gems(l 01 ). The country is composed of 4 main ethnic groups-Pashtuns (3 8% ), Tajiks 
(25%), Hazaras (19%), Uzbeks (6%). Ninety nine percent of Afghans are Muslims (101). 
The life expectancy at birth is 47 (3). Afghanistan Central Statistic Office estimated the 
GDP per capita of Afghanistan US $ 290 in 2005 (1 03). Two decades of civil war lost 
country's opportunity for socio-economic development. Recent estimates of human 
development index ranks Afghanistan second from the last (7). 
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3.2 Study area 
The trial was conducted in Kabul, which lies in a narrow valley along the Kabul River. It is 
located at 34°31 latitude North and 69°11 longitude East. Kabul is 1,800 m above sea level 
(104). During the winter (December-March) the average duration of sunlight is 6 hours, 
minimum temperature -8°C and maximum temperature 2°C. During the summer (June-
August) the average duration of sunlight is 12 hours, minimum temperature 16°C and 
maximum temperature 33°C
3
. Kabul is a multi-ethnic and multi-cultural city. Tajiks 
Sunnites forms the majority, followed by Shiite Hazaras and Farsiwans ( 1 05). 
According to UNICEF, the under-5 population in Kabul in 2003 was 441,000, and the 
under-5 mortality rate was 15511000 live births. The annual number of births was 110,126, 
and maternal mortality ratio was 700/100,000 live births in 2003. The female literacy rate 
was 35%, and the measles vaccination coverage was approximately 88% in 2003(1 06). 
Kabul city is composed of 18 city districts (Nawahi Shahri) in which 403,800 households 
live. 
The vitamin D supplementation trial was conducted in 5 districts of Kabul - the whole of 
district 1, major part of district 7, and small parts of districts 2, 3, and 8 (Table 4 ). The vast 
majority of the study population lived in Districts 1 and 7. District 1 is the nearest area to 
the study hospital (Maiwand Teaching Hospital), with majority of its population from 
Hazara ethnic group and socio-economically deprived. This is old part of Kabul with 
narrow, shaded lanes often with roofed tops between high walled mud houses; most houses 
have small courtyards with high walls and so for much of the day the courtyard is shaded 
from sun. The total population living in district 1 in 2005 was estimated 65,900 by CSO 
(1 07). The population of district 7 in 2005 was estimated 25,300. People in district 7 are 
from different ethnic groups. In districts 1, 2, 3 and 7, majority of the people live in hilly 
sites making their life very difficult especially in the winter. 
3 Source: BBC weather, December 18, 2008 (http//v.'WW.bbc.co.uk/weather/world/City gutdes<re-;ulb :,html 'tt= I I 1111' 1' 1"' l 
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3.3 Study Design 
This was an individually randomized double blind placebo controlled trial. The trial design 
is summarized in figures 3, 4 and 5. 
3.4 Study Population 
Children aged 1-11 months living in districts 1, 2, 3, 7 and 8 of Kabul city. 
3.5 Inclusion and exclusion criteria 
3.5.1/nclusion criteria 
• 1 to 11 month-old children living in the study areas 
• Parents gave consent to take part in the study 
3.5.2 Exclusion criteria 
• The family was expecting to move far away from the study area within 18 months 
after recruitment 
• The child was diagnosed with rickets or was known to had received a course of 
vitamin D treatment in the past 3 months before recruitment 
• The child had Kwashiorkor or Marasmus 
3.5.3 Temporary exclusion criteria 
• Children who had diarrhea, vomiting, or pneumonia were enrolled 2 weeks after 
recovering from the illness 
3.6 Primary End Point 
First x-ray confirmed pneumonia=: history of cough+ (increased respiratory rate for age4 
or chest in drawing or any danger sign 5) + chest x-ray evidence of pneumonia. 
4 RR/min:~60 (<2 months age), ~50 (2-<12 months age), ~40 (12-59 months age) 
5 Not drinking/breastfeeding, convulsion, vomiting everything, lethargic/unconscious, stridor in a calm child 
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3.7 Secondary End Points 
• Clinical pneumonia= history of cough + (increased respiratory rate for age or 
chest in drawing or any danger sign) detected at OPD, IPD or fortnightly house 
visit. 
• Repeat clinical pneumonia= any new case meeting the criteria of clinical 
pneumonia diagnosed 2:30
6
days after the first episode of pneumonia, detected at 
the OPD, IPD or fortnightly house visits. 
• Repeat x-ray confirmed pneumonia= any new case meeting the criteria of first x-
ray confirmed pneumonia occurring 2:30 days after an episode of x-ray confirmed 
pneumonia. 
• Severe pneumonia= cough+ chest in drawing detected at the OPD or IPD. 
• Very severe diseases = cough + any danger signs detected at the OPD or IPD 
• Hospitalization for any diseases 
• All cause and pneumonia specific mortality 
3.8 Sample size 
The expected incidence of the first or only episode of pneumonia in the placebo group was 
based on the following assumptions: (1) the incidence of acute lower respiratory infections 
(ALRI) in the placebo group will be 0. 65/child /year (1 0); (2) 12% of the ALRI will be 
pneumonia (1 0); (3) 25% of pneumonias will be repeat episodes during the 18 month 
follow-up period. (4) Thus the incidence of the first or the only episode of pneumonia in 
the placebo group will be 0.0585/child/year (0.65*0.12*0. 75). We assumed a 35% 
reduction in the incidence of pneumonia in the vitamin D group given that 73% of children 
have vitamin D deficiency in the study area (32), and that the incidence of pneumonia is 10 
times higher in vitamin D deficient than in normal children (14) (15). A study with 80% 
power and 95% significance to detect a 35% reduction in the incidence of pneumonia 
compared to the placebo group required 22079 child months per group (1 08). Since each 
child would be followed for 18 months, assuming a 20% loss to follow-up, the study 
6 Time for next episodes of pneumonia has been taken from the Gambian Study "Epidemiology and clinical 
features of pneumonia according to radiographic findings in Gambian children ·• [ 1] and a study conducted in 
Pakistan[3 5] 
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required 14 72 children per group. In order to facilitate randomization and allocation of staff 
this figure was rounded to 1500 child per group. 
Box 1: Definition of outcomes 
DEFINITION OF THE STUDY OUTCOMES 
Primary End Point was the first x-ray confirmed pneumonia plus clinical diagnosis of 
pneumonia (history of cough + (increased respiratory rate for age or chest in drawing or 
any danger sign). For x-ray confirmed pneumonia, the standard definition by WHO was 
used as following: 
"The presence of a dense or fluffy opacity that occupies a portion or whole of a lobe or of 
the entire lung, and/or the presence of fluid in the lateral pleural space between the lungs 
and chest wall ( 1). 
For the secondary outcomes, repeat clinical pneumonia was defined as any new case 
meeting the criteria of clinical pneumonia ~30 days after the first episode of pneumonia, 
detected at the OPD, IPD or fortnightly house visits. Severe pneumonia = cough + chest in 
drawing detected at the OPD or IPD. A very severe disease was cough+ any danger signs 
detected at the OPD or IPD. 
Bronchiolitis: history of cough +wheezing with or without increased respiratory rate for 
age or chest in drawing detected at OPD, IPD. An episode happening within 30 days 
after previous episode was counted as duplicate of that episode and excluded. 
3.9 Community Sensitization 
Each study district was composed of several subunits called Gozar. A Gozar had 10-15 
streets and approximately 500-700 households. Each Gozar had a head called Wakil who 
was selected by people in that area. In addition each study district had 2-3 mosques headed 
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by a mullah and a local security office (Hawza). The study field supervisors and I met the 
head of local municipalities, Wakils, and Mullahs in study district and explained the study 
objectives and procedures. A project information letter in local language was distributed to 
all community leaders to sensitize them to the aims and benefits of the study to the 
communities. Additionally, a supporting letter from the Ministry of Public Health (MoPH) 
was given to the head of municipalities to solicit their cooperation and letter from the local 
authorities sent to all Wakils for their support to the project. After initiation of the project, 
the field supervisors held regular monthly meetings with Wakils and head of municipalities 
to update them on project progress. At end of the study, the project management team met 
the head of municipalities and the head of communities and informed them on successful 
ending of the study. 
3.10 Ethics Consideration 
The study was approved by Ethics Review Board of the Ministry of Public Health (MoPH), 
Afghanistan, and the Ethics Committee of the London School of Hygiene and Tropical 
Medicine. The application form for review board of MoPH, Afghanistan is attached in 
annex 1. All study tools, including study consent form were submitted to the review boards 
for verification and approval. Because this study followed the previous pilot study of 
vitamin D and pneumonia in the same field and clinical setting in Kabul in 2007, to some 
extent the review board in the Ministry of Public health, Afghanistan was aware about the 
technical details of the study. The approval letter from MoPH Ethics review board is 
attached in annex 2. The ethics committee of LSHTM also reviewed the study, and 
approved all procedures, safety, and technical features of the study. The approval letter by 
LSHTM Ethics committee is attached in annex 3. 
The ~tudy was reviewed by two technical monitoring committees: 
The first was called Oversight Committee, and was based in Kabul. The committee had 
members from MoPH, MoHE, Maiwand Teaching Hospital, UNICEF, WHO and London 
School of Hygiene and Tropical Medicine, all based in Kabul. The members were provided 
with study progress report each quarter, in addition to regular oversight committee 
meetings held quarterly in the beginning, and 6 monthly later on. In the meetings, in 
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addition to study progress, members were updated on number of children died during the 
past quarters of the study and the possible causes of deaths. 
The second monitoring committee, data safety monitoring board (DSMB) had two 
members from London School of Hygiene and Tropical Medicine (Prof Christopher Whitty 
and Dr Sarah Steadke), one member from Afghan MoPH ethics committee (Dr Mir Lais 
Mustafa), and representative from an independent research organization in Kabul affiliated 
with John Hopkins University (Dr Philippe Bounhoure). The DSMB discussed the safety 
and other technical points during the first phone conference call in the beginning of the trial 
and approved the trial design, SOPs and time table of the study. The DSMB noted that this 
is a low risk trial because vitamin D is widely used and it has a good side effect profile. 
The DSMB agreed that all deaths and any other serious adverse effects (SAEs) for which a 
causal link to the study drugs cannot be ruled out should be reported to the DSMB chair 
within 48 hours of identification by email. A summary of all other SAEs should be 
reported quarterly to the DSMB by the study team. The DSMB decided that no formal 
interim analysis of the effect of vitamin Don the incidence of pneumonia is required due to 
low risk. However the incidence of SAEs was monitored by the DSMB and if a substantial 
difference has been observed between the study groups, a formal statistical analysis would 
have been carried out by the DSMB. 
The study team reported all deaths to DSMB members within 48 hours, which contained a 
member from ethics committee of MoPH, Afghanistan as well. All other hospital 
admissions were reported to DSMB members quarterly. 
Before starting the trial, technical details of the study were discussed with community 
leaders, such as Mullah's and Head of Shuras, as well as, with head of local municipalities 
to see if they might have any concern. The community leaders did not raise a particular 
concern about any aspect of the study, rather, promised to provide as much support as they 
could. 
Half of the trial area was part of the vitamin D pilot study done in 2007. Therefore, 
majority of people in those parts knew about vitamin D. In other parts of the study, few 
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concerns were raised by people during the follow up. Some of families were concerned 
whether vitamin D might cause infertility in their children. Some other families thought 
vitamin D is too strong for their children and make their kids highly sexually active when 
they grow up. The study field supervisors met the families that raised such concerns and 
assured them that vitamin D does not have such adverse effects. Other than these two 
points, no other concerns were raised in the communities. 
Data Safety and Confidentiality 
• All staff was trained in the principles and practices to maintain confidentiality. All 
staff had signed a confidentially clause as part of their employment contract. 
• All data forms were kept in locked cupboard that was accessible to the data manger 
and Pis only 
• The personal information of all study children were kept in a separate data form 
which was linked to the rest of data form through a unique coding, so that access to 
the personal data was limited to the data manager and Pis only. 
• All hard copies of the study data forms (questionnaires) will be disposed after 10 
years. Only study investigators will have access to electronic copy of the data 
3.11 Training of study staff 
3.11.1 Assessment of clinical parameters by field workers 
From October - November 2007, 42 female field workers, and 3 field supervisors were 
trained in IMCI guidelines, and standard operating procedures of the trial. Participants 
worked in groups and learnt how to assess respiratory rates, chest in drawing, skin pinch, 
and other clinical measurements. In addition, the field workers were given clinical 
demonstration of dehydration and malnutrition in children admitted to the Indira Gandhi 
Institute of Child Health in Kabul. . 
3.11.2 Consenting and completing study forms 
The field staff practiced the process of consenting and obtaining written consent in groups 
of six. The study staff role played and practiced in pairs the process of completing all study 
forms including the consenting form. All study forms were translated into the local 
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language (Dari) and were field tested. During the field testing field workers did the 
interview in pairs, and each pair interviewed 3 to 4 families with each study form over a 
period of 2-3 days. After each day of field practice, field workers discussed their findings 
and the study forms were amended if deemed to be necessary. 
3.11.3 Clinical assessment of children at the study hospital 
The study protocol, standard operating procedures and the study forms were discussed with 
the three study clinicians and two senior clinical supervisors. Then they were trained along 
with field workers in IMCI guidelines using video clips and clinical demonstration. The 
consistency in counting respiratory rate and observing chest in drawing was assessed by 
comparing the study clinicians' observations with that of the trainer. 
3.11.4 Radiography 
Four study radiographers were trained in standard techniques of radiography by an expert 
WHO consultant. The training consisted basic theories of radiography and its physics rules, 
and practice of taking X-rays at the appropriate positions and optimum level of exposure to 
x-ray radiation. 
3.11.5 Collecting venous blood samples 
One study phlebotomist was trained on how to take consent for collecting blood samples, 
how to fill the blood collection form, and how to take care of blood samples drawn before 
transporting to the laboratory for centrifugation and freezing. 
3.11.6 Refresher Training 
All field workers and field officers were given refresher training for two days in June, 2008 
in measuring clinical parameters and completing study forms. Refresher training was 
rd 
conducted on 23 December 2008 for field staff. The aim was to refresh on how to collect 
correct information about indoor air pollution. One-day training was conducted for field staff 
on 25•h March 2009. The training was a refresher session about anthropometric 
measurements such as weight, height, and head circumference, as well as, refreshing on use 
of breast feeding, and economic status forms. The training included practical sessions at 
Pediatric ward of Maiwand Teaching Hospital and preceded the administration of these 
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fonns in the field. Subsequent refresher trainings were undertaken for field and clinical 
staff during last two quarters of the study to assess the quality of work and resolve if there 
were some technical problems. 
3.12 Screening, Consenting and recruitment 
Three supervisors sketched and counted the total number of houses in the study areas. 
There were approximately 14000 houses. The study area was divided into 3 study zones 
(district 1 as zone one, districts 7 and 8 as zone two, and districts 2 and 3 as zone three) and 
allocated to one supervisor for day to day running of the project. Each study zone was 
divided into 4 sub zones, and each sub zone was assigned to 1 recruitment team consisting 
of 10 field workers and 1 team leader. The field workers worked in pair and visited all 
households in their allocated area. If a family had a child aged between 1 and 11 months, 
they marked the number of eligible children on the door. If a family did not have any 
eligible child, they marked zero on the door. If an eligible child was absent on the day of 
visit, the team returned on the next day to recruit the absentee child into the study. 
Study children were enrolled from 61h November to 2nd December 2007. If a family had an 
eligible child, the field worker explained the objectives of the project and its benefits to the 
family and child. If a family was interested in their child to be in the study, the field worker 
read details of the study procedures from the infonnation sheet and asked the mother if she 
was willing to participate. In addition to mother a second person (mostly child's father) was 
also requested to give consent. If both parents gave consent, they were requested to give 
their thumb prints in the consent fonn, in the presence of a witness who also either signed 
or thumb printed the consent fonn. For each child, two consent fonns were filled: one copy 
was given the family and the second one was filed in the project office (Annex 4). 
If a family consented, data on socio-demographic characteristics of the child and parents 
(age, education, profession and occupation), height, weight, head circumference, and illness 
history were collected using the recruitment fonn (Annex 5). If a family did not consent, or 
the inclusion criteria was not met, the field workers collected socio-demographic 
characteristic of parents and the reasons for not consenting in recruitment fonns. 
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Each field worker enrolled approximately 10 children daily, and each study child was 
provided with Photo ID card. The parents were requested to bring the photo ID card 
whenever the child was brought to the study hospital for consultation. The photos on the 
ID cards were updated on a 6-monthly-basis due to rapid growth of the children. Families 
were provided with a contact number on the ID card to call in case they face any problem in 
the hospital or if they need to contact the project management. (Annex 6). 
A pictorial signs and symptoms card was given to the mothers at recruitment to record 
health problems of their children in between home visits by field workers. The card 
included pictorial signs of cough, fever, skin rash, vomiting and diarrhea for mothers to 
better recognize and recognize the health problems. The pictorial card was in a matrix 
format - the pictures of the signs were on the top of columns and the days between the 
fortnightly visits by field workers were in the rows. The mothers were asked to tick the 
corresponding box of sign and the date if a child had any illness. The pictorial cards were 
replaced fortnightly. (Annex 7). 
All information included in the study forms was approved by study Ethics Review Boards 
prior to application in the field. 
3.13 Randomization and concealment 
An independent statistician randomized study number 0001 to 3050 in variable blocks to 
vitamin D and placebo in equal numbers (block of 20 with equal ratio) and gave it to a 
pharmacist in AKUH hospital in Karachi. The Pharmacist in AKUH prepared the vitamin 0 
and Placebo and filled in syringes labeled with unique ID numbers provided by the 
independent statistician. Syringes for vitamin D group were filled with 100,000 IU vitamin 
03 in 1 ml olive oil, and syringes for placebo group had only 1 ml olive oil. The dosage of 
vitamin D was the same for children in all age groups and the same dose was filled to 
respective syringes for all 6 rounds. The labeling included the manufacturing and expire 
dates of the vitamin D/placebo contents for each round. The syringes were freshly prepared 
and transported to the study site on quarterly basis. For each round, the syringes were 
transferred up to 2 weeks prior to the starting date of dose administration, and the syringes 
were transferred to study site under manufactures' recommended temperature and storage 
conditions. 
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At recruitment, the field workers allocated one syringe to each child sequentially. The study 
number for each recruited child was the unique code number of the syringe that was 
administered at round one for each child. The vitamin D and the placebo (olive oil) were of 
same color (pale yellow) and same quantity (1 ml) and therefore all project staff, as well as, 
the families were blinded to vitamin D and placebo status of the syringes. During the 
subsequent round each child was administered vitamin D or placebo from a syringe that had 
his/her unique ID number by a pair of field workers. One field worker checked the label of 
the syringe whether it was the same ID number recorded in the Photo ID card and it was 
verified by the second field worker before giving the content of the syringe to a given child. 
If a family had two children in the study, the field workers took out only one syringe from 
their bag at one time to avoid mistakes in administration of the intervention (see SoP 5 
Annex 8). 
Vitamin D or placebo was administered quarterly. The first dose was in November, 2007, 
the second in February 2008, the third in May 2008, the fourth in August and the fifth dose 
in December 2008. The sixth dose was given in March 2009. In each round vitamin D 
administration form was used to record the details of drug administration (Annex 9). 
3.14 Active surveillance 
Study children were visited at home fortnightly to assess their health status and also to 
determine health seeking behavior and practices. In each home visit, field workers asked 
about signs and symptoms during the past two weeks, the treatments given to the child, and 
where the child was taken for any illness (two-weekly assessment form- annex 1 0). Field 
workers also checked chest in drawing, body temperature, signs of dehydration by skin 
pinching, and counted respiratory rate. The pictorial cards given to the family on the last 
visit was checked whether mothers marked the signs and symptoms child had, as well as, if 
the marked signs corresponded to the signs mother mentioned about health status of her 
child during the past two weeks. Regretfully, most mothers were either forgetting to mark 
the signs and symptoms in pictorial cards, or losing the card, making it a less effective 
approach. Nevertheless, in each home visit, the families were provided with a new pictorial 
card in order to keep them engaged to the study. If a child was absent during the 
household visit an absentee form (Annex 11) was completed to determine the period 
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families were absent from the study area, where they lived in that period, if the child got 
any serious illness in absent period and to determine when they returned to the study area. 
Moreover, information about risk factors of pneumonia such as breast feeding, economic 
status, indoor air pollution, family crowding, anthropometric measures, and exposure to 
cigarette smoke was collected in different seasons during the fortnightly visits according to 
study schedule. Over all 36 two-weekly home visits were performed from the beginning till 
end of project in May 2009. 
Verbal autopsy interviews with families that lost their child during the study were 
conducted 40 days after the child's deaths. WHO- standard verbal autopsy form was 
translated into local language, and used for interviews. All death cases were coded 
according to ICD-1 0 WHO standard format and reported to data safely monitoring board. I 
coded the causes of death in Kabul, and the study supervisor at LSHM (Daniel 
Chandramohan) verified the coding before those cases were reported to DSMB. The details 
of death cases with ICD-1 0 codes are summarized in Table 16. 
3.15 Passive surveillance 
Study children were brought to the hospital either if a field worker referred him/her, or if 
parents themselves thought their child was sick. Children brought to the hospital were first 
seen at OPD irrespective of severity of their illness. At OPD the study doctors identified 
children from the photo ID card and the bracelet in their hands. If the bracelet was missing, 
or the ID card did not have the photo, the attending study doctor confirmed the child ID 
using the records in the study office with the assistance of study supervisors. Full clinical 
history about past two weeks, health seeking and treatments given prior to attending the 
hospital and all clinical signs including respiratory rate, and chest recession were collected 
using the OPD form (Annex 12). 
Patients with serious conditions were referred from OPD to IPD for admission according to 
the study protocols (Annex 13). At admission first a full history of sign and symptoms, 
treatments given at home, and place of treatment were collected. Then a full clinical, 
laboratory and x-ray examinations were conducted as appropriate and all the data was 
recorded in the IPD form (Annex 14). The data on prognosis and the final diagnosis was 
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completed at discharge. If a family refused admission, appropriate treatment was advised at 
home, and was asked to come back for follow up in two days. 
All children with clinical diagnosis of pneumonia were advised chest x-ray. In the x-ray 
form (Annex 15) the study number, date of chest x-ray and position of chest x-ray were 
recorded. The chest x-rays were archived and sent to radiographers in the ARI unit of 
Pakistan Institute of Medical Sciences (PIMS) for assessment. All chest x-rays were read 
by two radiologists independently. The findings of the two radiologists were compared by 
the radiology coordinator and if there was a discrepancy between the two radiologists the x-
ray was read by a third radiologist independently. The diagnosis agreed by any two 
radiologists was deemed to be the final diagnosis. 
3.16 Vitamin D/Placebo Administration 
All doses of Vitamin D (1 00,000 IU D3) and Placebo were successfully administered to 
children, who were present in the study at each round. Only a few protocol violations 
happened and these were immediately reported to study management and recorded. As 
already mentioned, the same drug dosage (1 00,000 IU D3) was freshly ordered from 
Karachi Pharmacy Department for each round and they filled the syringe for each round 
using the same randomization list provided by our independent statistician. We did not 
have the resources to monitor the work of the pharmacy department at AKU and to check 
whether the right amount of vitamin D was filled in each syringe. We did not do quality 
check of the contents of a random sample of syringes because it was very expensive. 
However we collected blood samples from a randomly selected 600 children to compare 
the level of serum vitamin D in two groups. The comparison of the serum vitamin D levels 
between the two groups was used as a proxy to determine the quality and contents of the 
syringes. The total doses administered each round and the protocol violations happened are 
shown in the CONSORT chart (Figure 3). 
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3.17 Vitamin D Adverse Effects 
During 18 months of project implementation, no signs of vitamin Dover dosage or adverse 
effects was detected or reported. All field workers and field supervisors closely monitored 
the drug administration processes to detect any over dosage. When contents of a syringe 
were administered to a child in each round, the respective field worker observed the 
children for at least half an hour for sign and symptom of vitamin D over dosage listed in 
vitamin D administration form. Moreover, families were asked to contact the respective 
field worker, field supervisor or project management team if the child experienced any 
delayed adverse events. All families were provided with contact telephone numbers of the 
management team, field workers and field supervisors. Two extended focused group 
discussion were conducted with pediatricians from two pediatric hospitals to ask for their 
opinions and concerns about vitamin D intoxication and all its aspects such as predisposing 
factors, toxic doses etc. The findings are discussed in discussion section. 
3.18 Reading of chest x-rays 
Three radiologists from ARI unit of Pakistan Institute of Medical Sciences (PIMS) read the 
study chest x-rays using the standard WHO vaccine trial protocol. They used WHO 
Proforma for Standardized Interpretation of pediatric chest radiographs for the diagnosis of 
pneumonia(bacterial) (1 09). The radiologists were trained by WHO and had the experience 
of working with international research projects .. The results from each reader were entered 
into database by data manager and their opinions were compared. If two readers agreed on 
the same result, that was reported as the final result. If two independent readers did not 
agree on the same results, those x-rays were passed to the third radiologist for confirmation. 
A case was confirmed as pneumonia if unilateral or bilateral infiltration or consolidation 
with or without effusion was observed in x-rays by two independent readers. Figure 6 
shows two samples of chest x-rays diagnosed as significant pathology for pneumonia, and 
figure 7 shows two samples of chest x-rays where one of the two readers disagreed to 
diagnose as pneumonia, and they were confirmed as pneumonia after third reader's opinion. 
3616 chest x-rays were read by independent radiologists. 833 x-rays were reported positive 
for pneumonia. The positive cases of pneumonia were matched with clinical data to see if 
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the date for each case matched with the records a child was seen either in OPD or IPD. Of 
833 x-rays with positive pneumonia, 19 cases (1 0 from vitamin D and 9 from Placebo 
groups) did not match with OPD, IPD or two weekly home visit data and were dropped 
from analysis. Of 814 positive chest x-rays, 440 were from vitamin D and 337 were from 
Placebo groups. The agreement between the two independent radiologists was reasonable 
(Kappa= 0.85, P< 0.001) and the total chest x-rays interpreted by two readers as either 
pneumonia or non-pneumonia is summarized in table 30. 258 x-rays were read by 3rd 
radiologists because of the discrepancy in the findings of the first two readers. The third 
reader's reading was taken as the final diagnosis. 
3.19 Blood sampling and assessment of serum vitamin D levels 
We collected around 120 blood samples 5 times during the 18 months of project's 
implementation. Children were randomly selected for each round. The time for blood 
sampling was arranged to account for pharmacodynamic and seasonality of vitamin D 
deficiency. All families were asked for consent before drawing the blood. From each child 
up to 5ml blood was drawn and stored in a vacutainer tubes inside the cold vaccine carrying 
box before transferring all samples to a clinic. In the clinic samples were immediately 
centrifuged and the plasma was kept in a separate tube refrigerated. Both the phlebotomist 
in the field and the nurse in the clinic filled a form recording child's unique ID, amount of 
blood/plasma drawn and the date. A total of 668 blood samples were drawn, of which 345 
were from vitamin D and 323 from placebo groups. The samples were transferred to 
Manchester hospital for measuring serum vitamin D level. The list of samples was given to 
the lab technologist without disclosing the study codes. 
The serum 25(0H)D levels were determined by IDS-iSYS Multi-Discipline Automated 
Chemiluminescent assay (Immunodiagnostic Systems Ltd, Boldon, Tyne and Wear UK) at 
Manchester Royal Infirmary, Supra-Regional Vitamin D Reference Laboratories accredited 
to IS09001 :2000 and IS013485:2003 and participating in the Vitamin D Quality 
Assurance Scheme (DEQAS). 
Of 668 sample serums, 632 (332 from vitamin D and 300 from placebo groups) were able 
to be tested. The rest of samples were not enough for processing. 
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3.20 Assessment of contextual and potential risk factors of pneumonia 
Data on child's currently breastfeeding status, and reasons for not breastfeeding were 
collected twice during the project life using the breastfeeding fonn (Annex 16). Data on 
number of people sleeping in the child's bed room were also collected and recorded in the 
same form. The section on breastfeeding status was repeated in the second winter. 
In the beginning of winter 2007, the level of indoor air pollution was assessed by asking 
about smoking in the family, cooking and heating system (Annex 17). Exposure to cigarette 
smoke was assessed as one of potential risk factor for pneumonia. Additionally, indoor air 
pollution was assessed by measuring what type of heating device a family used during the 
winter, as well as, how long each device was on during a day on average (section 3.22.2). 
The socio-economic status of the households was assessed by ownership of common assets. 
Using the principle component analysis, we developed the wealth index based on 
household characteristics and assets. From this index, wealth quintiles were obtained 
ranging from least poor to poorest as a final measure of economic status of a household 
(section 3.22.2). 
Mother's total birth was determined by asking about total death and living children she 
had (Annex 18). In this study, total alive children were used as a measure of crowding in 
addition to number of people sleeping in the child's bedroom. 
Baseline nutritional status was assessed by measuring weight of children at recruitment 
(fonn A, annex 5). In this study the weight for age z-score was used for assessing the 
nutritional status (section 3.22.2). Age of children, as well as, mothers' and fathers' 
education as influencing factors for pneumonia was assessed at recruitment (form F, annex 
2). 
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3.21 Data Entry and Data Processing 
All data collection forms were manually checked daily and errors were corrected by the 
respective field worker. Some forms that required cross-checking with the families were 
taken back to the families for completion. Only the field worker who completed a given 
form was allowed to correct data errors in that form. If the respective field worker was not 
available, the field supervisors and the project manger were authorized to correct the data 
errors if appropriate. 
Data were checked again at data entry point. If any mistake or inconsistency was found, the 
form was sent back to the field for correction. Data entry was done parallel to data 
collection. The database was developed using Microsoft office Access 2003 with necessary 
validation rules to avoid data entry errors. All forms were entered twice by two different 
data clerks. The data management team developed a query system in database to detect if 
there was any inconsistency between first and second entries. If the system was detecting 
any error, the data assistant was checking the forms to determine the problem and correct it. 
I also checked all data in Kabul during the preliminary analysis to find out if there was any 
data entry error or data inconsistency, and proper feedback was provided to data 
management team for respective corrections. The database was backed up on a daily basis 
to avoid any data loss. Statistical analysis was undertaking by using statistical data 
management package Stata, version 10. The main analysis was carried out in the basis of 
intention to treat, but per protocol analysis was also conducted to compare the result with 
that of intention to treat. The identity of study subjects was not revealed to all investigators 
and institutions involved with project's analysis part such as blood tests and x-ray 
interpretation till all the analysis was performed. 
3.22 Study Timeline 
The enrolment started on ih November 2007 and completed on 2nd December 2007. The 
first dose of vitamin D/placebo was administered at recruitment and the rest of the doses 
were given 3 monthly. The last dose was given in February 2009. The active and passive 
surveillance ended in May/June 2009. Date entry, data cleaning and data archiving were 
finished in October 2009. 
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3.23 Analytical methods 
3.23.1 Baseline characteristics 
The frequencies and percentages of baseline characteristic that are binary/categorical 
variables (age of the child, mothers' and father's education, marital status and working 
status) were compared between the two study groups using Chi square test. The 
distributions of continuous variables (child's age) were compared between the groups using 
means (and SD) or medians (and inter-quartile range) .The distribution of potential risk 
factors of pneumonia namely child's age, mother's education, father' education, families 
economic status, indoor air pollution and exposure to cigarette smoke, family crowding, 
breast feeding and nutritional status were also compared between the two groups using Chi 
square test to assess the robustness of randomization. The background characteristics were 
compared between children with no episode of pneumonia, single episode of pneumonia 
and multiple episodes of pneumonia. A logistic regression model was used to test the 
association between potential predictors and single or multiple episodes of pneumonia. 
3.23.2 Potential Risk Factors for Pneumonia 
The following potential risk factors for pneumonia were measured: Indoor air pollution 
(exposure to cigarette smoke and type of heating device), lack of breastfeeding, crowding 
(number of people sleeping in child's bed room, and number of alive children from the 
same mother), malnutrition (weight for age z-score), poverty (household's asset 
ownership), child's age, mother's education, and fathers' education. Analysis method for 
each risk factor is described below: 
Indoor air pollution 
Indoor air pollution was measured by a composite variable derived from the type of heating 
device used by families and the length of time the device was on in 24 hours of the past 
week during winter season on average. Indoor air pollution was quantified by an air 
pollution score ranging from 0 to 5. The scoring matrix is shown in Table 6. The indoor air 
pollution score from each source was summed up and categorized into no/low pollution 
(score <0.5), medium (score 0.5-2) and high pollution (score 3-5). 
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Malnutrition 
Nutritional status was measured by baseline weight for age z-score. Using the standard 
WHO reference weight for age, nutritional status was categorized as follows: No 
Malnutrition: Weight for age Z-Score 2: -1; Mild Malnutrition: Weight for Age -2 -s; Z-score 
<-1; Moderate Malnutrition: Weight for age -3 -s; Z-score <-2; Severe Malnutrition: Weight 
for age Z-Score < -3 
Lack of breastfeeding 
A child was defined as not breastfed if he/she had never been breastfed or if he/she was 
ever breastfed but not currently breastfed (one month after recruitment at time of interview) 
Crowding 
Crowding was measured by two separate variables. Overcrowding was defined either if 2: 5 
people were sleeping in child's bedroom or if a family got 2:8 children alive from the same 
mother. Total number of people sleeping in child's bedroom was classified into three 
categories (-s; 2, 3-4, or -s; 5 peoples sleeping in child's bedroom). Number of children alive 
from the same mother was also classified into three categories (-s; 3, 4-7, or -s; 8 children). 
Exposure to cigarette smoke 
Was measured by child's exposure to the number of cigarettes all family members smoked 
inside the child's room on average on a daily basis and categorized as follow: none; 
exposed to 1-9 cigarettes per day; 10-19 cigarettes per day or exposed to 2: 20 cigarettes 
per day. 
Economic status 
Economic status was assessed by total assets a family owned. A principle component 
analysis was carried out using the asset information. All assets were tested for association 
among each other to check for consistency. Study children were classified into five 
economic quintiles: 
a. Better off (Highest quintile) 
b. Less poor 
c. Poor 
d. Very poor 
e. Poorest (Lowest quintile) 
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Child's age 
Child's age at recruitment was considered as a risk factor for pneumonia. Children were 
classified into three age groups based on age at enrolment: <2 months; 2-5 months; 6-12 
months. 
Mother's and father's education 
Mother's and father's education were measured by asking if they had any formal education 
or not. 
3.23.3 Person Time At risk and End points 
A clinical episode of pneumonia was defined as those cases observed in: 1) the 2 weekly 
visit records; 2) the out patient records; and 3) the inpatient records according to the criteria 
for the first and repeat episodes of pneumonia (text box on definition of the study 
outcomes). The time to an episode was calculated as time from recruitment or previous 
episode allowing at least 30 days (35), (1) between two episodes to be counted as a new 
episode. An episode happening within 30 days after previous episode was counted as 
duplicate of that episode and excluded. If a child was not seen for more than 45 days at the 
two weekly visits or at the OPD/IPD records, they were censored for that period of the 
study. Such a child could reenter the study when next seen. Any overlap between episodes 
reported in the 2 weekly visits, outpatients or inpatients was accounted for with an inpatient 
episode taking first priority and an outpatient episode second. 
Children who were missed during the follow up visits were included in intention to treat 
analysis if they re-appeared any time during the fo11ow up or the final home visit at the end 
of the study. If not present in the final home visit, they were censored from the point they 
were last seen either in the hospital or home. 
For the primary endpoint, data on chest x-rays were combined with clinical data to measure 
the rate of first and repeat episodes of x-ray confirmed severe and non-severe pneumonia in 
vitamin D and placebo groups. The same criteria were applied for censoring and accounting 
for repeat episodes as mentioned above. 
57 
Rate ratios for the first episode of pneumonia for the Vitamin D group were compared to 
the placebo group using Cox proportional hazard models. Time to the first episode in the 
Vitamin D group was compared to that in the placebo group using log rank tests and 
proportional hazards models. Percent failure, incidence rate ratios (with 95% CI's) together 
with numbers of cases and censored children were given at specified time points (every 
three months). Kaplan Meier plots were used to display the survival curves for both 
groups. Initial models were used to determine the effect of Vitamin D compared to placebo 
(unadjusted for other factors) on the primary outcome. 
Violation of the assumptions of proportionality in the Cox models were assessed via model 
Schoenfield residuals and examined graphically with plots of a survival transformation over 
time. 
Similar analysis was carried out for repeat episodes and all other secondary outcomes. 
Effect of potential risk factors of pneumonia, such as, child's age, mothers and fathers 
education, economic status, family crowding, breastfeeding status, indoor air pollution , 
child's sex , exposure to cigarette smoke, and malnutrition (weight for age z-score) were 
assessed on the rate of first and repeat episodes of severe and non-severe x-ray confirmed 
pneumonia using Cox regression model. Only covariates with a significant effect in 
unadjusted analysis were kept in the adjusted model. 
3.23.4 Per Protocol Analysis 
We conducted 3 different per protocol analyses. The first was based on initial study 
protocol where children in vitamin D and placebo groups who received two consecutive 
doses of the drug within 60 days or more than 120 were excluded, and the remaining of 
children were kept for analysis. In the second per protocol analysis, only the children who 
received at least 4 consecutive doses of the drug at the right time (interval between doses 
was not less than 60 days and not more than 120 days) were kept for analysis. In the third 
per protocol analysis we planned to restrict the analysis to those children who had received 
all 6 doses at the right time, but we were unable to do this because no children had received 
all 6 does at the right time. Therefore the third analysis was restricted to children who had 
received 5 doses of the drug in the right time. In per protocol analyses, children whose 
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randomization was violated (received the wrong dose or received a high dose of vitamin D 
from other sources) were excluded. 
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CHAPTER4:RESULTS 
4.1 Trial profile 
From 14000 households sketched in the study area, 3060 children were assessed for 
eligibility and 3046 (1524 children in vitamin D group and 1522 children in placebo group) 
were recruited in the study. Of 14 children excluded, 2 children did not meet the inclusion 
criteria and 12 children/families did not want to participate. Of 2 children, one was 
suffering from severe malnutrition, and the second had received a high dose of vitamin D 
within 3 months before recruitment. Those who refused to participate (12 families), either 
did not want to go to study hospital or did not want field workers to go to their houses. 
Some of them did not participate without any reason. The reasons for exclusion from the 
study and the follow up rate are shown in Figure3. After the first quarter refusal and lost to 
follow up was 34 in vitamin D group and 26 in placebo group. Three children had died 
from Vitamin D group and 2 children from placebo group. At the end of second quarter, 
refusal and lost to follow up increased to 35 in vitamin D and 41 in placebo groups. Six 
children died in vitamin D group and 1 child from placebo group. Before the 4th quarter, we 
had 45 children lost to follow up and refused to participate in vitamin D group and 47 
children of those in placebo group. One child from vitamin D group and one from placebo 
group had died. After the 4th quarter 50 children were refusal and lost to follow up in 
vitamin D group and 72 children in placebo group. Only 2 children had died from Placebo 
group. By the end of study in May 2009, we had a total 206 children refusal and lost to 
follow up in vitamin D group and 207 children in placebo group. The cumulative deaths in 
vitamin D group was 10 and in placebo group was 7(Figure3). In final follow up visit in 
May 2009, 2616 (1312 vitamin D and 1304 placebo) children were present in the study and 
17 had died. (Figure3). The number of children lost to follow up during the study was 
pretty low and many children lost, rejoined the study later and rates were similar between 
the two groups (Figure 3). 
60 
4.2 Socio-demographic characteristics of study children 
The mean age for study children in vitamin D group was 6.2 months (95% CI: 6.02- 6.34) 
and for children in placebo group was 6.2 (95% CI: 6.04- 6.35) at recruitment (Table 7). 
In both vitamin D placebo groups almost half of the children were male (53.2% and 51.2% 
respectively). 
Majority of mothers in vitamin D and placebo groups were aged 20-39 years (90.7% and 
88.9% respectively). More than half of mothers in both groups did not have any formal 
education (62.4% and 65.2% respectively) (Table 7). Of mothers, who attended any formal 
education, the majority studied until grade 6 (primary school) in both groups (51.5% in 
vitamin D group and 48.5% in placebo group). In comparison to mothers, more than half of 
fathers in both groups had attended any formal education (71.2% in vitamin D and 70.4% 
in placebo groups). More than 90% of fathers in both groups were currently working (Table 
7). More than 95% of mothers in both groups were currently married and the only wife of 
their husbands. Majority of fathers in both groups were from Tajik nationality (69.7% in 
vitamin D versus 70.5% in placebo groups). All baseline characteristics were evenly 
distributed between vitamin D and placebo groups and the slight differences were not 
statistically significant. 
4.3 Baseline Potential Risk Factors 
The distributions of potential risk factors of pneumonia at the baseline in the two groups are 
shown in Table 8. As expected almost all risk factors were evenly distributed between 
vitamin D and placebo groups. The distribution of poverty was similar between the groups. 
In vitamin D group 10.8% of families were in the better of group compared to 10.4 % in 
placebo group. Similarly, 16.7% in vitamin D group and 15.5% in placebo groups were in 
the poorest group. Similar percentages of children in both groups were malnourished 
(44.9% in vitamin D and 44.1% in placebo groups); of whom, 5.7% of children in vitamin 
D group and 5.1% in placebo group were severely malnourished (weight for age z-score) .. 
Exposure to number of cigarettes smoked inside the child's room was similar, and 57% of 
children in both groups were not exposed to any indoor cigarette smoke. Only 4.7% in 
vitamin D and 4.9% in placebo groups were exposed to more than 20 cigarettes smoked per 
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day inside the child's room. Similar number of people was sleeping in child's bed room. 
Percentage of 5 or more people sleeping in child's bedroom in vitamin D group was 41.1% 
in comparison to 39.5% in placebo group. Almost 60% of children in both groups were 
currently breastfed. In vitamin D group 47.8% of children were exposed to high indoor air 
pollution compared to that of placebo (48.9%). 
4.4 Characteristics of children in comparison to episode of pneumonia 
Overall, 82% of the study population (2496 children) did not get any episode of pneumonia 
during the 18 months of study follow up. Those who got only a single episode of 
pneumonia composed 13% of the population (395 children), and only 5% of the study 
population (155 children) got multiple episodes of pneumonia (two or more episodes) 
(Table 9). Number of children with first or only episode of pneumonia was higher in 
placebo group, while more children in vitamin D group got multiple episodes of pneumonia 
(Figure 8 and Table 1 0). 
Among children who had 2:2 episodes of pneumonia the proportion of 9-12 month old 
children was higher than that among children who had no episodes of pneumonia or just 
one episode of pneumonia. (44.5% vs. 27%). Similarly, nearly quarter of children (23.9%) 
having 2:2 episodes of pneumonia were from the poorest socio-economic quintile while the 
proportion of children in the poorest quintile was relatively lower among those who had no 
episodes of pneumonia (15.3%) but these differences were not statistically significant. The 
proportion of children exposed to high indoor air pollution was higher among those who 
had no episodes of pneumonia (43.4%) or one episode of pneumonia (44.3%) while this 
was lower among children who had 2:2 episodes of pneumonia (38.1 %). 2: 5 people sleeping 
in the same room as the child was higher among the children who had 2:2 episodes of 
pneumonia (50.9%) compared to that among children who had no pneumonia (39.3%). 
Father's lack of formal education was lower (27.6%) in children who did not get any 
episode of pneumonia compared to that for children who got a single episode of 
pneumonia(34.4%) and those who got two or more episodes of pneumonia(40%). The 
percentage of children who had vitamin D was higher in children who had two or more 
episodes of pneumonia (58.1 %) compared with those who had a single episode of 
pneumonia (47.3%) or did not have an episode of pneumonia (49.9%) (Table9). 
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After adjusting for background characteristics that were statistically significant in 
unadjusted model, child's age, indoor air pollution and vitamin D were the only predictors 
of multiple episodes of x-ray confirmed pneumonia. Age 9-12 months at enrolment was a 
strong predictor of multiple episodes of pneumonia (adjusted OR 3.4; 95%CI: 1.4 - 7.9, 
p=0.03) compared to children with no episodes of pneumonia (Table 1 0). Children exposed 
to medium or high indoor air pollution appear to be protected from multiple episodes of 
pneumonia compared to children exposed low air pollution (Table 1 0) The exposure to 
vitamin D is a predictor of multiple episodes of pneumonia compared to those who were 
exposed to placebo (OR 1. 7; 95% CI 1.1 - 2.8). 
The incidence rate of x-ray confirmed pneumoma was highest in winter, followed by 
spring, autumn and summer seasons (Figure 9). The incidence was higher in vitamin 0 
group compared to that in the placebo group in winter, spring and autumn seasons. The 
incidence in summer was almost the same for both groups (Figure 8). 
4.5 Primary Endpoint 
The incidence rate of first or only episode of x-ray confirmed all severe and non-severe 
pneumonia in vitamin D group was 0.145 per child year (95% CI: 0.129- 0.164), and in 
the placebo group was 0.137 per child year (95% CI: 0.121 - 0.155). The incidence rate 
ratio was 1.06 (95% CI: 0.89- 1.27; p=0.47) (Table 11 ). 
The incidence rate of first or only episode of x-ray confirmed severe pneumonia in vitamin 
D and placebo groups were almost the same 0.02 per child per year (95% CI: 0.01 - 0.03). 
The incidence rate ratio was 1.1(95% CI: 0.73- 1.72, p= 0.58). The incidence rate of first 
or only episode of x-ray confirmed very severe diseases including very severe pneumonia 
in vitamin D group was 0.006 per child year (95% CI: 0.003 - 0.011) and 0.004 per child 
year (95% CI: 0.002 - 0.008) in the placebo group. The incidence rate ratio was 
1.45(95%CI: 0.61- 3.39, p= 0.39). (Tablell). 
The survival graph (Figure 1 0) of time to the first or only episodes of x-ray confirmed 
severe and non-severe pneumonia shows that children in both vitamin D and Placebo 
groups had almost similar probability of survival without an episode of pneumonia. The 
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incidence rate ratios together with confidence limits for primary end points are graphically 
presented in Figure 12. 
The test for non proportional hazards was not significant with p>0.05. 
4.6 Secondary Endpoints 
4.6.1 Repeat Episodes ofX·Ray Confirmed Pneumonia 
The incidence rate of repeat episodes of x-ray confirmed severe and non-severe pneumonia 
in vitamin D group was 0.07 per child year (95% CI: 0.06 - 0.08) compared to 0.04 per 
child year (95% CI: 0.03 - 0.05) in the placebo group. The incidence rate ratio was 1.68 
(95% CI: 1.28- 2.21; p <0.001) (Table 12). The incidence rate of repeat x-ray confirmed 
sever pneumonia was 0.004 per child year (95% CI: 0.002- 0.009) compared to 0.003 per 
child year (95% CI: 0.001 - 0.007) in placebo group. The incidence rate ratio was 1.25 (95 
CI: 0.49 - 3.17; p=0.63). There were not repeat episodes of very severe diseases in both 
groups (Table 12). The incidence rate ratios together with confidence limits for repeat 
episode of severe and non-severe x-ray confirmed pneumonia are graphically presented in 
Figure 13. 
4.6.2 First or only Episode of clinical Pneumonia 
The incidence rate of first or only episode of severe and non-severe clinical pneumonia in 
vitamin D group was 1.38 per child per year (95% CI: 1.30- 1.47) compared to 1.46 per 
child per year (95% CI: 1.37 - 1.55) in placebo group. The incidence rate ratio was 0.95 
(95% CI: 0.87- 1.03; p=0.27). The incidence rate of first or only episode of severe clinical 
pneumonia in vitamin D group was 0.08 per child per year (95% CI: 0.07 - 0.1 0) which 
was similar in placebo group 0.08 per child per year (95% CI: 0.07- 0.09). The incidence 
rate ratio was 1.08 (95% CI: 0.86 - 1.35; p= 0.49). The incidence rate of first or only 
episode of clinical very severe diseases in vitamin D group was 0.08 per child per year 
(95% CI: 0.07- 0.09) which was comparable to that in the placebo group 0.09 per child per 
year(95% CI: 0.07 - 0.1 0). The incidence rate ratio was 0.90 (95% CI: 0.72 - 1.12; p= 
0.36) (Table 11 ). The incidence rate ratios together with confidence limits for first or only 
severe and non-severe clinical pneumonia are graphically presented in Figure 14. 
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4.6.3 Repeat Episodes of Clinical Pneumonia 
The incidence rate of repeat episodes severe and non-severe clinical pneumonia in vitamin 
D group was 1.15 per child per year (95% CI: 1.11 - 1.19) compared to 1.08 per child per 
year (95% Cl: 1.04 - 1.13) in the placebo group. The incidence rate ratio was 1.06 (95% 
Cl: 1.00- 1.12; p=.04) (Table 12). The incidence rate of repeat severe clinical pneumonia 
in vitamin D group was 0.02 per child per year (95% CI: 0.01 - 0.03) compared to 0.03 
(95% CI: 0.02- 0.04) in placebo group. The incidence rate ratio was 0.92 (95% Cl: 0.63 -
1.35; p=0.68). The incidence rate of repeat clinical very severe diseases in vitamin D and 
placebo groups was almost the same 0.02 per child per year (95% CI: 0.01 - 0.03). The 
incidence rate ratio was 1.12 (95% CI: 0.72- 1.74; p= 0.59) (table 12). The incidence rate 
ratios together with confidence limits for repeat episode of severe and non-severe clinical 
pneumonia are graphically presented in Figure 15. 
4.6.4 All Episodes of X-ray confirmed Pneumonia 
The incidence rate of all episodes of x-ray confirmed severe and non-severe pneumonia in 
vitamin D group was 0.195 per child year (95% CI: 0.177 - 0.216) and in the placebo 
group was 0.161 per child year (95% CI: 0.144 - 0.179). The incidence rate ratio was 1.22 
(95% CI: 1.05 - 1.41; p=0.008) (Table 13). The incidence rate of all episodes of x-ray 
confirmed severe pneumonia in vitamin D was 0.027 per child year (95% CI: 0.021 -
0.036) and in the placebo groups was 0.023 per child per year (95% CI: 0.017 - 0.031 ). 
The incidence rate ratio was 1.17 (95% CI: 0.79- 1.72, p= 0.42). The incidence rate of all 
episodes of x-ray confirmed very severe diseases including very severe pneumonia in 
vitamin D group was 0.006 per child year (95% CI: 0.003- 0.011) and 0.004 per child year 
(95% CI: 0.002- 0.008) in the placebo group. The incidence rate ratio was 1.44 (95%CI: 
0.61 - 3.39, p= 0.39). (Table 13). 
4.6.5 All Episodes of Clinical Pneumonia 
The incidence rate of all episodes of clinical severe and non-severe pneumonia in vitamin D 
group was 1.656 per child year (95% CI: 1.601 - 1.713) and in the placebo group was 
1.594 per child year (95% CI: 1.540 - 1.650). The incidence rate ratio was 1.04 (95% CI: 
0.99 - 1.09; p=0.11) (Table13). The incidence rate of all episodes of clinical severe 
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pneumonia in vitamin D group was 0.103 per child year (95% CI: 0.090 - 0.118) and in 
placebo groups was 0.100 per child per year (95% CI: 0.087- 0.115). The incidence rate 
ratio was 1.03 (95% CI: 0.85- 1.25, p= 0.73). The incidence rate of all episodes of clinical 
very severe diseases including very severe pneumonia in vitamin D group was 0.095 per 
child year (95% CI: 0.083- 0.11 0) and 0.101 per child year (95% CI: 0.088- 0.116) in the 
placebo group. The incidence rate ratio was 0.94 (95% CI: 0. 77 - 1.15, p= 0.57). 
(Tablel3). 
4.6.6 Time to repeat episodes of pneumonia after vitamin DfPlacebo administration 
To determine whether a higher rate of repeat x-ray confirmed pneumonia in vitamin D 
compared to placebo group was due to recent vitamin D supplementation and a high serum 
vitamin D, we measured the mean time (number of days) to repeat episodes of x-ray 
confirmed pneumonia after the most recent dose of vitamin D or placebo. The mean 
number of days to a repeat episode of pneumonia post vitamin D was 63.5 (95% CI: 47.2-
79.8) and that in the placebo groups was 67.1 (95% CI: 44.5 - 89. 7). The difference in 
mean number of days was not statistically significant between the two groups (P-value = 
0.39) (Table 14). 
4.6. 7 All Cause and Pneumonia specific Mortality 
By end of project's implementation in May 2009, 17 children had died due to different 
causes. Of those, 10 cases were from vitamin D and 7 cases were from Placebo groups. The 
mortality rate in the study cohort was 4.2 (95% CI: 2.4 - 6.7) 11000 child year with 4.9 
(95% CI: 2.4- 9.1) /1000 child years in vitamin D and 3.4(95% CI: 1.3 -7.1) /1000 child 
years in placebo groups. The mortality rate ratio was 1.42 (95% Cl: 0.49 - 4.41; p=0.24). 
The difference in the all cause mortality rate between the two groups was not statistically 
significant. However the study was not powered enough to detect an effect of vitamin D on 
reducing mortality. Three children in vitamin D group and 2 children in placebo group died 
due to pneumonia associated with other health problems. Two cases from vitamin D group 
and 2 cases from Placebo died due to some other bacterial conditions such as bacterial 
meningitis and septicemia. The rest of death cases in both groups happened either due to 
chronic non-infectious reasons or due to accidental causes. Of these, 2 children died due to 
head trauma (TV fallen on child), one child was chocked by pill, two children died from 
possible congenital heart disease and neonatal jaundice respectively, one child was 
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suffocated by mattress while sleeping, and another child died due to neuroblastoma. The 
detailed causes of mortality derived from verbal autopsy are shown in Table 17. 
4:6.8 Hospitalization for any diseases 
The incidence rate of first or only episode of hospital admission in vitamin D group was 
0.07 per child per year (95% CI: 0.06- 0.08) which was the same for placebo group. The 
incidence rate ratio was 1.00 (95% CI: 0. 79- 1.27, p= 0.99). The incidence rate of repeat 
hospital admission for vitamin D group was 0.02 per child per year (95% CI: 0.01 - 0.03) 
and almost the same for placebo group {0.03(95% CI: 0.02 - 0.04)}. The incidence rate 
ratio was 0.79 (95% CI: 0.53 - 1.19, p= 0.26) (Table 18). The probability of survival 
without an episode of hospital admission was similar between the two groups (Figure 11 ), 
and the test for non proportional hazards was not significant (p>0.05). 
The mean number of days of hospitalization for various illness was 0. 7 (95% CI: 0.4- 1.0) 
compared to 0.8(95% CI: 0.5 - 1.1) in placebo group (Table 19). Almost 80% of children in 
both groups hospitalized for different illnesses were discharged in within a day. Number of 
hospitalization days ranged from 0 - 10 days in vitamin D group (SD=l.9) compared to 0 -
7 days (SD=1.8) in placebo group. Almost 4% of children in vitamin D group and 5% in 
placebo group were hospitalized for severe pneumonia (IMCI criteria). Febrile convulsion 
caused 1.8% of hospitalization in vitamin D group and 1.7% in placebo group. Equal 
number of children from both groups ( 15 children from each group) was hospitalized for 
bronchiolitis. Bronchial asthma caused 0.7% of admissions in vitamin D group and 0.8% of 
that in placebo group. Finally, admission for Urinary Tract Infection (UTI) was 1.1% in 
vitamin D group and 1.4% in placebo group. The causes for hospitalization are summarized 
in Table 19. 
4. 7 Per protocol analysis based on initial protocol: 
Majority of study children (97%) entered the per protocol analysis using the initial protocol 
criteria discussed in section 3.23.4. Of those, 49.9% were from the vitamin D group and 
50.1% from the placebo group. 
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The results from per protocol analysis of x-ray confirmed and clinical severe and non-
severe pneumonia using the initial protocol are not very different from those of intention to 
treat analysis: 
4. 7.1 First or only Episode of X-Ray confirmed Pneumonia 
The incidence rate of first or only episode of x-ray confirmed all severe and non-severe 
pneumonia in vitamin D group was 0.14 per child year (95% CI: 0.12- 0.16), compared to 
0.13 per child year (95% CI: 0.12- 0.15) in the placebo group. The incidence rate ratio was 
1.06 (95% CI: 0.88 - 1.27; p=0.54). (Table 19). The incidence rate of first or only episode 
of x-ray confirmed severe pneumonia in vitamin D group was very similar to that in 
placebo group: 0.024 per child year (95% CI: 0.018- 0.033) in vitamin D group versus 
0.028 per child year (95% CI: 0.014- 0.028) in the placebo group. The incidence rate ratio 
was 1.23 (95% CI: 0.79- 1.91; p=0.35). The incidence rate of first or only episode of x-ray 
confirmed very severe diseases including very severe pneumonia in vitamin D group was 
0.006 per child year (95% CI: 0.003 - 0.0 12) compared to 0.005 per child year (95% CI: 
0.002- 0.009) in the placebo group. The incidence rate ratio was 1.33 (95%CI: 0.56- 3.17; 
p= 0.51) (Table 20). 
4.7.2 Repeat Episodes of X-Ray Confirmed Pneumonia 
The incidence rate of repeat episodes of x-ray confirmed severe and non-severe pneumonia 
in vitamin D group was 0.07 per child year (95% CI: 0.06 - 0.08) compared to 0.04 per 
child year (95% CI: 0.03 - 0.05) in the placebo group. The incidence rate ratio was 1.69 
(95% CI: 1.27- 2.25; p <0.001) (Table 20). The incidence rate of repeat x-ray confirmed 
severe pneumonia in vitamin D group was 0.005 per child year (95% CI: 0.003- 0.010) 
compared to 0.003 per child year (95% CI: 0.001 - 0.007) in the placebo group. The 
incidence rate ratio was 1.67 (95% CI: 0.61 - 4.59; p=0.31) (Table 21 ). 
4. 7.3 First or only Episode of clinical Pneumonia 
The incidence rate of first or only episode of severe and non-severe clinical pneumonia in 
vitamin D group was 1.01 per child year (95% CI: 0.94- 1.07) compared to 1.03 per child 
year (95% CI: 0.96 - 1.09) in the placebo group. The incidence rate ratio was 0.98 (95% 
CI: 0.89 - 1.07; p=0.68). The incidence rate of first or only episode of severe clinical 
pneumonia in vitamin D group was 0.09 per child year (95% CI: 0.07 - 0.1 0) which was 
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similar in placebo group 0.08 per child year (95% CI: 0.07- 0.09). The incidence rate ratio 
was 1.11 (95% CI: 0.88 - 1.40; p= 0.38). The incidence rate of first or only episode of 
clinical very severe diseases in vitamin D group was 0.08 per child year (95% CI: 0.06 -
0.09) compared to 0.09 per child year (95% CI: 0.07 - 0.11) in the placebo group. The 
incidence rate ratio was 0.86 (95% CI: 0.68- 1.08; p=0.21) (Table 20). 
4. 7.4 Repeat Episodes of Clinical Pneumonia 
The incidence rate of repeat episodes severe and non-severe clinical pneumonia in vitamin 
D group was 1.17 per child year (95% CI: 1.12 - 1.22) compared to 1.08 per child year 
(95% CI: 1.04 - 1.13) in the placebo group. The incidence rate ratio was 1.08 (95 CI: 1.01 
- 1.14; p=0.02 (Table 20). The incidence rate of repeat severe clinical pneumonia in 
vitamin D group was 0.024 per child year (95% CI: 0.017- 0.032) compared to 0.023 per 
child year (95% CI: 0.017 - 0.031) in placebo group. The incidence rate ratio was 1.04 
(95% CI: 0.68- 1.59; p=0.84). The incidence rate of repeat clinical very severe diseases in 
vitamin D group was 0.022 per child year (95% CI: 0.016 - 0.030) which was similar to 
that in the placebo group 0.020 per child year (95% Cl: 0.014- 0.028). The incidence rate 
ratio was 1.10 (95% CI: 0.71- 1.72; p=0.66) (Table 21). 
4.8 Per protocol analysis with at least 4 consecutive doses of vitamin D/placebo 
Assuming 4 consecutive quarterly doses of drug would cover all 4 season during a year, we 
restrict the analysis for children who received at least 4 consecutive doses of vitamin D or 
placebo in the right time. Using this criteria, 69% of the study cohort entered the per 
protocol analysis (2111 children). Of those, 50.3% was from vitamin D group and 49.7% 
from placebo group. 
The results from this analysis for x-ray confirmed severe and non-severe pneumonia were 
very similar to that using the initial protocol presented earlier, while the results for clinical 
pneumonia were slightly different in two. The results are described below: 
4.8.1 First or only Episode of X-Ray confirmed Pneumonia 
The incidence rate of first or only episode of x-ray confirmed all severe and non-severe 
pneumoma in vitamin D group was 0.14 per child year (95% CI: 0.13- 0.18), compared to 
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0.13 per child year (95% CI: 0.11- 0.15) in the placebo group. The incidence rate ratio was 
1.12 (95% CI: 0.91-1.37; p=0.26). (Table21). The incidence rate offirst or only episode 
of x-ray confirmed severe pneumonia in vitamin D group was 0.025 per child year (95% 
Cl: 0.018- 0.035) in vitamin D group versus 0.019 per child year (95% CI: 0.013- 0.028) 
in the placebo group. The incidence rate ratio was 1.29 (95% CI: 0.80-2.11; p=0.28). The 
incidence rate of first or only episode of x-ray confirmed very severe diseases including 
very severe pneumonia in vitamin D group was 0.006 per child year (95% CI: 0.003 -
0.112) compared to 0.005 per child year (95% CI: 0.003- 0.011) in the placebo group. The 
incidence rate ratio was 1.23 (95%CI: 0.49- 3.12; p= 0.65) (Table 22). 
4.8.2 Repeat Episodes of X-Ray Confirmed Pneumonia 
The incidence rate of repeat episodes of x-ray confirmed severe and non-severe pneumonia 
in vitamin D group was 0.07 per child year (95% CI: 0.06 - 0.09) compared to 0.04 per 
child year (95% CI: 0.03 - 0.05) in the placebo group. The incidence rate ratio was 1. 75 
(95% Cl: 1.29- 2.39; p <0.001) (Table 22). The incidence rate of repeat x-ray confirmed 
severe pneumonia in vitamin D group was 0.006 per child year (95% Cl: 0.003 - 0.012) 
compared to 0.002 per child year (95% CI: 0.001 - 0.006) in the placebo group. The 
incidence rate ratio was 3.29 (95% CI: 0.91 - 11.96; p=0.07) (Table 23). 
4.8.3 First or only Episode of clinical Pneumonia 
The incidence rate of first or only episode of severe and non-severe clinical pneumonia in 
vitamin D group was 1.39 per child year (95% CI: 1.29- 1.49) compared to 1.51 per child 
year (95% CI: 1.40 - 1.62) in the placebo group. The incidence rate ratio was 0.93 (95% 
CI: 0.84 - 1.03; p=0.19). The incidence rate of first or only episode of severe clinical 
pneumonia in vitamin D group was 0.09 per child year (95% CI: 0.08- 0.11) compared to 
0.07 per child year (95% CI: 0.05- 0.08) in the placebo group. The incidence rate ratio was 
1.31 (95% CI: 1.01 -1.71; p= 0.04). The incidence rate of first or only episode of clinical 
very severe diseases in vitamin D group was 0.07 per child year (95% CI: 0.05 - 0.08) 
compared to 0.09 per child year (95% CI: 0.08- 0.11) in the placebo group. The incidence 
rate ratio was 0. 74 (95% CI: 0.57- 0.95; p=0.02) (Table 22). 
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4.8.4 Repeat Episodes of Clinical Pneumonia 
The incidence rate of repeat episodes severe and non-severe clinical pneumonia in vitamin 
D group was 1.18 per child year (95% CI: 1.12 - 1.23) compared to 1.11 per child year 
(95% CI: 1.05 - 1.16) in the placebo group. The incidence rate ratio was 1.06 (95% CI: 
0.99 - 1.14; p=0.07 (Table 22). The incidence rate of repeat severe clinical pneumonia in 
vitamin D group was 0.03 per child year (95% CI: 0.02- 0.04) compared to 0.02 per child 
year (95% CI: 0.01 - 0.03) in placebo group. The incidence rate ratio was 1.30 (95% CI: 
0.82- 2.08; p=0.23). The incidence rate of repeat clinical very severe diseases in vitamin D 
group was 0.022 per child year (95% CI: 0.016 - 0.031) which was very similar to that in 
the placebo group 0.023 per child year (95% CI: 0.016 - 0.031 ). The incidence rate ratio 
was 0.99 (95% Cl: 0.61 - 1.59; p=0.96) (Table 23). 
4.9 Per protocol analysis with at least 5 consecutive doses ofvitamin D/placebo 
None of study children had received all 6 consecutive doses of vitamin D/placebo in the 
right time. The maximum number of consecutive doses received in the right time was five. 
Restricting the analysis for this sub group, 64% of the study cohort entered the per protocol 
analysis under above criteria (1971 children). Of those, 50.2% was from vitamin D group 
and 49.8% from placebo group. 
The results from this analysis were very similar to that from the analysis restricted to 
children who received at least 4 consecutive dose of vitamin D/placebo in the right time. 
4. 9.1 First or only Episode of X-Ray confirmed Pneumonia 
The incidence rate of first or only episode of x-ray confirmed all severe and non-severe 
pneumonia in vitamin D group was 0.14 per child year (95% CI: 0.12- 0.16), compared to 
0.13 per child year (95% CI: 0.11 - 0.15) in the placebo group. The incidence rate ratio was 
1.06 (95% CI: 0.85 - 1.31; p=0.61 ). (Table23). The incidence rate of first or only episode 
of x-ray confirmed severe pneumonia in vitamin D group was 0.03 per child year (95% CI: 
0.02- 0.04) in vitamin D group versus 0.02 per child year (95% CI: 0.01 - 0.04) in the 
placebo group. The incidence rate ratio was 1.32 (95% CI: 0.81 - 2.16; p=0.26). The 
incidence rate of first or only episode of x-ray confirmed very severe diseases including 
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very severe pneumonia in vitamin D group was 0.005 per child year (95% CI: 0.002 -
0.01 0) compared to 0.006 per child year (95% CI: 0.003- 0.011) in the placebo group. The 
incidence rate ratio was 0.87 (95% CI: 0.31- 2.39; p= 0.78) (Table 24). 
4. 9.2 Repeat Episodes of X-Ray Confirmed Pneumonia 
The incidence rate of repeat episodes of x-ray confirmed severe and non-severe pneumonia 
in vitamin D group was 0.07 per child year (95% CI: 0.06 - 0.09) compared to 0.04 per 
child year (95% CI: 0.03 - 0.05) in the placebo group. The incidence rate ratio was 1.75 
(95% CI: 1.26- 2.39; p <0.00 1) (Table 24). The incidence rate of repeat x-ray confirmed 
severe pneumonia in vitamin D group was 0.007 per child year (95% CI: 0.004 - 0.0 13) 
compared to 0.002 per child year (95% CI: 0.001 - 0.006) in the placebo group. The 
incidence rate ratio was 3.31 (95% CI: 0.91- 12.03; p=0.06) (Table 25). 
4. 9.3 First or only Episode of clinical Pneumonia 
The incidence rate of first or only episode of severe and non-severe clinical pneumonia in 
vitamin D group was 1.39 per child year (95% CI: 1.29- 1.49) compared to 1.51 per child 
year (95% CI: 1.41 - 1.63) in the placebo group. The incidence rate ratio was 0.93 (95% 
CI: 0.84 - 1.03; p=0.17). The incidence rate of first or only episode of severe clinical 
pneumonia in vitamin D group was 0.09 per child year (95% CI: 0.08 - 0.11) compared to 
0.07 per child year (95% CI: 0.05- 0.09) in the placebo group. The incidence rate ratio was 
1.32 (95% CI: 1.01 - 1.74; p= 0.04). The incidence rate of first or only episode of clinical 
very severe diseases in vitamin D group was 0.07 per child year (95% CI: 0.05 - 0.08) 
compared to 0.09 per child year (95% CI: 0.08- 0.11) in the placebo group. The incidence 
rate ratio was 0.70 (95% CI: 0.54- 0.93; p=0.01) (Table 24). 
4. 9.4 Repeat Episodes of Clinical Pneumonia 
The incidence rate of repeat episodes severe and non-severe clinical pneumonia in vitamin 
D group was 1.17 per child year (95% CI: 1.11 - 1.22) compared to 1.10 per child year 
(95% CI: 1.05 - 1.16) in the placebo group. The incidence rate ratio was 1.06 (95% CI: 
0.99- 1.13; p=0.1 0 (Table 24). The incidence rate of repeat severe clinical pneumonia in 
vitamin D group was 0.03 per child year (95% CI: 0.02- 0.04) compared to 0.02 per child 
year (95% CI: 0.01 - 0.03) in placebo group. The incidence rate ratio was 1.29 (95% CI: 
0.80- 2.1 0; p=0.29). The incidence rate of repeat clinical very severe diseases in vitamin D 
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group was 0.023 per child year (95% CI: 0.016 - 0.032) which was very similar to that in 
the placebo group 0.024 per child year (95% CI: 0.016- 0.032). The incidence rate ratio 
was 0.99 (95% CI: 0.61 - 1.61; p=0.98) (Table 25). 
4.10 Effect of risk factors on the incidence of pneumonia 
The univariate analysis showed a statistically significant association of first or only episode 
of x-ray confirmed severe and non-severe pneumonia with child's age, indoor air pollution, 
family crowding, and father's education (Table 26). After adjusting for all risk factors, 
child's age and indoor air pollution were strongly associated with first or only episode of x-
ray confirmed severe and non-severe pneumonia. The incidence of pneumonia was higher 
in 6-12 month old infants compared to that in infants <2 months of age (RR=l.73; 95% CI: 
1.04 - 2.89; p=0.04). The incidence rate ratio of pneumonia in children exposed to high 
indoor air pollution was lower compared to children exposed to low indoor air pollution 
(RR=0.80; 95% CI: 0.62- 1.04, p=0.003) (Table 26). 
The univariate analysis showed that child's age, economic status, indoor air pollution, 
nutritional status, mother's any formal education, father's any formal education and vitamin 
D were potential risk factors for the incidence of repeat episodes of x-ray confirmed severe 
and non-severe pneumonia (Table 27). However in the multivariate analysis after adjusting 
for the effects of covariates, only father's education, vitamin D and indoor pollution were 
associated with the risk of repeat episodes of pneumonia. The incidence rate ratio in 
children exposed to high indoor air pollution was lower compared to those children who 
had low exposure to air pollution (RR=0.69; 95% CI: 0.49- 0.97, p=O.OOl). The incidence 
rate ratio for children whose fathers did not have any formal education was higher 
(RR=1.68; 95% CI: 1.21 - 2.32, p=0.002) compared to children whose fathers had some 
formal education. Surprisingly, vitamin D was found to be a significant risk factor for the 
incidence of repeat all x-ray confirmed pneumonia. The incidence rate ratio of repeat 
episodes of pneumonia in children who got vitamin D was 1.93(95% CI: 1.40 - 2.65, 
p<O.OOl) compared to children in the placebo group (Table 27). 
Indoor air pollution, family crowding and father's education showed significant association 
with the incidence rate of first or only episode of x-ray confirmed severe pneumonia. After 
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adjusting for other factors, low indoor air pollution was highly associated with incidence 
rate of first or only episode of x-ray confirmed severe pneumonia. The risk of first episode 
x-ray confirmed severe pneumonia was almost 65% lower in high pollution group 
(RR=0.37, 95% CI: 0.18- 0.73, p=0.002) compared to that in low pollution group (Table 
28). 
Univariate analysis revealed a statistically significant association between father's 
education and the risk of first or only episode of x-ray confirmed very severe diseases, 
however, this association was not significant when adjusted for the effect of the other risk 
factors (Table 30). 
4.11 Episodes of Bronchiolitis 
The overall incidence of bronchiolitis (definition given in box 1) in this study was 0.10 per 
child year (95%CI: 0.09- 0.12). The incidence in vitamin D group was 0.116 per child year 
(95%CI: 0.095- 0.114) and in the placebo group was 0.089 per child year (95%CI: 0.071 -
0.112). The incidence rate ratio was 1.28 (95% CI: 0.95 -1.72, p=0.11) (Table 32). 
The incidence of bronchiolitis was highest in the winter followed by spring, summer and 
autumn seasons respectively. The incidence was higher in vitamin D group for all seasons, 
except the summer, but these differences are not statistically significant (Figure 16). 
4.12 Effect of vitamin D supplementation on serum vitamin D level 
Of 668 blood samples drawn and sent for testing, 637 samples (334 from vitamin D and 
303 from placebo groups) were tested. The quantity of blood in the remaining samples was 
not enough for processing. Almost 90% of children in vitamin D group tested had a high 
level of serum vitamin D (50-250nmol/L) one week after the first dose of vitamin D 
administration (Table 33). Among these, one child got a very high level of serum 25(0H) D 
more than 250nmol/L. 
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Seventy one percent of children in Vitamin D group tested had a serum 25(0H) D level 
(50-250nmol/L) 2 months after administration of the first dose compared to only 17% of 
children in the placebo group with such a level. Ninety three percent of children in Vitamin 
D group tested had a serum 25(0H) D level 50-250nmol/L 2 weeks after administration of 
the third dose compared to only 53% of children in the placebo group with such a level 
(Table 33). 
The proportion of children having serum 25(0H) D levels 50-250nmol/L decreased to 42% 
three months after the administration of the first dose of vitamin D and to 51% four months 
after the administration of the 6th dose of vitamin D. However only 23% of children in the 
placebo group had serum 25(0H) D levels 50-250nmol/L three months after administration 
of the first dose (table 33). The mean level of serum 25(0H) D three months after the first 
dose was 55.5 nmol/L in vitamin D group compared to that in the placebo group which was 
39.6 nmol/L (Table 34). 
Over all, children in Vitamin D group got a higher serum concentration of 25(0H) D 
compared to that in the placebo group, particularly immediately after receiving vitamin D 
supplements. Number of children with severe and moderate vitamin D deficiency was 
higher in placebo group compared to that in vitamin D group. Of 303 children in control 
group, 17.5 % had severe vitamin D deficiency {25(0H) D <20nmol/L}, 49.8% had 
vitamin D insufficiency {25(0H) D 20-<50 nmol/L}, and 32.3% had a normal level of 
vitamin D {25(0H) D 2:50nmol/L}. Only 2 out of 334 children in vitamin D group (0.6%) 
had a very high serum 25(0H) D (>250nmol/L) considered undesirable. 
Figrue 17 shows the mean level of serum 25(0H) D in different seasons in a sample of 
study children. Almost in all seasons the mean serum 25(0H) D level was higher in vitamin 
D group compared to that in placebo group. The placebo group had the lowest serum 25 
(OH) D levels during the winter followed by autumn season. Interestingly, the mean level 
of 25(0H) D was not that different in summer between the two groups (Figure 17). 
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CHAPTER 5: DISCUSSION 
5.1 Primary and secondary end points 
Despite some previous evidence of an association between low serum vitamin D level and 
pneumonia in children, this study found no effect of vitamin D on decreasing incidence of 
first or only episode of x-ray confirmed severe and non-severe pneumonia {RR=1.06, 95% 
CI: 0.89- 1.27, p= 0.47). Surprisingly, the incidence rate of repeat x-ray confirmed severe 
and non-severe pneumonia was higher in the vitamin D group compared to that in placebo 
group (RR=l.68, 95% CI: 1.28- 2.21; p <0.001 ). Similarly, the incidence rate of all x-ray 
confirmed severe and non-severe pneumonia was also higher in the vitamin D group 
compared to that in the placebo group (RR=l.22, 95% CI: 1.05 - 1.41; p=0.008). These 
results from intention to treat analysis are consistent with those in all 3 types of per 
protocol analysis. These findings are at odds to the observations in two case-control studies 
in India and Ethiopia, where children with low vitamin D level had higher rate of 
pneumonia compared to those with normal level of vitamin D(14), (15). However, lower 
sample sizes, difference in study design, and role of other possible confounder factors in 
those two case-control studies could be the possible reasons for the inconsistency between 
the previous case control studies and our randomized controlled trial. 
The incidence rates of repeat episodes of both x-ray confirmed or unconfirmed severe and 
non-severe clinical pneumonia in vitamin D group were higher compared to that in the 
placebo group in intention to treat analysis. However, in the per protocol analyses of those 
who received at least 4 or 5 consecutive doses of the drug in the right time, the higher risk 
of repeat clinical pneumonia in the vitamin D group was not statistically significant. 
Nonetheless, the finding in intention to treat analysis is in contrary to results of a study of 
vitamin D supplementation along with antibiotics for children admitted with pneumonia in 
a hospital in Kabul. In that hospital based randomized controlled trial, vitamin D 
significantly reduced the incidence rate of repeat episodes of clinical pneumonia in children 
in the vitamin D group compared to the placebo group (RR= 0.78; 95% CI: 0.64- 0.94, 
p=O.Ol) (87). However, the sample size in that study was much lower(456 children) and 
blood samples were not collected to check if the intervention group really had a higher 
serum vitamin D level and whether the effect was due to vitamin D. Nevertheless, the 
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higher incidence of repeat episodes of pneumonia, and as a result, the incidence of all x-ray 
confirmed severe and non-severe pneumonia in the vitamin D supplemented group does not 
seem plausible given that repeat episodes of pneumonia were reduced by vitamin D 
supplementation to children with pneumonia in a population with similar socio-biological 
characteristics. It is important to consider whether regular vitamin D supplementation 
reduced immunity and there by increased incidence of pneumonia. However since the 
incidence of first episode pneumonia did not differ between the vitamin D and placebo 
groups in this trial, higher rates of repeat pneumonia could not be explained by this 
phenomenon. Moreover, the mean number of days to repeat episodes of pneumonia after 
the latest vitamin D/placebo dose was similar between the two groups which is inconsistent 
with the notion that a high level of vitamin D increased the risk of repeat episodes of 
pneumonia in supplemented group (Table 14 ). 
Among the study children only 13 % (395 children) had only one episode of pneumonia 
and 5% ( 155 children) had~ 2 episodes of pneumonia while the remaining 82% of children 
had no episodes of pneumonia at all. The first or repeat episodes of pneumonia do not 
seem to be due to clustering, or being developed by a specific group of children. In line 
with main risk factors for repeat episode of pneumonia, child's age (older age at 
enrollment) and vitamin D exposure were the main predictors for children with multiple 
episodes of x-ray confirmed pneumonia. Exposure to vitamin D as a risk factor for repeat 
episodes of pneumonia needs more investigation for a plausible explanation. Additionally, 
exposure to high pollution was a protective predictor for children with multiple episodes of 
x-ray confirmed pneumonia, which was found in the analysis of risk factors for pneumonia 
as well. Using heating devices with proper chimneys (Figure 18) during the winter 
producing good heating with minimal smoke could be the most plausible explanation for 
this finding. Though it shows we did not use an appropriate tool to measure indoor air 
pollution in this study, this finding is of more value in Afghanistan context, where people 
cannot afford expensive heating devices or central heating system which costs much more. 
Due to the lack of repetitive records of cases with possible chronic cough (cough for more 
than 30 days), data for chronic lower respiratory infections, particularly pulmonary 
tuberculosis, could not be presented, which could have been an interesting finding, or might 
have changed definition of our repeat episodes of pneumonia. 
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Residual confounders, particularly, outdoor air pollution common in Kabul city, might 
affect study's outcomes. However all other risk factors of pneumonia were evenly 
distributed between two arms and the study had a large sample size. Thus the effect of 
residual confounders is unlikely to be the reason for this unexpected finding. 
The compliance rate was satisfactory and loss to follow up due to migration, refusal or 
death was not remarkable to affect study's power. The study outcomes were measured by 
experienced pediatricians, and the primary end point was confirmed by experienced 
radiologists using WHO standards for defining pneumonia. Despite adhering to WHO 
protocol for defining X- ray confirmed pneumonia used in vaccine trials, it could be 
debated whether our definition is specific enough to ascertain pneumonia, particularly 
because detecting childhood pneumonia is not easy by chest radiographs in the early stages 
of the disease. Misclassification of pneumonia by radiographs cannot be ruled out. 
However since the radiologists who read the X-rays were blind to the study groups, 
therefore, any misclassification is likely to be distributed equally between the two groups. 
If this type of misclassification had occurred, the power of our study would have reduced. 
Nevertheless since the incidence rate of first episode of pneumonia using any definition is 
so similar between the two groups, any reduction in the power of the study would have no 
influence on our conclusion. 
The estimates of serum 25 (OH) D in a random sample of children showed that vitamin D 
supplementation had indeed raised the level of serum 25(0H) D in intervention group after 
first and third doses. Therefore, lack of protection against pneumonia is not likely to be due 
to insufficient supplementation or misclassification of exposure status. Because the trial 
had a large cohort, and both families and study team were blind on exposure status of study 
subjects, misclassification of any other causes of raised respiratory rate, such as 
bronchiolitis, as well as, under/over reporting of outcome would be evenly distributed 
between the two arms. 
The incidence rate of first or only episode of x-ray confirmed severe and non-severe 
pneumonia in placebo group (IR=0.137 per child year, 95% CI: 0.121- 0.155) was much 
higher than that of among 6-51 weeks Gambian children (IR=0.04 per child-year, 95% CI: 
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0.037- 0.043) (1). The incidence rate of first or only episode of clinical severe and non-
severe pneumonia in the placebo group{ 1.46 (95% CI: 1.37- 1.55)} was also higher than 
the incidence of all clinical pneumonia among unvaccinated Gambian children in Gambian 
pneumococcal vaccine trial ( IR=0.287 per child-year, 95% CI: 0.277 - 0.298), compared 
to children 2-35 months in Himalayan parts of Pakistan where the annual incidence rate of 
all clinical pneumonia was 0.30 per child-years, and in comparison to overall incidence of 
pneumonia among under-5 children in south-east Asia (IR=0.36 per child-year) (35), (1) , 
(8). Environmental pollution might be a possible reason why children in Kabul had a higher 
incidence of pneumonia compared to all other settings. 
Using different time periods to define repeat episodes of x-ray confirmed and clinical 
pneumonia did not affect the results. Both 15 days and 30 days gap between episodes to 
define an episode of repeat pneumonia produced similar results. The rate ratios for repeat 
episodes of severe and non-severe x-ray confirmed and clinical pneumonia were almost the 
same in both scenarios. 
The incidence of x-ray confirmed pneumonia was highest during the winter followed by 
spring season (Figure 9). Though vitamin D deficiency was also high during the winter, the 
serum vitamin D level was higher in intervention group compared to the placebo group 
during the spring (Figure 17). Overall, children in placebo group had a desirable serum 
vitamin D level during the spring and summer seasons, compared to that in winter and 
autumn, which possibly indicates the role of sun light in producing vitamin D. A higher 
incidence of pneumonia during the winter and spring is also very typical of countries with 
cold climate such as Afghanistan. 
The rate of hospital admissions was not different between vitamin D and placebo groups. 
Both first and repeat episodes presented similar rates indicating vitamin D does not reduce 
not only the risk of pneumonia, but also the risk of other hospital admitted cases such as 
diarrhea, febrile convulsion, urinary tract infection and other illnesses presented earlier. 
The incidence rate of bronchiolitis was not different between the two groups, showing that 
vitamin D does not reduce the risk of viral infections as well; however more evidences and 
studies are required to confirm this finding. There might be some misclassification of 
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bronchiolitis as clinical pneumonia; however, give~ that our study pediatricians were all 
experienced clinicians, it is less likely that a case with typical wheezing as a good indicator 
of bronchiolitis could have been classified as clinical pneumonia. 
The incidence of bronchiolitis was highest during the winter, followed by sprmg and 
summer seasons in both groups (Figure 16). It shows a typical seasonality of cases with 
wheezing that peaks during the cold seasons. 
Analysis of data from this study about effect of vitamin D on the incidence of first or repeat 
episode of diarrhea also did not find any significant role of vitamin D on decreasing the 
incidence of diarrhea. The overall incidence rate of diarrhea was 3.62 (95% CI: 3.46- 3.79) 
in the vitamin D group and 3.45 (95% CI: 3.30- 3.61) in the placebo group. The incidence 
rate ratio was 1.05 (95% CI: 0.99 - 1.12; p=0.13). The analysis was done based on 
intention to treat and the results for per-protocol analysis were not different from that of 
intention to treat. Approximately 80% of children admitted to the hospital for different 
illnesses were discharged in the same day. This could either be due to lower severity of 
illnesses as a result of proper referral and counseling our field and clinical staff provided 
during the visits, or because our clinical staff did not keep admitted children for longer 
period for economic and bed occupation reasons. 
Number of children died during the 18 months of the project was 17, of which, 1 0 were 
from intervention and 7 from control groups. Three children in vitamin D and 2 children in 
placebo groups died due to pneumonia-associated reasons. The number of deaths due to 
pneumonia is much lower than UNICEF best estimation attributing 23% under-5 mortality 
to pneumonia in Afghanistan and in north western of Pakistan, where the annual pneumonia 
specific mortality was estimated 14 deaths per 1000 under-5 children(3 5). 
The overall mortality rate in the study cohort was 4.17/1000 child years (4.89/1000 child 
years in vitamin D and 3.44/1000 child years in placebo groups) and the probability of 
dying in 18 months was 2.3% (23/1000 children alive at one month of age). The probability 
of death in 1-11 month old infants was 1. 83%7 . Thus mortality rate in 1-11 month old 
7 The probability of death was calculated using survival analysis in Stata. For infants 1-11 months old, the 
analysis was confined to the time children turned one month old till they turned 12 months old. 
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infants in our cohort is almost 18/1000 children alive at one month of age. The national 
infant mortality in 2009 was estimated at 121/1000 (4). Typically 50% of infant mortality 
occurs before 1 month of life (3). Thus the mortality rate nationally would be 6011000 alive 
at one month of age. It appears that the mortality rate in our study cohort is much lower 
than the expected rate nationally (at least 3 times lower). In 2008 Roberts et al (5) estimated 
the under-5 mortality rate at 0.018 per child year in the study area using a validation 
method. In this method all deaths in past 60 days were recorded from key informants and 
the mortality rate for estimated population was calculated in the area. The mortality rate 
was validated by comparing it with two independent lists of deaths using capture-recapture 
analysis method. Assuming infant mortality rate accounts for almost 70% of under-5 
mortalities, and approximately 50% of infant mortalities are due to neonatal causes, the 
mortality rate in age group similar to that in our study cohort(infants over one month at 
baseline) was roughly 0.006 (95% CI: 0.004 - 0.017) per child year. The mortality 
estimation by Roberts et al took place in the beginning of this trial in the parts constituting 
almost 60% of our trial area. Therefore, comparison of mortality rate in our control group 
with that of determined by Roberts et al could give a rough estimation of the impact the 
implementation process had on lowering mortality rate in the area. This impact could be 
explained by reasons such as appropriate two-weekly check up at households, proper 
referral to study hospital, and appropriate treatment and counseling given to families by our 
pediatricians. The impact of trials on lowering overall mortality rates has been determined 
in other studies as well. In Tanzania, during a randomized controlled trial about protective 
efficacy and safety of three anti-malarial regimens for intermittent preventive treatment of 
malaria in infants, the estimated child mortality rate among study children (8-16 weeks at 
enrolment) was found to be 75% lower than the expected child mortality based on national 
estimates. The reduction in placebo group was remarkable, with only 5 out of 32 deaths 
happened in placebo group in this study. (11 0). A cluster randomized controlled trial about 
effect of IMCI on child mortality and nutrition in Bangladesh found that the overall under-5 
mortality in intervention and non-intervention groups dropped to 49.3 and 50.0 per 1000 
live births respectively during the last 2 years of the trial compared to 70.0 and 65.6 per 
1000 live births respectively during the first 2 years of the trial ( 111 ). Thus the vast 
reduction in all cause mortality observed in our study cohort is not surprising given that the 
study children were provided the best care possible available at the time in Kabul. 
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5.2 Risk factors of pneumonia 
Analysis of risk factor for pneumonia found different results compared to results found in 
other studies. 
Previous studies detected an association between childhood pneumonia and indoor-air 
pollution, child sex, family crowding, breastfeeding and severe malnutrition (37), (38), 
(112), (42). Child's age was a risk factor for first episode of pneumonia, while number of 
children sleeping in child's bedroom, malnutrition, child sex, cigarette smoke, and mother's 
education were not significantly associated with pneumonia. Children aged 6-12 months at 
enrolment had the highest incidence rate ratio of pneumonia (RR=2.01, 95% CI: 1.12-
3.63) compared to children <6 months of age at enrolment. This finding is at odds to that 
in a cohort study of children in Pakistan where children 2-5 months had the highest 
incidence rate ratio compared to reference group aged 24-35 months old (RR=4.33, 95% 
CI: 3.53- 5.32) (35). On the other hand, the finding is in line with Gambian pneumococcal 
vaccine trial where the incidence of x-ray confirmed pneumonia was highest in children 
aged 12-17 months old (IR=46/1 000 child-years, 95% CI: 40 - 54) compared to younger 
and higher age groups(l ). The higher incidence of pneumonia in children higher than 6 
months might probably be due to the fact that in Afghanistan children get exposed to 
environment al risk factors such as outdoor air pollution and extreme cold weather once 
they start walking and play outdoors. 
In this study we did not find child's sex as a risk factor for pneumonia, while study in 
Pakistan found that the incidence rate of pneumonia for male children was higher compared 
to that in females (RR=1.14, 95% CI: 1.01 - 1.29) (35). Surprisingly the incidence of first 
episodes as well as, repeat episodes of severe and non-severe pneumonia was higher in 
children with no exposure to high indoor air pollution compared to those exposed to higher 
indoor air pollution (type of fuel used for heating and the length of time the heating device 
was on). Children exposed to no indoor air pollution had approximately 50% higher chance 
of getting first episode x-ray confirmed severe and non-severe pneumonia compared to 
group exposed to higher pollution. This finding is not in line with findings in previous 
review of literatures (112) and a study in Nepal, where number of hours per day children 
spent near fire place was highly associated with risk of acute respiratory infections (38). 
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The higher rate of pneumonia in children unexposed to indoor air pollution might be either 
due to information bias, or due to inaccurate measurement of indoor air pollution in this 
study. It could be possible that a misclassification of indoor air pollution status might have 
happened as a result of people's inappropriate reporting of their exposure status or 
improper recording of families' exposure by field data collectors. Moreover, the questions 
and the matrix used for defining and classification of indoor air pollution status might not 
be specific enough to measure the indoor air pollution status accurately. In other studies , 
the indoor air pollution have been measured differently , such as hours children spent near 
fire place (38), time children spent with their mother at cooking place (113). Similarly, the 
heating device using wood or other solid fuel in our study (Figure 18) were designed such 
that majority of smoke emitted were directed out by a pipe, permitting less/no smoke inside 
the living room. This could be another reason why using such devices, even using solid 
fuel, had protective effect for pneumonia probably due to warmth produced inside the 
rooms children lived and slept. Due to increasing outdoor air pollution in Kabul city as a 
result of growing number of population, increasing number of second hand cars, 
inappropriate sanitations system, and too much dust from unpaved streets, the higher 
incidence of pneumonia could be due to exposure to outdoor air pollution rather than indoor 
air pollution, which needs further investigation. 
Father's education was found to have a protective effect against the incidence of repeat x-
ray confirmed severe and non-severe pneumonia. The role of maternal education on 
decreasing the risk of infectious diseases in children has been observed in many studies 
before, but the protective role of father's education for pneumonia is an interesting 
observation in this study. It might be due to the fact that men in Afghan context have a 
dominating role in decision making in various ways. For example their education might 
play a significant role on determining the early signs of the disease for cases experienced 
the first episode of the diseases. Similarly, educated fathers could suggest proper indoor 
measures in the family in order to avoid re-occurrence of disease, such as explaining risk 
factors of diseases to the rest of family, appropriate warming of the house, and hygienic 
practices necessary for prevention of microbial diseases. On the other hand, it does not 
seem plausible that father's education did not protect children from getting the first episode 
of disease. 
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Unexpectedly, children who got vitamin D had higher incidence rate of repeat x-ray 
confirmed severe and non- severe all pneumonia compared to placebo group. This 
observation is in contrary to study hypothesis. The matched case control study in Greenland 
found that high level of vitamin D (> l40nmol/L) was associated with the risk of 
tuberculosis. Firstly, that study was conducted on people aged 8-74 years old, and secondly, 
the outcome was tuberculosis, which has a different pathophysiology. We did not assess the 
serum vitamin D levels in the whole study cohort to determine how many children 
developed high serum vitamin D level after each dose administration. However blood 
samples from a random sample of children taken at two points showed that only few 
children developed a very high serum vitamin D level. Furthermore, if high vitamin D level 
could reduce immunity, it would affect incidence of first episodes of pneumonia as well 
which was not the case in this study. Although the length of time after a vitamin D dose to 
produce any immunity effect is not well known, the mean number of days between last 
dose of vitamin D/placebo and the episodes of repeat pneumonia was also not different 
between the two groups in this study. 
We did not find any association of severe malnutrition with overall x-ray confirmed and 
non-confirmed severe and non-severe pneumonia. This is inconsistent with findings in a 
case control study of under-2 year children in some parts of Brazil, where the odds of 
weight for age z-score<-3 was 4.57 (95% CI: 2.93 - 7.13) higher in pneumonia cases 
compared to healthy controls (42). One possible reason might be a lower rate of severe 
malnutrition in our study area and probably in the whole Kabul city as a result of effective 
interventions against malnutrition in tertiary Pediatric hospitals and local clinics, and free 
administration of treatment for malnutrition by national and international NGOs for more 
than a decade. As presented earlier, only 5% in each study group was suffering from severe 
malnutrition at baseline. 
Kabul is a province with an altitude of 1800 m above sea level (1 04 ). Previous studies in 
Pakistan (35)and Colorado ( 43)found that children living in areas with altitude of more than 
1980 m and 2500 m above sea level (respectively) will have a higher risk of developing 
pneumonia and other respiratory diseases compared to those living in lower altitudes. 
Though the altitude in Kabul is not higher compared to those cut off points, the incidence 
of childhood pneumonia is still very high. This indicates that the risk of pneumonia in 
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others parts of Afghanistan with high altitudes, such as Badakhshan in north-eastern part of 
the country, might be higher compared to that in Kabul. 
5.3 Serum vitamin D levels 
The blood test done in a random sample of 303 children in control group showed that 17.5 
% of children had severe vitamin D deficiency {25(0H) D <8ng/ml}. This finding is 
different from the findings of a study carried out in similar population in Kabul in 2005 by 
Manaseki-Holland et al, which showed that 73% of 108 children aged 6-48 months had 
vitamin D concentration below 8ng/ml (32) . Similarly, the study in 2005 found 96.2% of 
children with vitamin D concentration below 15ng/ml, while our study showed that 50% of 
children had vitamin D insufficiency {25(0H) D 8-<20ng/ml}. Almost one third of 
children in control group (32.7%) had a normal level of vitamin D {25 (OH) D 2:20ng/ ml}, 
which suggests a better nutritional status among the study children. This could be partly 
due to improvement in economic status of families over the 3 year period, or due to the fact 
that study in 2005 was conducted during a short period in winter season in a smaller 
sample. Children in intervention group had a higher level of serum vitamin D after 
administration of vitamin D compared to that in placebo group. This suggests that there was 
no protocol violation of allocation to respective study groups and also the vitamin D 
supplementation was effective to raise the serum vitamin D levels. Moreover, a higher 
serum vitamin D level in intervention group suggests the reliability of syringe contents 
produced by AKU pharmacy. Any acute or chronic adverse effect associated with vitamin 
D supplementation was not reported during the study. However, if there was any chronic 
toxic effect of vitamin Dafter the study, we were not able to trace them. 
In line with previous studies showing that 100,000 IU vitamin D could provide a good 
protection against vitamin D deficiency without risk of side-effects in infants(99), our study 
also detected a desirable level of vitamin D among intervention group with no side-effects. 
Only 0.6% of children in intervention group had a 250HD level > 150ng/ml considered to 
be high .This suggests that such dosages might increase level of vitamin D to an un-
expected levels in few percentages of children with certain social or health background and 
should be considered in future studies. 
85 
5.4 Perceptions of Health care providers 
During the life of project we conducted two focused group discussion (FGOs) with 
pediatricians from two large tertiary pediatric hospitals to explore their ideas about adverse 
effects of vitamin 0 after administration of the dose we have been given to our study 
children. In both FGDs, they thought that only children who receive vitamin 0 on a daily 
basis, or more often might develop signs of over dosage. They also commented that from 
their clinical experience, they have never confronted a case of vitamin Dover dosage after 
3 consecutive doses of 600,000 IU vitamin D in their patients. They suggested that some 
children might develop some chronic conditions, such as kidney diseases in long term, 
which might need further investigation after this study is completed. They thought, it would 
be a good idea to compare those likely conditions with the level of vitamin 0 in serum tests 
carried out in this study to find out if there might be any association. 
5.5 Immunological role of vitamin D 
The immunological role of vitamin D has been studied previously but needs further 
investigation. In this study we focused only on association between vitamin D status and 
incidence of pneumonia in children. We did not explore the exact immunological impact of 
vitamin D administration through laboratory investigations. Previous studies found that 
vitamin D has a role on expression of anti microbial cathelicidin by macrophages in 
response to microbial agents. Additionally, it has been shown that 1, 25(0H) 2D3 is an 
immune system modulator and promotes the immune responses. The immunological role of 
vitamin D in response to microbial diseases has not been described in different age groups 
and we do not know if the physiological mechanisms are similar in adults and children. It is 
possible that vitamin D might play an import role in enhancing immunity in adults and 
older children, but less so in infants and young children. It is not clear how long it takes 
after vitamin D administration to improve the immunological status and body's 
immunological responses. We measured the incidence of pneumonia during three months 
post administration of vitamin D over 18 months in total. Perhaps 3 months might not be 
long enough to see a substantial impact on children's immunity and reduction in incidence 
of microbial diseases. Studies have revealed an association between subclinical vitamin D 
deficiency and increased risk of tuberculosis in adults (81 ), (82). Given that tuberculosis is 
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a chronic illness, one could speculate that vitamin D deficiency might only impact chronic 
inflammatory processes rather than acute conditions such as pneumonia and diarrhea. 
Moreover, studies on role of vitamin D on tuberculosis have focused on adults only. As 
mentioned earlier, the inflammatory processes might not behave same ways between 
children and adults, and vitamin D might modulate inflammatory processes in adults better 
and differently than that of children. Further studies of time lag between vitamin D 
administration and improvement in immune status are needed to evaluate the effect of 
vitamin Don microbial infections. 
It is possible that effectiveness of vitamin D supplementation to reduce the risk of 
pneumonia might depend on other factors that we do not know yet, such as deficiency of 
other important vitamins and minerals as a result of poor dietary resources, or people's lack 
of knowledge on balanced healthy foods for children. Similarly, the sufficient level of 
serum 25(0H) D necessary for stimulating immunity in response to infections has not been 
clearly studied. 
The study conducted by Manaseki-Holland and colleagues in the same parts of Kabul in 
2007 found that a single dose of 100.000 IU vitamin D along with antibiotics in the active 
phase of infection can reduce the incidence rate of repeat episodes of pneumonia in young 
children. Methodological differences such as definition of pneumonia and quality assurance 
procedures might be possible reasons for this inconsistency in the results between the two 
studies done in the same population. Nevertheless, this could be because production of 
cathelicidins in vitamin D depleted children is significantly dependent on stimulation of 
TLR on macrophages and monocytes by bacterial antigens, and the up-regulation of 
CYP2BI-hydorxylase and VDR necessary for production of cathelicidins could only take 
place when vitamin D is supplemented in the active phase of the infection rather than 
supplemented as a preventive measure. On the other hand, vitamin D might enhance the 
immunity in chronic infections and certain genotypes such as observed in a recent small 
multi-center randomized controlled trial of vitamin D in adults with sputum smear-positive 
tuberculosis in London, UK. The study found that vitamin D significantly hastened sputum 
culture conversion in patients with tt genotypes (81 ). Another trial in the UK also found 
that a single dose vitamin D enhanced immunity to mycobacterium tuberculosis (82). 
Similarly, the link between vitamin D deficiency and risk of TB was detected among 
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Vietnamese men. Therefore, the trial needs to be repeated in other settings, where people 
might be genetically different. 
Recent findings on role of vitamin D on enhancing immune response to mycobacterium 
tuberculosis, and its complementary role on successful treatment of TB suggest that further 
studies are needed to investigate the beneficial effects of vitamin D in the treatment of TB. 
Afghanistan has a high annual incidence of TB (168/1 00 000/year) (114) and high to 
moderate rate of vitamin D deficiency and thus, Afghanistan is an appropriate setting for 
such studies. 
Vitamin D supplementation did not show any effect on reducing incidence of diarrheal 
diseases as well, which highly contributes to burden of diseases and mortality in under-5 
children in Afghanistan. No study has been done on effect of vitamin D on reducing risk of 
diarrheal diseases in other parts of the world. Since the effect of vitamin D may depend of 
genetic variations, further studies in different settings may be needed to confirm or refute 
this observation. 
5.6 Dose of vitamin D supplementation 
For convenience of implementation and based on previous studies showing that 100,000 IU 
vitamin D can provide the best protection against vitamin D deficiency without the risk of 
over dosage, we decided to use 3 monthly supplementation of 100,000 IU vitamin D in this 
trial. The trial found that 3 monthly supplementation of 100,000 IU vitamin D was a safe 
intervention, keeping serum 25(0H)D to a sufficient level necessary for protection against 
vitamin D deficiency and its further consequences such as vitamin D rickets. Although only 
few cases of clinical rickets were observed in this study (in both vitamin D and placebo 
groups), children in more economically deprived parts of the country, where vitamin D 
deficiency might be higher, could benefit from more frequent administration of vitamin D. 
Only two children developed a toxic level of serum 25(0H) D (> 150ng/mL) immediately 
after 1st and 3rd doses. These children did not show any signs of vitamin D over dosage, 
but caution should be undertaken while using such a high dose in the future. On the other 
hand, such high doses could produce long term side effects, which are not yet known and 
need to be traced in the future. 
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5. 7 Generalisability of the findings 
Findings in this study could be inferred to population with similar background 
characteristics living in similar settings, however, due to possible genetic variations, these 
findings might not be generalisible to children in different settings, particularly to settings 
where the risk of vitamin D deficiency and the incidence of pneumonia are lower. Due to 
lack of surveillance system and proper studies in Afghanistan, it is difficult to clearly 
understand similarities and differences of socio-economic status among different parts 
within the country. As a result, it is not appropriate to generalize findings from this study 
done in few districts in Kabul to the whole population. Afghanistan is a poor country with 
lack of quality food and proper living conditions, but findings from this study revealed that 
people in our study areas were not in extreme poverty and only a small proportion of study 
children were severely malnourished. Therefore, they might not be a good representative of 
children of same age group living in other parts of the country, where socio-economic 
deprivation is more prominent. We found that vitamin D administration increased serum 
vitamin D in intervention group. Therefore, biologically, it may give similar results if we 
conduct such studies in other parts of the country with the hypothesis that Afghan children 
are sharing similar genetic properties, while it may not be applicable to children in 
surrounding countries where their immune system may react differently in response to 
vitamin D supplementation. 
Despite vitamin D did not reduce the incidence of pneumonia; vitamin D supplementation 
could be a cheap and effective intervention for improving vitamin D status in poor settings 
like Afghanistan, particularly due to the fact that such countries are deprived of quality 
food, such as fortified milk and calcium enriched food resources. Our study revealed that 3-
monthly vitamin D administration could keep serum vitamin D in a desired level necessary 
for body's metabolism. Because normal level of serum vitamin D is a key for proper 
intestinal absorption of calcium, children in poor countries could benefit if they are 
provided with three-monthly oral vitamin D supplementation. 
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5.8 Alternative Interventions for Control of Pneumonia in Children in 
Afghanistan 
The important recommended strategies by WHO for controlling childhood pneumonia are 
as follow ( 115): 
• Vaccination 
• Case management through implementing IMCI 
• Improvement of nutritional status 
• Control of indoor air pollution 
WHO recommends measles, pertussis, Hemophilus Influenza Type b (Hib) conjugate and 
pneumococcal conjugate vaccines for prevention of childhood pneumonia (115). The first 
two vaccines have been introduced to routine immunization programs for many decades in 
most countries, including Afghanistan, while the Hib and pneumococcal conjugate vaccines 
are newly introduced to some developing countries, due to its high cost. The efficacy of 
Hib vaccine determined by case-control studies ranged from 20 to 40% against 
radiologically confirmed pneumonia (115). Similarly, the efficacy of pneumococcal 
conjugate vaccine against radiologically confirmed pneumonia has been reported 20 - 37% 
(115). The Global Alliance for Vaccines and Immunization (GA VI) has been supporting 
eligible countries for introduction ofHib vaccine. In Afghanistan, for the first time, the Hib 
vaccine was introduced and supported by GA VI in 2009, and now it is part of routine 
immunization for children in most provinces (116). The pneumococcal conjugate vaccine 
has not yet been introduced in Afghanistan. Afghan MoPH annual report 2008 shows that 
DPT3 and measles vaccinations' coverage reached 85 and 75 percent respectively in 2008 
(117). The measles vaccination is delivered through routine immunization programs in 
clinics along with DPT, as well as, through national immunization campaigns launched 
each year. Although the MoPH has set higher coverage targets for these vaccines, current 
insecurity in many parts of the country is a major barrier. 
The second strategy for controlling pneumonia is implementation of IMCI. IMCI was first 
introduced in mid 1990s by WHO and UNICEF in order to reduce mortality due to 
pneumonia, diarrhea, measles, malaria and malnutrition through immunization, counseling 
and case management components (111 ). The effectiveness of IMCI in reducing pneumonia 
and overall mortality is not well known. In a cluster randomized controlled trial in Matlab, 
Bangladesh in 2007, the effect of IMCI was studied on childhood mortality and nutrition. 
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The Study randomly assigned 10 clusters into IMCI and 10 clusters into non-IMCI usual-
service groups (total population 350 000) and started implementing IMCI in intervention 
group in Feb 2002. After 3 years, it was found that the overall mortality was reduced in 
both intervention and non intervention groups. In the final 2 years of the study, the 
mortality rate (except deaths happened in first week of life) was 13.4% (95% CI: 14.2-
34.3) lower in IMCI compared to control areas, but the difference was not statistically 
significant (p=0.030) (111 ). In Afghanistan IMCI was introduced in 2003 (118) and its 
facility component has being implemented by NGOs and governmental health facilities in 
all 34 provinces since 2008. The community based IMCI has currently being implemented 
in 17 provinces of Afghanistan. In our study, IMCI guidelines were used for the 
management of sick children and we noticed a substantial reduction in mortality in both 
intervention and controls groups compared to the previous estimates. However this 
reduction in mortality could be due to improved access to health services and not 
necessarily due to implementation if IMCI guidelines. 
Although IMCI has been a useful intervention for controlling the childhood morbidity, in 
our study, we found that only 10% of all clinical cases of pneumonia (using IMCI protocol) 
were confirmed as pneumonia by chest x-rays (WHO standard protocol for diagnosis of x-
ray confirmed pneumonia). It shows that IMCI protocol is not specific enough for 
diagnosis of true pneumonia; however, we do not know how strictly the IMCI guidelines 
were applied in diagnosis of pneumonia by our clinicians. If the IMCI has exactly been 
followed for diagnosis of pneumonia, it could be a concern for community based health 
programs, where IMCI is used as a tool for detection and treatment of pneumonia. 
Moreover, it could be a bigger concern because staff working in communities such as 
community health workers (CHWs), have little medical knowledge compared to 
pediatricians, which could predispose to an overestimation of pneumonia episodes, and as a 
result, over prescription of antibiotics which would lead to antibiotic resistance. 
The third component for controlling pneumonia is improving nutritional status. Afghan 
MoPH has reported the prevalence of under-five underweight as 39.3 % in 2004 (117). 
Moreover, exclusive breastfeeding is reported 40-70% in Afghanistan (117), which is 
desirable in a country with low literacy and high poverty rates where families cannot afford 
expensive fortified infant formulas. The quality of food introduced after weaning remains a 
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challenge which has significant implications on child's wellbeing during critical first 5 
years of life. Enhancing child nutritional status has been challenged by ongoing insecurity 
and its economic consequences in Afghanistan. As described before, zinc supplementation 
has shown better protective effects against pneumonia and diarrhea. Therefore, it could be 
a reasonable intervention for prevention of pneumonia and child mortality in Afghanistan. 
The Afghan MoPH has included zinc supplementation in its strategy for the treatment of 
diarrhea (119), but it has not been introduced in all parts of the country yet. UNICEF, 
Afghanistan provides zinc supplementation for Afghan NGOs only during diarrhea 
treatment campaigns. Supplementation of zinc for treatment of pneumonia has not been 
introduced in Afghanistan so far. 
Indoor air pollution in the form of burning solid household fuels, as described in literature 
review section, is a well-known risk factor for pneumonia in children, particularly if used in 
simple stoves common in some developing countries. As described in GAPP report 2007, 
usage of efficient wood stoves with chimney can lower the risk of overall pneumonia by 
15% in children less than 18 months of age (115).This fact was revealed in our current trial 
as well, where children exposed to common stove types with proper chimney using solid 
fuels had lower risk of pneumonia compared to those exposed to other types of heating 
devices. In Afghanistan, particularly in Kabul, outdoor air pollution poses a more serious 
challenge for controlling pneumonia. Due to huge number of second-hand cars, a very high 
number of streets unpaved, and usage of common unsanitary toilets, children in Kabul are 
at high risk of all respiratory diseases including pneumonia. Though the Afghan 
government has recently doubled the number of official off days from one to two days per 
week to reduce environmental pollution due to car traffic, the problem of unsanitary toilets 
and unpaved streets remains a remarkable challenge, which requires a substantial economic 
investment by governmental and private sectors. 
5. 9 Conclusion 
The study did not find a protective effect of 3-monthly supplementation of 100.000 IU 
vitamin Don reducing the incidence of pneumonia in infants and young children in Kabul. 
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The High incidence of pneumonia in this study indicates that pneumonia is still a main 
contributor to the burden of children's morbidity, and needs more effort to improve the 
quality of health service provision. Improving the quality of health services is important 
because our study had a significant impact on reducing all cause child mortality. The 
marked reduction in mortality is most likely due to the quality of services we provided, 
such as proper referral, providing quality medicine, using a standard protocol for diagnosis 
and treatment of the cases, and finally availability of health care provider when a child was 
sick and the families needed a medical staff to be there. The last point is more important 
because my personal experience from working in remote areas of Afghanistan shows that 
health care providers could not be accessed always except the official time they work in a 
health center. Due to the fact that children's diseases, particularly pneumonia, develop very 
quickly, availability of medical staff during the day and night is very crucial for on time 
provision of medical care and prevention of severe disease and death. 
Although it is not clear how carefully the IMCI tools were applied for diagnosis of 
pneumonia, only around 10% of pneumonia cases detected clinically were confirmed by 
chest radiography. Therefore, programs using IMCI for diagnosis of pneumonia, especially 
in the community level with majority of their staff with insufficient medical training, 
should be careful with possible overestimation of pneumonia and over prescription of 
antibiotics and the consequent antibiotic resistance. 
Heating devices commonly used in Afghanistan showed a protective effect for pneumonia. 
This observation should be studied further and if proved to be correct, this heating device 
could be promoted further inside the country, and probably in other countries with cold 
climate and lack of resources for provision of central heating. 
Three-monthly administration of 100.000 IU vitamin D was shown to be a safe intervention 
for keeping a desired level of serum vitamin D for protection against vitamin D deficiency 
and its further health hazards. However, it did not show an effect on reducing the incidence 
of pneumonia and other acute infectious conditions such as diarrhea or bronchiolitis. 
Because the level of serum vitamin D required to producing a desirable immunity necessary 
for reduction of infectious diseases is not well known, further investigations are needed in 
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order to determine a better dosage and dosage frequency to produce a desirable immune 
effect necessary for combating infections. 
Findings in this study could be generalized only to a similar setting and to a similar 
population and not generalisible to settings with different socio demographic and biological 
characteristics. Due to differences in genetic features among populations of different 
countries, it might be worth repeating such a study in other parts of the world. 
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FIGURES 
Figure 1: Estimates of incidence of clinical pneumonia in different regions of the world by 
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Figure 2: Global causes of child deaths, 2008 














Figure 3: Trial Profile 
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Figure 4: Study Design and Project Timeline for Intervention and Data Collection Points 
1. Enrolled infants 1-11 months old (n=3046), 
whose parents give consent , and meet the 
inclusion criteria 
2. Randomized individually in blocks to either 
vitamin D or placebo (n= 3046) 
Intervention Group 
100,000 IU Vitamin D at enrolment and 




Placebo (olive oil resembling vitamin D) 
at enrolment and then quarterly for 18 
months ( 6 doses in total) 
1. Active surveillance for incidence of pneumonia 
(fortnightly house visits for 18 months) 
2. Passive Surveillance for incidence of pneumonia based at 
the study hospital 
3. Collected data on additional risk factors of pneumonia in 
different seasons during follow up period through 
fortnightly home visits 
4. Took Chest x-rays for suspected cases of pneumonia in 
the study hospital 
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Figure 5: Timeline for study interventions, and data collection points 
t Start date: Nov 2007 I 
Enrolment 
randomization 
Month O(Nov-2007) month3 
Fortnightly active surveillance of pneumonia by home visits 
I End date: M~y2009 J 
I Dailv passive surveillance of pneumonia at the studv hospital l 
__.. 
month 6 month9 month 12 month15 month18 (May-2009) 
l4weeks l4weeks I I I I I I I I I I I I I I I I I I I I I I l 4weeks Lweeks 1 1 1 11 Lweeks r 4weeks 
VitaminD/ 
Placebo dose 1 
VitaminD/ 
Placebo dose 2 
Data collection points and tools 
Enrolment 
1. Vitamin D/Placebo 
Administration 
2. Enrolment Forms 
3. Consent Form 
Ouarterl,l:: vitamin D/ Placebo 
administration visit 
l. Vitamin D administration 
Form 
VitaminD/ 
Placebo dose 3 
Passive surveillance at hospital 
1. Out Patient Form 
2. In-patient Form 
3. Chest x-ray Form 
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VitaminD/ VitaminD/ 
Placebo dose 4 Placebo dose 5 
Fortnil!htii: active surveillance 
1. Home visit form 
t 
Once durin~:; the active surveillance 
I. Breastfeeding and Living Status Form 
Vita minD/ 
Placebo dose 6 
2. Sun-exposure and indoor air pollution Form 
3. Economic and vaccine status form 
4. Sun-exposure Form 
5. Breastfeeding and indoor air pollution Form 
Figure 6: Chest x-rays from study children diagnosed with significant pathology for 
pneumonia 
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Figure 7: Chest x-rays from study children, where one of the two readers disagreed to 
di nose them as onia and were confirmed as eumonia after 3rd reader's op inion 
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Figure 9: Incidence of of x-ray confirmed pneumonia by season in vitamin D and placebo 
groups 
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Figure 10: Proportion of Children without First or Only Episode of X-Ray Confirmed Severe 
and Non-Severe Pneumonia during 18 Months 
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Placebo 1477 (88) 1375 (82) 1252 (14) 1199 (9) 1169 (39) 1099 (13) 0 
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Figure 12: Comparison of first or only episodes of severe and non-severe x-ray confirmed 
pneumonia in vitamin D and placebo groups 
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Figure 13: Comparison of repeat episodes of severe and non-severe x-ray confirmed 
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Figure 14: Comparison of first or only episodes of severe and non-severe clinical pneumonia 










"' 0::: Q) 1. 2 • -·R-R--·-------··-·--------~··-·-----.. ---·--·-·-·-·---·-•R _________ _ 
v 
c:: 
~ 1 - - ----t--·-------------·-·-··f---·--·-·------~4 ----------
0' 8 ---------·-·-----------·-··-------------------~----- -----·-----
0.6 ·---------------------·----·---··-·--------·-·------------
0.4 +--------------r--------------r-----------~----------------, 
All Pneumonia Simple Pneumonia Severe Pneumonia Very Severe diseases 
Figure 15: Comparison of repeat episodes of severe and non-severe clinical pneumonia in 
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Figure 16: Incidence of bronchiolitis by season in vitamin 0 and placebo groups 
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Figure 17: Mean serum vitamin 0 levels (nmoi/L) in vitamin D and placebo over study period 
(Nov 2007- July 2099) (N=636) 
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Figure 18: Local heating device (Chari & Bokhari) used during winter in Kabul city 
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TABLES 
Table 1: Estimates of incidence and number of new cases per year of clinical pneumonia in 
children aged less than 5 years, by WHO regions 
Country Predicted no. of Estimated incidence 
new cases (millions) (e/cy) 
India 43.0 0.37 
China 21.1 0.22 
Pakistan 9.8 0.41 
Bangladesh 6.4 0.41 
Nigeria 6.1 0.34 
Indonesia 6.0 0.28 
Ethiopia 3.9 0.35 
Democratic Republic of the Congo 3.9 0.39 
V1etNam 2.9 0.35 
Philippines 2.7 0.27 
Sudan 2.0 0.4B 
Afghanistan 2.0 0.45 
United Republic of Tanzania 1.9 0.33 
Myanmar 1.8 0.43 
Brazil 1.8 0.11 
e/cy, episodes per child-year. 
Source: Bulletin ofthe World Health Organization, 2008 
Table 2: Risk factors related to the host and the environment that affects Incidence of 
childhood pneumonia in the communities in developing countries 
Definite risk factors 
Malnutrition (wr~lght fot .-tlW : ~v:ot o •: 2) 
Low birth wPiuJ,t ( ,~ 2f,(}(l ~1) 
Non· exclw;ive brew;tkedtrlg (durirt~J the 111 ~:;t 4 111unths c;l!ife) 
l <tt"k of mnil:;lm:; immuni:atinn (within tllP tir:•t 1/ months nt lif11} 
lnl'ioor nit pdlution 
Cro\\~Jing 
Likely risk factors 
r•mental :;{11\tf<Jilg 
ZirK deficiettry 
Mother':; experierKtl "'~a careqiv,~r 
Concornit.:mt rlif;•n';(•s (e.g. diurrhoe~t. heart dlr;t~ar.e, nslhn~<l) 




High dltitudtl (cold alr) 
Vitamin A dtJ!icietKy 
Birth oninr 
Outdoor air pqllulion 
Source: Bulletin of World Health Organization, 2005. 
117 
Table 3: Trials evaluated the role of vitamin 0 in treatment or prevention of infections 
Age group Vitamin D dose Main end point Outcome Reference and study 
country 
Vitamin 0 significantly red uced the 
Manaseki-Holland et a l (87), 
453 chi ldren l-36 months old 
Single dose of I 00,000 IU 0 3 Risk of repeat episodes 
risk of repeat episodes of pneumonia 
2010 
a long with antib iotic treatment of pneumonia Kabul , Afghanistan 
for pneumonia 
(IMCI criteria) (P= .0 I ) 
Vitamin 0 significantly hastened 
100,000 IU 03 on days 7, 14, 
sputum culture conversion in patients 
146 adults with sputum smear Sputum culture with tt genotype ofthe Talq vitamin 0 Martineau et al (8 1 ), 20 II 
positive TB 
28 and 42 along with anti T B 
convers ton receptor polymorphisim London, UK 
treatment 
(HR=8.09, P= .02) 
Abi lity ofwhole blood 
count to restrict 
Vitamin 0 significantly enhanced 
luminescence, and 
192 healthy adult TB contacts 
Single dose of I 00,000 IU 03 
hence, restrict growth 
abi li ty of participants ' whole blood Martineau et al (82), 2007 
fo llowed for 6 weeks count to restrict BCG-hux London, UK 
of mycobacterium in 
luminescence (P=.03) 
vitro 
I 00,000 IU 0 3 or placebo 
Sputum conversion Wejse ( 120), 2009 
365 adults with given at baseline, 5 mo, and 8 No difference in sputum conversion, 
pulmonary TB months ofTB therapy 
rates over time Guinea-Buissau 
23% greater sputum conversion rate at 
10,000 IU/d vitamin 0 or Sputum smear 
6 wk in vitamin 0 group versus 
67 adults with smear positive placebo (P = .002) Nursyam et a l ( 12 1 ), 2006 
pulmonary TB 
placebo given for first 6 wk of conversion at 6 wk 
22 .5% greater rate of radiographic Indonesia 
TB Radiographi c 
treatment improvement 
improvement in vitami n 0 group 
versus pl acebo 
1 18 
Table 3: Trials evaluated the role of vitamin D in treatment or prevention of bacterial and viral infections (Cont.) 
Age group Vitamin D dose Main end point Outcome 
Reference and study 
country 
I ,000 IU/d vitamin D 
24 ch ildren ( 1.5-13 y) given m Clinical improvement 
16% higher rate ofTB symptom Morcos et a l ( 122), 1998 
with pulmonary and combination with in TB-related signs 
reso lution in vitamin D group Egypt 
extra-pulmonary TB standard TB therapy, or and symptoms 
TB therapy alone 
27 chi ldren (3-12 y) with 2:6 
respiratory or antibiotic requi ring 60,000 IU vitamin 
Freq uency of 
Difference in infection rates 
Rehman ( 123 ), 1994 
illnesses in prior 6 months and 20 D weekly x 6 wk between groups 
children (3-12y) with :S I respiratory or no supplement 
respiratory infection in 
no longer significant in 6 mo after 
India 
orantibiotic-requiring illness in in control group 
6 mo after intervention 
interventi on 
prior 6 months 
334 school children aged 6- 15 years 
1200 IU/day 03 for 4 Risk of influenza type A Vitamin D significantly reduced the Urashima et a l (86), 20 10 
months infection risk of influenza type A infection Japan 
Table 4: Total Population in Districts 2, 3 and 8 with Their Categories 
District Total population Male Female 
02 80,200 4 1600 38,600 
0 3 96,900 50400 46,500 
08 210,300 109200 I 0 I, I 00 
11 9 
I 
Table 5: Study timeline 
""" -Q. ~ = ~ < 0 ~ Activities ... ~ = ,Q ..... b.() ... ""') ,Q Q 4.1 ~ 4.1 I ~ I = I Q :z Q ~ I 4.1 ""') ~ ... = < :z 
"" 
~ = Q. 
~ 
4.1 4.1 ~ ~ Q 00 
Enrolment X 
Interventions X X X X X X 
Active surveillance X X X X X X X X X X X X 
Passive surveillance X X X X X X X X X X X X 
Date entry X X X X X X X X X X X 
Data cleaning X X X 
Data analysis X X 
Report writing X X X 
Dissemination of 
finding 
Table 6: Indoor air-pollution score matrix 
Length of time 
each device 
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Table 7: Baseline socio-demographic characteristics of ch ildren, mothers, and fathers 
Vita min D (n=1524) Placebo (n=l 522) 
Children n (%) n (%) 
Sex 
Male 8 11 (53 .2) 780 (5 1.2) 
Female 71 3 ( 46.8) 742 (48 .8) 
Age in months 
Med ian (IQR) 6 ( 3-9) 6 (4-9) 
Mean (95% CI) 6.2 (6 .02 - 6.34) 6.2 (6 .04 - 6.35) 
< 2 months 132 (8 .7) Ill (7.3) 
2 to <6 5 10 (3 3 .5) 537 (35.3 ) 
6 to 12 882 (57 .8) 874 (57.4 ) 
Mother s 
Age in yea rs 
<20 98 (6.4) Il l (7 .3) 
20-39 138 1 (90. 7) 1352 (88.9) 
40+ 44 (2.9) 58 (3 .8) 
Any formal education 
Yes 573 (37.6) 529 (34.8) 
No 95 1 (62.4) 993 (65.2 ) 
Level of education in years 
None 95 1 (62.4) 993 (65.2) 
1-6 272 ( 17 .8) 256 ( 16.8) 
7-9 140 (9.2) 11 9 (7 .8) 
I 0-1 2 11 4 (7.5) I I I (7 .3) 
Univers ity or co ll ege 47 (3. 1) 42 (2 .8) 
Marital status 
Married , on ly wife 1469 (96.4) 1477 (97 .0) 
Married, more wives 52 (3 .4) 42 (2 .8) 
Widowed 2 (0. 1) 2 (0 .1) 
Separated 0 ( - ) (0.07) 
Divorced (0 .07) 0 ( - ) 
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Table 7: Baseline socio-demographic characteristics of children, mothers and fathers (cont.) 
Mothers 
Vitamin D (N=1524) Placebo (N=1522) 
n (%) n (%) 
Mother currently working if ever 
worked8 
Yes 50 ( 4 7.2) 58 (54 .7) 
No 56 (52.8) 48 (45.3 ) 
Fathers 
Age in years 
<20 4 (0.3) 6 (0.4) 
20-39 1185 (77 .8) 1173 (77. 1) 
40+ 335 (21.9) 343 (22.5) 
Missing 0 ( - ) 0 ( - ) 
Any formal education 
Yes 1.085 (71 .2) 1072 (70 .4) 
No 439 (28.8) 449 (29.5 ) 
Do not Know 0 ( - ) (0. 1) 
Level of education in years 
None 439 (28.8) 449 (29.5) 
1-6 279 (18.3) 263 ( 17.3 ) 
7-9 250 (16.4) 256 (16.8) 
I 0-12 377 (24.7) 395 (25.9) 
Semi-formal studies 9 (0 .6) 12 (0.8 ) 
University or college 170 ( I 1.2) 146 (9.6) 
Father's ethnicity 
Tajik 1.063 (69. 7) 1074 (70.5) 
Pashton 352 (23. 1) 336 (22.1) 
Uzbek 27 ( 1.8) 21 ( 1.3 ) 
Hazara 62 (4. 1) 74 (4.9) 
Other 19 ( 1.2) 16 ( 1.1 ) 
Do not know (0 .1) (0. 1) 
Fathers currently working 
Yes 1442 (94.6) 1427 (93 .8) 
No 82 (5.4) 95 (6.2) 
8 Only asked if mother had ever worked 
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Table 8: Pneumonia risk factors in vitamin D and placebo groups 
Risk facto rs Vita min D Placebo 
(N=1524) (N=l522) 
P-va lue 
Economic status n % N % 
Better Off 164 I 0.8 159 I 0.4 0.77 
Less Poor 262 17.2 266 17.5 
Poor 226 14.8 247 16 .2 
Very Poor 226 14.8 227 14.9 
Poorest 254 16.7 235 15.5 
Missing 392 25 .7 388 25 .5 
Malnutrition 
(weight for age z score) 
z-score :=:: -I 812 53.3 832 54 .7 0.67 
-2 :S z-score <-I 4 15 27.2 399 26 .2 
-3 :S z-score <-2 183 12.0 195 12.8 
z-score <-3 87 5. 7 77 5.1 
Missi ng 27 1.8 19 1.2 
Indoor smokers 
inside the child's room 
No one 900 59.1 889 58.4 0.62 
I person 420 27.6 442 29.0 
2-3 persons 39 2.6 34 2.2 
Missing 165 10.8 157 I 0.3 
Exposure to number of cigarettes 
smoked indoor 
No Exposure 870 57.1 867 57.0 0.99 
1-9 cigarettes 359 23 .6 367 24.1 
I 0-1 9 cigarettes 58 3.8 57 3.7 
:=:: 20 cigarettes 72 4.7 74 4.9 
Missi ng 165 10.8 157 10.3 
People sleeping in child's bedroom 
:S 2 people 223 14.6 238 15.6 0.86 
3 -4 peop le 508 33 .3 519 34 .1 
:=:: 5 people 627 4 1.1 60 1 39 .5 
Missing 166 10.9 164 I 0.8 
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Table 8: Pneumonia risk factors in vitamin D and placebo groups (cont.) 
Risk factors Vitamin D Placebo 
(N:::;l524) (N=l522) P-value 
Ever breastfed n % N % 
Yes 1463 96.0 1457 95 .7 0.67 
No 22 1.4 28 1.8 
Missing 39 2.6 37 2.5 
Currently breastfed 
Yes 894 58 .7 902 59.3 0.16 
No 589 38.6 580 38 .1 
DK 0 2 0.1 
Missing 41 2.7 38 2.5 
Exposure to indoor air pollution 
Low /No pollution 360 26 .5 365 26 .8 0.68 
Medium Pollution 350 25.7 332 24 .3 
High Pollution 649 47.8 668 48 .9 
Number of children from same mother 
:S3 467 30.6 468 30 .7 0.63 
4-7 493 32 .3 467 30 .7 
2:8 85 5.6 93 6.1 
Missing 479 31.4 494 32 .5 
Child's sex 
Male 811 53.2 780 51.2 0.27 
Female 713 46.8 742 48 .8 
Child's age in months 
< 2 months 132 8.7 Ill 7.3 0.28 
2 till <6 510 33.5 537 35 .3 
6 til112 882 57.8 874 57.4 
Mother's any formal education 
Yes 573 37.6 529 34.8 0.10 
No 951 62.4 993 65 .2 
Fathers any formal education 
Yes 1085 71.2 1072 70.4 0.55 
No 439 28 .8 449 29 .5 
Do not Know 0 0.1 
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Table 9: Background characteristics of children with number of x-ray confirmed severe and non severe pneumonia episodes 
Characteristics Categories 
No pneumonia Pneumonia (only one episode) Pneumonia ( ~ 2 episodes ) 
p-value 
N=2496 N=395 N=l55 
n 0/o n 0/o n 0/o 
< 3 months 434 17.4 60 15.2 13 8.4 <0.001 
Child's age at 3 to <6 670 26.8 85 21.5 28 18. 1 
recruitment in 
months 6 to <9 719 28 .8 143 36.2 45 29.0 
9 to 12 673 27.0 107 27. 1 69 44.5 
Better Off 274 11.0 36 9.1 13 8.4 0. 14 
Less Poor 433 17.3 74 18.7 21 13 .5 
Economic status Poor 376 15.1 71 18.0 26 16.8 
Very poor 358 14.3 64 16.2 31 20.0 
Poorest 38 1 15.3 71 18.0 37 23 .9 
Missing 674 27.0 79 20.0 27 17.4 
Yes 1502 60.2 235 59.5 78 50.3 0.03 
Currently No 916 36.7 !56 39.5 76 49.0 
breastfed 
OK I 0.1 I 0.2 0 
Missing 77 3.0 3 0.8 I 0.7 
Low/no pollution 545 21.8 115 29. 1 65 41.9 <0 .001 
Indoor air Medium pollution 
597 23 .9 64 16.2 2 1 13.6 
pollution status 
High pollution 1083 43.4 175 44.3 59 38. 1 
Missing 271 10.9 41 I 0.4 10 6.4 
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Table 9: Background characteristics of children with number of x-ray confirmed severe and non severe pneumonia episodes (cont.) 
No pneumonia Pneumonia (only one episode) Pneumonia(~ 2 episodes) 
p-value Characteristics Categories N=2496 N=395 N=155 
n 0/o n 0/o n % 
z-score ~ -1 1370 54.9 204 51.6 70 45 .2 0.15 
-2 :::= z-score <-1 655 26.2 112 28.4 47 30.3 
Malnutrition 
(weight for age -3 ::; z-score <-2 308 12.3 45 11.4 25 16.1 
z-score) 
z-score <-3 126 5. I 27 6.8 II 7.1 
Missing 37 1.5 7 1.8 2 1.3 
No Exposure 1426 57.1 226 57.2 85 54.8 0.86 
I-9 cigarettes 584 23.4 96 24.3 46 29.7 
Exposure to 
indoor cigarette 1 0-19 cigarettes 94 3.8 I4 3.5 7 4.5 
smoke 
~ 20 cigarettes I2I 4.8 18 4.6 7 4.5 
Missing 27I I0.9 4I I0.4 10 6.5 
::;3 780 31.2 I09 27.6 43 27.7 0.08 
Children from 4-7 768 30.8 I32 
33.4 55 35.5 
same mother 2: 8 I34 5.4 32 8.1 I2 7.7 
Missing 814 32.6 I22 30.9 45 29.1 
::; 2 people 364 14.6 65 16.5 15 9.7 0.007 
People sleeping in 3 -4 people 855 
34.3 114 28.9 44 28 .4 
child's bedroom 2: 5 people 982 39.3 176 44.5 79 50.9 
Miss ing 295 11.8 40 10.1 17 11.0 
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Table 9: Background characteristics of children with number of x-ray confirmed severe and non severe pneumonia episodes (cont •. ) 
No pneumonia Pneumonia (only one episode) Pneumonia( 2::2 episodes) 
Characteristics Categories N=2496 N=395 N=l55 
p-value 
n % n % n % 
Male 1304 52.2 203 51.4 84 54.2 0.84 
Child Sex 
Female 1192 47.8 192 48.6 71 45.8 
Mother's Yes 920 36.9 137 34.7 45 29.1 0.12 
any formal 
education No 1576 63.1 258 65.3 110 70.9 
Yes 1805 72.3 259 65.6 93 60.0 0.002 
Father's 
any formal No 690 27.6 136 34.4 62 40.0 
education 
OK 1 0.1 0 - 0 
Vitamin D Placebo 1249 50.1 208 52.7 65 41.9 0.07 
status Vitamin D 1247 49.9 187 47.3 90 58.1 
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Table 10: Predictors of single and multiple episodes of x-ray confirmed severe and non severe pneumonia 
Characteristics Categories 
Pneumonia Pneumonia 





95%CI OR OR 
< 3 months 1.0 - 0.43 1.0 - 0.03 
Child's age at recruitment in 
3 to <6 1.2 0.7- 1.9 2.0 0.8-5.1 
months 6 to <9 1.3 0.8-2.1 2.2 0.9-5.3 
9 to 12 1.5 0.9-2.4 3.4 1.4- 7.9 
Economic status Not poor 1.0 - 0.59 1.0 - 0.36 
Poor 1.1 0.8- 1.5 1.2 0.8-2.0 
Yes 1.0 - 0.05 1.0 - 0.39 
Currently breastfed 
No 0.7 0.5-0.9 0.8 0.5- 1.3 
Low/no pollution 1.0 - 0.31 1.0 - <0.00 1 
Indoor air pollution status Medium pollution 0.7 0.5- 1.2 0.3 0.1-0.5 
Hi gh pollution 0.9 0.7-1.4 0.5 0.3 - 0.8 
::;3 1.0 - 0.10 1.0 - 0.93 
Children from same mother 4-7 1. 2 0.8- 1.9 0.9 0.5 - 1.8 
~8 1.9 1.0-3.4 0.8 0.3 - 2.3 
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95%CI OR9 OR 
:S 2 people 1.0 - 0.49 1.0 - 0.39 
People sleeping in child's 
3 -4 people 0.9 0.5- 1.5 0.6 0.3- 1.3 
bedroom 
2: 5 people 0.7 0.4-1.3 0.9 0.4-2.0 
Father's Yes 1.0 - 0.14 1.0 - 0.82 
any formal education No 1.3 0.9- 1.8 1.1 0.6- 1.7 
Vitamin D Placebo 1.0 - 0.71 1.0 - 0.02 
status Vitamin 0 1.1 0.8- 1.4 1.7 1.1-2.8 
9 Odds Ratio( OR) adjusted for the effect of other variables listed in the table 
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Table 11: Comparison of first/only episode of severe and non-severe pneumonia in vitamin D and placebo groups (intention to treat analysis) 
Vitamin D Placebo 
Incidence 
Person Person rate ratio 95%CI P-Value 
Type of Pneumonia Episode years Incidence 95%CI Episode years Incidence 95%CI 
at risk Rate at risk Rate 
x-ray confirmed 
All Pneumonia 260 1782 0.145 0.129 - 0.164 245 1782 0.137 0.121 - 0.155 1.06 0.89- 1.27 0.476 
Simple Pneumonia 230 1812 0.126 0. 1 I 1 - 0. 144 219 1814 0.120 0.105-0.137 1.05 0.87- I .2 7 0.566 
Severe Pneumonia 45 1989 0.022 0.016 - 0.030 40 1990 0.020 0.0 14 - 0.027 1.12 0.73- 1.72 0.579 
Very Severe diseases 13 2021 0.006 0.003 - 0.0 II 9 2018 0.004 0.002 - 0.008 1.45 0.61-3 .39 0.3 89 
- - - --
x-ray confirmed 
and non-confirmed 
All Pneumonia 1023 740 1.38 1.30 - 1.47 1030 705 1.46 1.3 7 - 1.55 0.95 0.87 - 1.03 0.274 
Simple Pneumonia 1012 817 1.23 1.16 - 1.31 997 791 1.25 1.18 - 1.34 0.98 0.90- 1.07 0.748 
Severe Pneumonia 160 1847 0.086 0.074- 0.101 149 1854 0.080 0.068 - 0.094 1.08 0.86 - 1.35 0.499 
Very Severe diseases 151 1899 0.079 0.067 - 0.093 167 1895 0.088 0.075 - 0.102 0.90 0.72 - 1.12 0.364 
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Table 12: Comparison of Repeat Episodes of severe and non-severe pneumonia in vitamin D and placebo groups (intention to treat analysis} 
' 
. 
Vitamin D Placebo ' 
. 
' Incidence 
Person ' Person Rate ratio 95%Cl P-Value 
Type of Pneumonia Episode years Incidence 95%CI Episode years Incidence 95%CI ' 
at risk Rate at risk Rate 
x-ray confirmed 
All Pneumonia 138 2031 0.07 0.06- 0.08 82 2027 0.04 0.03 - 0.05 1.68 1.28-2.2 1 <0.001 
Simple Pneumonia 96 2031 0.04 0.04- 0.06 51 2027 0.02 0.02- 0.03 1.88 1.34-2.64 <0.001 
Severe Pneumonia 10 2031 0.004 0.002 - 0.009 8 2027 0.003 0.00 l - 0.007 1.25 0.49-3.17 0.63 
Very Severe diseases 0 2031 0 n/a 0 2027 0 nla n/a n/a n/a 
x-ray confirmed 
and non-confirmed 
All Pneumonia 2338 2029 1.15 l.ll - l.l9 2200 2025 1.08 1.04-1.13 1.06 1.00- 1.12 0.04 
Simple Pneumonia 1945 2029 0.95 0.91 - 1.00 1825 2025 0.90 0.86- 0.94 1.06 0.99- 1.1 3 0.05 
Severe Pneumonia 50 2029 0.02 0.01 - 0.03 54 2025 0.03 0.02- 0.04 0.92 0.63- 1.35 0.68 
Very Severe diseases 43 2029 0.02 0.01 - 0.03 38 2025 0.02 0.01-0.03 1.1 2 0.72- 1.74 0.59 
13 1 




Person Person rate ratio 





at risk Rate at risk Rate 
x-ray confirmed 
All Pneumonia 398 2031 0.195 0.177 - 0.2 16 327 2027 0.161 0.144 - 0.179 1.22 
Simple Pneumonia 329 2031 0.162 0.145 - 0.180 270 2027 0. 13 3 0.118 - 0.150 1.22 
Severe Pneumonia 56 2031 0.027 0.021 - 0.036 48 2027 0.023 0.017- 0.03 1 1.17 
Very Severe diseases 13 203 1 0.006 0.003 - 0.011 9 2027 0.004 0.002 - 0.008 1.44 
---- - - --
x-ray confirmed 
and non-confirmed 
All Pneumonia 336 1 2029 1.656 1.60 1 - 1.713 3230 2025 1.594 1.540 - 1.650 1.04 
Simple Pneumonia 2957 2029 1.475 1.405 - 1.510 2822 2025 1.393 1.343 - 1.445 1.05 
Severe Pneumonia 210 2029 0.103 0.090 - 0. 118 203 2025 0.100 0.087 - 0. 115 1.03 
Very Severe di seases 194 2029 0.095 0.083-0.110 205 2025 0.10 1 0.088 - 0. 11 6 0.94 
Table 14: Time to repeat episodes of x-ray confirmed severe and non-severe pneumonia after latest vitamin D/Piacebo dose 
Time to episode in day 
Mean ( 95% Cl ) 
Vitamin D 
N=81 










0. 79- 1.72 
0.6 1-3.39 
0.99- 1.09 
0.99 - 1.1 0 











Table 15: Comparison of first/only episode of severe and non-severe pneumonia in vitamin D and placebo groups (intention-to-treat analysis 15 
days gap for new episode) 
.J; 
Vitamin D Placebo 
Person Person Incidence ,, 
95%CI 
years Incidence years Incidence rate ratio 
Type of Pneumonia Episode 95%CI Episode 95%CI 
at risk Rate at risk Rate 
"' 
x-ray confirmed 
All Pneumonia 260 1782 0.14 0.13-0.16 245 1782 0.14 0.12- 0.15 1.06 0.89- 1.27 
Simple Pneumonia 230 1812 0.13 0.11 - 0.14 219 1814 0.12 0.10 - 0.14 1.05 0.87-1.27 
Severe Pneumonia 45 1989 0.02 0.02 - 0.03 40 1990 0.02 0.01 - 0.03 1.1 3 0.73- 1.72 
Very Severe diseases 13 2021 0.006 0.003- 0.011 9 2018 0.004 0.002- 0.008 1.45 0.62- 3.39 
x-ray confirmed & 
non-confirmed 
All Pneumonia 1023 740 1.38 1.30- 1.46 I 1031 704 1.46 1.38 - 1.55 I 0.95 0.87- 1.04 
Simple Pneumonia 1012 815 1.24 1.1 6 - 1.31 I 1000 786 1.27 1.19-1.35 I 0.98 0.89- 1.07 
Severe Pneum on ia 163 1847 0.09 0.07- 0.10 I 151 1854 0.08 0.07 - 0.09 I 1.08 0.87 - 1.35 














Table 16: Comparison of repeat episodes of severe and non-severe pneumonia in vitamin D and placebo groups (intention-to-treat analysis 15 
days gap for new episode) 
Vitamin D Placebo 
Person Person Incidence 
95% CI 
years Incidence years Incidence rate ratio 
Type of Pneumonia Episode 95%CI Episode 95%CI 
at risk Rate at risk Rate 
x-ray confirmed 
All Pneumonia 138 2031 0.06 0.06- 0.08 82 2027 0.04 0.03 - 0.05 1.68 1.28-2.21 
Simple Pneumonia 99 2031 0.04 0.04- 0.06 51 2027 0.02 0.02- 0.03 1.94 1.38- 2.72 
Severe Pneumonia 1 1 2031 0.005 0.002 - 0.009 8 2027 0.003 0.001 - 0.007 1.38 0.55-3.42 
Very Severe diseases 0 2031 0 n/a 0 2027 0 n/a n/a n/a 
--- - --- -- --
x-ray confirmed & 
non-confirmed 
All Pneumonia 2509 2030 1.23 I. 18 - 1.28 2360 2026 1.16 1.11- 1.21 1.06 1.00 - 1.1 2 
S imple Pneumonia 2099 2030 1.03 0.99- 1.07 1966 2026 0.9 0.92 - 1.0 I 1.06 1.00 - 1.13 
Severe Pneumonia 53 2030 0.03 0.02- 0.03 55 2025 0.03 0.02- 0.04 0.96 0.65- 1.40 











Table 17: Distribution and causes of deaths according to WHO IDD-10 codes between Vitamin D and Placebo groups 




8 Jan, 2008 Hospital VA-Ol.ll Meningitis G009 
unspecified 




18 Dec 2007 Home VA-10.02 respiratory diseases) P590 
unspeci tied 
Neonatal Jaundice 
Acute lower respiratory 
VA-01.13 infections including 
Jl89 
Pneumonia, 
immediate cause) pneumonia and acute unspec ified 
Severe malnutrition plus 




Severe malnutrition E42 
underlying cause) 
kwashiorkor 
Acute lower respiratory 




23 Feb 2008 Home 
immediate cause) pneumonia and acute unspecified 
and severe pneumonia plus 
-8 bronchitis) 
"= long term cerebral palsy 
.'.:::: VA-03 .02 
> underlying cause) Severe malnutrition 
E40 kwashiorkor 
Possibility of suffocation 
Other ill-defined and 
but 
26 Feb 2008 Home VA-99 Unspeci tic causes of death R99 unspecified causes of not confirmed 
mot1ality 
Meningiti s, 
9 March 2008 Hospi tal V A-0 1.11 Meningitis G009 
Hydrocephalus, Down 
syndrome and pneumoni a 
Acute lower respiratory 
14 March 2008 Home 
VA-01.13 infections including 
Jl89 
Severe pneumoni a plus 
immediate cause) pneumonia and acute convul sion 
bronchitis) 
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Table 17: Distribution and causes of deaths according to WHO IDD-10 codes between Vitamin D and Placebo groups (cont.) 
Study Group I Date of death Died at Verbal autopsy Verbal Autopsy Title lCD lCD Title Additional problems 
code code 
12 April 2008 Home VA-11.03 Accidental fall TV fallen over the child 
Q Diseases of circulatory Other and unspecified Probably congenital heart 
.5 21 April 2008 Home VA-04.99 system, unspecified I99 disorders of diseases a circulatory system 
~ 
::: 
~ ' The child was chocked by 
Misadventure to patient during 
24 June 2008 Home VA-12 
surgical and medical care 
pill 
4 Dec 2007 Hospital VA-01.99 
Infectious diseases, 
899 
Other and unspecified 
Septic Shock, unknown 
unspecified infectious diseases 
Acute lower respiratory 




Pneumonia and Septicemia 
pneumonia and acute unspecified 
bronchitis) 
1 0 April 2008 Home VA-02.98 Other specified carcinoma 
Neuroblastoma 
0 
.Q TV fallen over the child G,j 
3 July 2008 Home VA-11.03 Accidental fall (J ~ 
a: 
Acute lower respiratory 






Pneumonia and Septicemia 
hospital pneumonia and acute unspecified 
bronchitis) 
6 Sep 2008 Hospital VA-01.99 
Infectious diseases, 
899 
Other and unspecified Septicemia post 
unspecified infectious diseases operational 
3rd Feb 2009 Home VA-01.99 
Infectious diseases, 
899 
Other and unspecified Possibility of Bacterial 
unspeci tied infectious diseases Meningitis 
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Table 18: Comparison of hospital admissions in vitamin & placebo groups 
Vitamin D Placebo 
Person Person Incidence 95%CI p-value 





at risk Rate at risk Rate 
First/ only Admission 134 1918 0.07 0.06-0.08 134 1915 0.07 0.06-0.08 1.00 0.79- 1.27 0.99 
Repeat Admissions 
42 2030 0.02 0.01-0.03 53 2027 0.03 0.02-0.04 0.79 0.53- 1.19 0.26 
Table 19: Common causes and length of hospital admissions between vitamin D and placebo groups 
Vitamin D Placebo 
Causes n= 1524 n= 1522 
(determined by study clinicians) 
n % n % 
Severe pneumonia 64 4.2 81 5.3 
Watery di arrhea and 
22 1.4 16 1.1 
Moderate dehydration 
Febri le convulsion 28 1.8 26 1.7 
Asthma 10 0.7 12 0.8 
Bronchia l it is 15 1.0 15 1.0 
UTI I 17 1.1 22 1.4 
Length of stay at hospital in days N= 132 N= 146 
Mean (95%C I) 0.7 (0.4- 1.0) 0.8 (0.5- 1.1) 
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Table 20: Comparison of first/only episode of severe and non-severe pneumonia in vitamin D and placebo groups {Per-protocol analysis) 
·• 
Vitamin D Placebo 
,., 
Incidence 
Person Person Rate ratio 95%CI P-Value 





at risk Rate at risk Rate 
x-ray confirmed 
All Pneumonia 230 1620 0.14 0.12-0.16 219 1625 0.13 0.12-0.15 1.06 0.88- 1.27 0.54 
Simple Pneumonia 201 16SO 0.12 O.ll-0.14 195 1652 0.11 0.10-0.14 1.03 0.85- 1.26 0.71 
Severe Pneumonia 44 1787 0.024 0.018- 0.033 36 1794 0.020 0.014-0.028 1.23 0.79- 1.91 0.35 
Very Severe diseases 12 1819 0.006 0.003-0.012 9 1815 0.005 0.002-0.009 1.33 0.56-3.17 0.51 
x-ray confirmed and 
non-confirmed 
All Pneumonia I 915 910 1.0 I 0.94- 1.07 I 922 895 1.03 0.96- 1.09 0.98 0.89- 1.07 0.68 
Simple Pneumonia 902 949 0.95 0.89- 1.01 88S 947 0.93 0.87-0.99 1.02 0.93- 1.12 0.67 
Severe Pneumonia 148 1678 0.09 0.07-0.10 13S 1697 0.08 0.07-0.09 1.11 0.88 - 1.40 0.38 
Very Severe diseases 13S 1724 0.08 0.06-0.09 ISS 1704 0.09 0.07-0.11 0.86 0.68 - 1.08 0.2 1 
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Table 21: Comparison of Repeat Episodes of severe and non-severe pneumonia in vitamin 0 and placebo groups (per-protocol analysis) 
Vitamin D Placebo 
Incidence 
Person Person rate ratio 95%CI P-Value 
Type of Pneumonia Episode 
years Incidence 
95% CI Episode 
years Incidence 
95%CI 
at risk Rate at risk Rate 
x-ray confirmed 
All Pneumonia 125 1828 0.07 0.06-0.08 74 1824 0.04 0.03-0.05 1.69 1.27-2.25 <0.001 
Simple Pneumonia 88 1828 0.05 0.04-0.06 47 1824 0.03 0.02-0.04 1.87 1.31- 2.67 <0.001 
Severe Pneumonia 10 1828 0.005 0.003-0.010 6 1824 0.003 0.00 I - 0.007 1.67 0.61-4.59 0.31 
Very Severe diseases 0 1828 0 n/a 0 1824 0 n/a n/a n/a n/a 
x-ray confirmed and 
non-confirmed 
All Pneumonia 2134 1826 1.17 1.12 - 1.22 1977 1822 1.08 1.04- 1.13 1.08 1.01-1.14 0.02 
Simple Pneumonia 1779 1826 0.97 0.93- 1.02 1645 1822 0.90 0.86-0.94 1.08 1.01-1.15 0.02 
Severe Pneumon ia 44 1826 0.024 0.017- 0.032 42 1822 0.023 0.017- 0.031 1.04 0.68- 1.59 0.84 
Very Severe diseases 41 1826 0.022 0.016- 0.030 37 1822 0.020 0.014- 0.028 1.10 0.71 - 1.72 0.66 
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Table 22: Comparison of first/only episode of severe and non-severe pneumonia in vitamin D and placebo groups (Per-protocol analysis with 
at least 4 consecutive doses of vitamin 0/placebo) 
Vitamin D Placebo 
Incidence 
Person Person Rate ratio 95%CI 





at risk Rate at risk Rate 
x-ray confirmed 
A ll Pneum onia 194 1332 0. 14 0.13 - 0.18 172 1322 0.13 0.11-0.15 1.12 0.91- 1.37 
Simple Pneumonia 171 1356 0.13 0. 11 -0.15 152 1349 0.11 0.09-0.1 3 1.1 2 0.90- 1.39 
Severe Pneumonia 38 149 1 0.025 0.0 18- 0.035 29 1479 0.0 19 0.0 13-0.028 1.29 0.80-2. 11 
Very Severe diseases 10 1519 0.006 0.003 - 0.122 8 1499 0.005 0.003 - 0.0 II 1.23 0.49-3. 12 
x-ray confirmed and 
non-con firmed 
A ll Pneumonia I 754 54 1 1.39 1.29- 1.49 I 755 500 1.51 1.40- 1.62 0.93 0.84- 1.03 
S imp le Pneumonia 746 599 1.24 1.16-1.34 722 566 1. 27 1.18-1.37 0.98 0.88 - 1.09 
Severe Pneumonia 126 1379 0.09 0.08-0. 11 97 1398 0.07 0.05 - 0.08 I 1. 3 1 1.01 - 1.71 











Table 23: Comparison of Repeat Episodes of severe and non-severe pneumonia in vitamin D and placebo groups (Per-protocol analysis with 
at least 4 consecutive doses of vitamin 0/placebo) 
Vitamin D Placebo 
Incidence 
Person Person rate ratio 95%CI 





at risk Rate at risk Rate 
> ;,, 
x-ray confirmed 
All Pneumonia 110 1526 0.07 0.06-0.09 62 1508 0.04 0.03-0.05 1.75 1.29 -2.39 
Simple Pneumonia 75 1526 0.05 0.04-0.06 42 1508 0.03 0.02-0.04 1.78 1.21 - 2.58 
Severe Pneumonia 10 1526 0.006 0.003-0.012 3 1508 0.002 0.00 I - 0.006 3.29 0.91-11 .96 
Very Severe diseases 0 1526 0 n!a 0 1508 0 n!a n!a n!a 
------L__- - ------ --
x-ray confirmed and 
non-confirmed 
A ll Pneumonia 1796 1525 1.18 1.12- 1.23 1669 1506 I. I I 1.05- 1.16 1.06 0.99-1. 14 
Simple Pneumonia 1502 15 25 0.98 0.94- 1.03 1407 1506 0.93 0.88-0.98 1.05 0.98 - 1.13 
Severe Pneumonia 41 1525 0.03 0.02-0.04 31 1506 0.02 0.01 - 0.03 1.30 0.82 - 2.08 











Table 24: Comparison of first/only episode of severe and non-severe pneumonia in vitamin D and placebo groups (Per-protocol analysis with 
at least 5 consecutive doses of vitamin 0/placebo) 
Vitamin D Placebo 
Incidence 
Person Person Rate ratio 95%CI 





at risk Rate at risk Rate 
x-ray confirmed 
All Pneumonia 176 1253 0.14 0.12-0.16 166 1242 0.13 0.11-0.15 1.06 0.85- 1.31 
Simple Pneumonia 155 1275 0.12 0.10-0.14 146 1264 0.11 0.09-0.13 1.06 0.85- 1.32 
Severe Pneumonia 37 1395 0.03 0.02- 0.04 28 1394 0.02 0.01 - 0.04 1.32 0.81-2.16 
Very Severe di seases 7 1242 0.005 0.002-0.010 8 1410 0.006 0.003 - 0.0 II 0.87 0.31-2.39 
------- - - ------------ - - - - -
x-ray confirmed and 
non-confirmed 
All Pneumonia 704 506 1.39 1.29- 1.49 710 468 1.51 1.41 - 1.63 0.93 0.84- 1.03 
Simple Pneumonia 696 561 1.24 1.15- 1.33 677 531 1.27 1.18 - 1.37 0.97 0.88 - 1.08 
Severe Pneumonia 121 1289 0.09 0.08 - 0.11 93 1319 0.07 0.05 - 0.09 1.32 1.01 - 1.74 











Table 25: Comparison of Repeat Episodes of severe and non-severe pneumonia in vitamin D and placebo groups (Per-protocol analysis with 
at least 5 consecutive doses of vitamin 0/placebo) 
Vitamin D Placebo 
Incidence 
Person Person rate ratio 95%CI 





at risk Rate at risk Rate 
x-ray confirmed 
All Pneumonia 103 1429 0.07 0.06-0.09 59 14 19 0.04 0.03 - 0.05 1.75 1.26-2.39 
Simple Pneumonia 70 1429 0.05 0.04-0.06 40 14 19 0.03 0.02-0.04 1.74 1.18-2.56 
Severe Pneumonia 10 1429 0.007 0.004-0.0 13 3 141 9 0.002 0.00 1 - 0.006 3.3 1 0.91- 12.03 
Very Severe diseases 0 1429 0 n/a 0 1419 0 n/a n/a n/ a 
x-ray confirmed and 
non-confirmed 
All Pneumonia 1668 1428 1.17 1.11 - 1.22 1564 14 18 1.10 1.05 - 1.1 6 1.06 0.99- 1. 13 
Simple Pneumonia 1394 1428 0.97 0.93- 1.03 1318 14 18 0.93 0.88-0.98 1.05 0.97 - 1.13 
Severe Pneumonia 38 1428 0.03 0.02-0.04 29 14 18 0.02 0.0 1 -0.03 1.29 0.80 - 2. 10 











Table 26: Effect of different risk factors on the incidence rate of first or only episode of x-ray confirmed severe and non-severe pneumonia 
Risk factors Categories 
Person years Unadjusted 95%CI p-value 
Adjusted 
95%CI p-value 
Cases at risk 
IRR
10 IRR 
< 2 months 31 289 1.00 <0.001 1.00 0.04 
Child's age in 2 to <6 141 1274 1.04 0.70- 1.53 1.38 0.81 -2.36 months 
6 to 12 333 2001 1.54 1.07-2.22 1.73 1.04-2.89 
better Off 47 419 1.00 0. 12 
less Poor 84 670 l. I 1 0.77-1.58 
Economic status 
poor 91 595 1.36 0.95- 1.93 
very poor 88 564 1.38 0.97- 1.97 
Poorest 99 601 1.45 1.03-2.06 
Currently Yes 298 2082 1.00 0.96 
breastfed No 204 1459 0.99 0.83- 1.19 
Low/No 
159 827 1.00 <0.001 1.00 0.003 
Pollution 
Indoor air medium 81 852 0.50 0.38-0.66 0.55 0.39-0.77 
pollution status pollution 
high pollution 217 1594 0.72 0.58-0.88 0.80 0.62- 1.04 
z-score :::: -I 254 1947 1.00 0.10 
Malnutrition -2 ::; z-score <-I \45 942 1.17 0.96 - 1.44 
(weight for age 
z-score) -3 ::; z-score <-2 62 440 1.08 0.81- 1.42 
z-score <-3 36 183 1.49 1.05 - 2. I 2 
10 Incidence rate rati o 
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Table 26: Effect of different risk factors on the incidence rate of first or only episode of x-ray confirmed severe and non-severe 
pneumonia (cont.) 
Risk factors Categories Cases Person years Unadjusted 95%CI p-value 
Adjusted 
95%CI p-value 
at risk IRR 
IRR 
No Exposure 281 2 114 1.00 0.59 
Exposure to l-9 cigarettes 132 850 l.l 5 0.94- 1.42 
indoor cigarette 
smoke I 0-1 9 cigarettes 20 136 l.ll 0.70 - 1.75 
2: 20 cigarettes 24 172 1.05 0.69 - 1.59 -
:S3 138 1145 1.00 0.0 1 1.00 0.36 
C hildren from 
4-7 178 11 64 same mother 1.27 1.01- 1.58 1.07 0.77-1.47 
2:8 42 213 1.63 l.l6- 2.31 1.35 0.87- 2.10 
:S 2 people 71 545 1.00 0.02 1.00 0.53 
People sleeping in 
3 -4 people 145 11 94 0.93 0.70 - 1.24 0.80 0.54 - 1.1 8 child' s bedroom 
2: 5 people 234 1477 1.22 0.94- 1.59 0.88 0.58 - 1.32 
--
Male 275 39 1.00 0. 11 
C hild Sex 
fem ale 230 29 1.15 0.96 - 1.37 
Mother's Yes 167 13 12 1.00 0.08 1.00 0.78 
Any formal 
education No 338 2252 1.17 0.98 - 1.4 1 1.04 0.80 - 1.34 
Father 's Yes 327 2582 1.00 <0.001 1.00 0.25 
Any formal 
ed ucation No 178 982 1.41 1.18 - 1.69 1.1 6 0.90 - 1.49 
Vitami n D Placebo 245 1782 1.00 0.47 1.00 0 16 
status Vitamin D 260 1782 1.06 0.89 - 1.27 1.14 0.90 - 1.43 
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Table 27: Effect of different risk factors on the incidence rate of repeat episode of x-ray confirmed severe and non-severe pneumonia 
Person 
Adjusted Risk factors Categories Cases years at Unadjusted 95%CI p-value 95% CI p-value 
risk IRR 
IRR 
< 2 months 17 321 1.00 <0.001 1.00 0.06 
Child's age in 2 to <6 43 1405 0.57 0.39-2.09 0.82 0.43- 1.56 months 
6 to 12 160 2332 1.29 0.93-4.31 1.28 0.69-2.35 
better Off 18 465 1.00 <0.001 1.00 0.14 
less Poor 29 759 0.98 0.54- 1.77 1.09 0.59-2.03 
Economic status poor 28 686 1.05 0.58- 1.90 0.93 0.49 - 1.74 
very poor 47 654 1.85 1.08-3 .19 1.52 0.85-2.71 
Poorest 64 705 2.34 1.39- 3.95 1.55 0.87-2.75 




No 84 1700 0.85 0.64- 1.11 
Low!No Pollution 89 996 1.00 <0.001 1.00 0.00 1 
Indoor air 
med ium pollution 29 928 0.35 0.23-0.53 0.43 0.27-0.68 
pollution status 
high pollution 88 1798 0.55 0.41 - 0.73 0.69 0.49 - 0.97 
z-score ~ -I 97 2185 1.00 0.02 1.00 0.19 
Malnutrition -2 :S z-score <-I 65 1091 1.34 0.98- 1.83 1.03 0.71 - 1.49 
(weight for age 
z-score) -3 :S z-score <-2 34 507 1.51 1.02 - 2.23 1.25 0.79 - 1.96 
z-score <-3 19 214 2.00 1. 22 - 3.27 1.73 1.0 I - 2.93 
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Risk factors Categories Cases years at Unadjusted 95% CI p-value 95% CI p-value 
risk IRR 
IRR 
No Exposure 140 2389 1.00 0.23 
Exposure to 1-9 cigarettes 47 982 0.82 0.59-1.14 
cigarette smoke 1 0-1 9 cigarettes 12 154 1.33 0.74-2.40 
:::: 20 cigarettes 7 197 0.61 0.28- 1.30 
-
S3 63 1286 1.00 0.37 
Children from 
4-7 80 1340 1.22 0.88- 1.69 
same mother 
::::8 17 254 1.37 0.80-2.34 
S 2 people 31 614 1.00 0.49 
People sleeping in 
3 -4 people 70 1381 1.00 0.66- 1.53 
child's bedroom 
:::: 5 people 100 1669 1.19 0.79- 1.77 
Male 131 47 1.00 0.57 
Child sex 
female 89 35 0.92 0.70- 1.21 
Mother's Yes 58 1470 1.00 0.002 1.00 0.44 
any formal 
education No 162 2587 1.59 1.18-2.15 1.15 0.80 - 1.64 
Father's Yes 117 2895 1.00 <0.001 1.00 0.002 
any formal 
education No 103 1163 2.19 1.68-2.86 1.68 1.21 - 2.32 
Vitamin D Placebo 82 2027 1.00 
<0.001 1.00 <0.00 1 
status Vitamin D 138 2031 1.68 1.28-2.2 1 1.93 1.40 - 2.65 
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Table 28: Effect of different risk factors on the incidence rate of first or only episode of x-ray confirmed severe pneumonia 
Person 
Risk factors Categor ies Cases years at Unadjusted 
risk IRR 
95% C I p-value 
Adjusted 
95% C I p-value 
IRR 
< 2 months 6 3 15 1.00 0.65 
Child 's age in 2 to <6 26 1384 0.98 0.40 - 2.40 
months 
6-1 2 6 to 12) 53 2282 1.2 1 0.52 - 2.83 
better Off 7 459 1.00 0.09 1.00 0.26 
less Poor 9 749 0.79 0.29-2.11 0. 70 0.23 - 2.09 
Economic status 
poor 16 671 1.57 0.64- 3.81 0.95 0.34-2.65 
very poor 14 640 1.44 0.58 - 3.57 0.25 0.06 - 1.02 
poorest 22 683 2. 11 0.90 - 4.94 0.97 0.36-2.64 
-
C urrently Yes 52 23 19 1.00 0.69 
breastfed No 33 1635 0.9 1 0.59 - 1.4 1 
Low!No Po llution 35 964 1.00 <0.001 1.00 0.002 
Indoor air 
Medium poll ution 10 918 0.29 0. 14 - 0.60 0.2 1 0.07 -0.6 1 
pollution Status 
High pollution 34 1766 0.53 0.33-0.85 0.37 0.18-0.73 
z-score ?. -1 47 2146 1.00 0.29 
Malnutrition -2 ::; z-score <-I 22 1068 0.94 0.56- 1.56 
(weight for age 
-3 ::; z-score <-2 7 500 0.64 0.29- 1.42 z-score) 
z-score <-3 8 207 1.75 0.82-3.7 1 
No Exposure 48 2347 1.00 0.37 
Ex posure to 1-9 cigarettes 20 960 1.0 I 0.60 - 1.7 1 
indoor ciga rette 
I 0- 19 cigarettes 
., 151 0.96 0.30-3 .09 smoke .) 
?. 20 cigarettes 8 190 2.06 0.97 -4.35 
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Table 28: Effect of different risk factors on the incidence rate of first or only episode of x-ray confirmed severe pneumonia (cont.) 
Person 
Adjusted 
Risk factors Categories Cases years at Unadjusted 95% CI p-value 95% CI p-value 
risk IRR 
IRR 
:::;3 19 1272 l.OO 0.06 l.OO 0.59 
Children from 
4-7 36 1301 1.86 1.06-3.24 1.39 0.57-3.39 
same mother 
::::8 7 248 1.91 0.80-4.55 0.85 0.20- 3.49 
People sleeping 
:::; 2 people 8 604 1.00 0.01 1.00 0.96 
in child's 3 -4 people 19 1323 1.08 0.47-2.48 0.86 0.27-2.68 
bedroom) 
::=: 5 people 47 1657 2.16 1.02-4.57 0.89 0.27-2.91 
Male 49 46 l.OO 0.87 
Child sex 
female 36 34 1.03 0.66- 1.59 
Mother's Yes 32 1442 l.OO 0.79 
any formal 
No 53 2538 0.94 0.60- 1.46 education 
Father's Yes 49 2852 1.00 0.006 l.OO 0.29 
any formal 
No 36 1128 1.84 1.20-2.84 1.42 0.74-2.71 education 
Vitamin D Placebo 40 1990 l.OO 0.58 1.00 0.76 
status Vitamin D 45 1989 1.13 0.74- 1.73 1.10 0.59- 2.04 
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Table 29: Effect of different risk factors on the incidence rate of first or only episode of x-ray confirmed simple pneumonia 
Risk factors Categories Case 
Person Unadjusted 
95% CI p-value 
Adjusted 
95% CI p-value 
years at risk IRR IRR 
< 2 months 27 295 1.00 <0.001 1.00 0.001 
Child's age in 2 to <6 116 1299 0.98 0.64- 1.49 1.40 0.79-2.48 
months 
6 to 12 306 2033 1.63 1.10-2.42 2.09 1.21 - 3.57 
better Off 42 423 1.00 0.22 
less Poor 76 679 1.12 0.77- 1.63 
Economic status 
poor 80 606 1.33 0.91- 1.93 
very poor 77 576 1.34 0.92- 1.96 
Poorest 89 615 1.45 1.00-2.09 
Currently 
Yes 260 2128 1.00 0.63 
breastfed No 186 1476 1.04 0.86- 1.26 
Low/No Pollution 137 852 1.00 <0.001 1.00 0.003 
Indoor air medium pollution 73 860 0.53 0.40-0.70 0.55 0.39-0.78 pollution status 
high pollution 193 1622 0.74 0.59-0.92 0.79 0.61 - 1.04 
z-score 2 -I 223 1980 1.00 0. 11 
Malnutrition -2 :S z-score <-I 130 963 1.19 0.96- 1.48 
(weight for age -3 :S z-score <-2 56 445 I. I I 0.83- 1.49 
z-sco re) 
z-score <-3 32 187 1. 51 1.04-2.19 
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Table 29: Effect of different risk factors on the incidence rate of first or only episode of x-ray confirmed simple pneumonia (cont.) 
Risk factors Categories Case 
Person 
Unadjusted 95%CI p-value 
Adjusted 
95% Cl p-value 
years at risk 
IRR 
IRR 
No Exposure 253 2145 1.00 0.81 
Exposure to 1-9 cigarettes 113 873 1.08 0.87- 1.36 
indoor cigarette 
smoke 1 0-19 cigarettes 18 139 1.10 0.68- 1.78 
~ 20 cigarettes 19 177 0.90 056- 1.44 
S:3 125 1161 l.OO 0.02 1.00 0.09 
Children from 
4-7 156 1193 1.21 0.96- 1.53 1.10 0.86-1.41 
same mother 
~8 39 220 1.65 1.15-2.3 7 1.52 1.05-2.22 
S: 2 people 64 551 1.00 0.11 
People sleeping 
in child 's 3 -4 people 131 1209 0.93 0.69- 1.25 
bedroom 
~ 5 people 204 1512 1.1 6 0.88- 1.54 
Male 243 40 1.00 0.12 
Child sex 
female 206 30 1.15 0.96- 1.39 
Mother's Yes 147 1334 1.00 0.07 1.00 0.48 
any formal 
education No 302 2293 1.1 9 0.97- 1.45 1.09 0.84 - 1.43 
Father's Yes 291 26 19 1.00 <0.00 1 1.00 0.2 1 
any formal 
education No 158 1008 1.39 1.1 5- 1.69 1.1 7 0.9 1- 1.51 
Vitamin D placebo 2 19 1814 1.00 0.56 
1.00 0.48 
status Vitamin D 230 1812 1.05 0.88 - 1.27 1.09 0.86 - 1.37 
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Table 30: Effect of different risk factors on the incidence rate of first or only episode of x-ray confirmed very severe diseases 




95% CI p-value years at risk IRR IRR 
< 2 months 4 3 19 1.00 0.30 
Child's age in 2 to <6) 7 1397 0.40 0.11 -1.37 months 
6 to 12 1 I 2324 0.37 0.12-1.18 
better Off 2 462 1.00 0.75 
less Poor 4 754 1.22 0.22-6.69 
Economic status poor 2 684 0.68 0.09-4.83 
very poor 5 649 1.78 0.34-9.20 
Poorest 5 701 1.65 0.32 - 8.50 
Yes 10 2361 1.00 0.19 
Currently 
breastfed No 12 1652 I. 73 0.75-4.02 
Low/No Pollution 8 990 1.00 0. 17 
Indoor air medium pollution 2 927 0.26 0.05 - 1.25 
pollution status 
high pollution 10 1789 0.68 0.27 - 1.74 
z-score ~ -I II 2175 1.00 0.63 
Malnutrition -2 :S z-score <-I 5 1086 0.91 0.3 1 - 2.62 
(weight for age 
z-score) 
-3 :S z-score <-2 5 504 1.96 0.68 - 5.64 
z-score <-3 I 2 14 0.92 0. 11 - 7.16 
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Table 30: Effect of different risk factors on the incidence rate of first or only episode of x-ray confirmed very severe diseases (cont.) 
Risk factors Categories Cases 
Person Unadjusted 
95% CI p-value 
Adjusted 
95% CI p-value 
years at risk IRR IRR 
No Exposure II 2380 1.00 0.84 
Exposure to 1-9 cigarettes 7 976 1.54 0.59-3.98 
indoor cigarette 
smoke 10-19 cigarettes 1 154 1.39 0.17- 10.78 
~ 20 cigarettes 1 196 1.10 0.14-8.52 
--
::;3 6 1283 1.00 0.78 
Children from 
4-7 8 1333 1.28 0.44-3.71 
same mother 
~8 2 251 1.72 0.34-8.52 
:'S 2 people 3 609 1.00 0.73 
People sleeping in 
3 -4 people 6 1334 0.91 0.22-3.65 
child's bedroom 
~ 5 people II 1695 1.33 0.37-4.76 
Male 15 47 1.00 0.23 
Child sex 
female 7 35 0.57 0.23- 1.44 
Mother's Yes 4 1467 1.00 0.06 1.00 0.20 
any formal 
education No 18 2573 2.57 0.87- 7.59 2.09 0.68-6.41 -
Father's Yes II 2885 1.00 0.03 1.00 0.09 
any formal 
education No II 1155 2.49 1.08- 5.76 2.09 0.88-4.96 
Vitamin D Placebo 9 2018 1.00 
0.39 1.00 0.37 
status Vitamin D 13 2021 1.45 0.62-3 .39 1.47 0.63- 3.44 
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Table 31: Level of agreement between two readers for chest x-rays 
Reader 2 
Total 
Pneumonia No pneumonia 
n (%) n (%) n (%) 
I. Pneumonia 763 (85) 62 (2.3) 825 (22.8) ~ 
"0 
~- 2657 (97. 7) ~ 
No pneumonia 134 ( 15) 2791 (77.2) a: 
Total 
897 (1 00) 2719 (1 00) 3616 (100) 
Table 32: Comparison of all bronchiolitis episodes in vitamin D and placebo groups {intention to treat analysis) 
Vitamin D Placebo 
Person Person Incidence 95% CI P-value 
years Incidence years Incidence Rate ratio 
Episode 
at risk Rate 
95% CI Episode 
at risk Rate 
95%CI 
Bronchiolitis 
100 859 0.116 0.095- 0.141 75 834 0.089 0.071 - 0.112 1.28 0.95- 1.72 0. 11 
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Table 33: Vitamin D level in blood samples of intervention and non-intervention groups after each 3-montly dose administration 
Intervention (25 OH)D serum Concentration Control (25 OH)D serum Concentration 
n (%) n (%) 
<5 5-<15 15-<20 20-150 >150 <5 5-<15 15-<20 20-150 >150 
ng/ml ng/ml nglml ng/ml nglml nglml nglml nglml nglml nglml 
Timing of sample 
to supplementation <12.5 12.5-<37.5 37.5-<50 50-250 >250 <12.5 12.5-<37.5 37.5-<50 50-250 >250 
nmol/L nmol/L nmol/L nmol/L nmol/L nmol/L nmol/L nmol/L nmol/L nmol/L 
1st sample 
Nov 2007 0 (-) I ( 1.4) 2 (2.9) 65 (94.2) I ( 1.5) 0 (-) 29(41.4) 19 (27.2) 22 (31.4) 0 (-) 
I week after I 51 dose) n= 139 
2"d Sample 
Jan 2008 0( -) 10(15.9) 8 (12.7) 45 (71.4) 0 (-) 5 (7.1) 46(65 .7) 7 (10.0) 12 ( 17.2) 0 (-) 
2months after dose I) n= 13 3 
3rd sample 
3 months after dose I and just Feb 2008 I ( 1.6) 15 (24.2) 20 (32.3) 26 (41.9) 0 (-) 7 (11. 7) 30 (50.0) 9(15.0) 14 (23.3) 0 (-) 
before dose 2) n= 122 
4th Sample 
May 2008 0 (-) 0 (-) 5 (5.9) 78 (92 .9) 1 ( 1.2) 0 (-) 18 (31.6) 9 (15 .8) 30 (52 .6) 0 (-) 
2 weeks after 3 rd dose) n= 141 
51h Sample 4 months after 6th 
July 2009 0 (-) 3 (5 .5) 24 (43.6) 28 (50.9) 0 (-) 0 (-) 9(19.6) 16 (34.8) 21 (45 .6) 0 (-) 
dose) n = 101 
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Table 34: Vitamin 0 serum levels measured at different stages in samples of study children 
Intervention serum 25(0H)D Control serum 25(0H)D 
concentrations concentrations 
Timing of sample to 
Month of sample 
supplementation 
Mean Cl Mean CI 
nmoUL nmoUL nmoUL nmoUL 
I week after first dose 
Nov (2007) 129.5 (111.1- 147.9) 42.9 (38.7- 47.0) 
(n=140) 
2 months after first dose Jan (2008) 76.3 (64.5- 88.2) 33.0 (28.0- 38 .0) 
(n=133) 
3 months after dose 1 and 
Feb (2008) 55.5 (46.0- 65 .0) 39.6 (28.5 - 50. 7) 
just before dose 2 
n=122 
2 weeks after 3 rd dose May (2008) 104.9 (89.8- 120.0) 52.9 (45.3- 60.6) 
(n=141) 
4 months after dose 6 51.9 (49.0- 54.9) 50.1 (45 .0- 55 .1) 
(n= 101) July (2009) 
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ANNEXES 
Annex 1: ERB application for Ethics Committee of MoPH, Afghanistan 
Introductory Questionnaire 
Title of protocol: Double-blind randomised controlled trial investigating the effect of 
vitamin D supplementation on the incidence of pneumonia 
Principle Investigator: Daniel Chandramohan 
Department of Infectious and Tropical 
London School of Hygiene & Tropical Medicine 
0044-2079272322 
0044-207 5 80907 5 
Daniel.chandramohan@ishtm.ac.uk 













Non- approved use or non-approved dose for approved drugs 




Other (please specify): 
2. What is the purpose of the study? 
Pneumonia is the prime killer of infants in developing countries globally accounting for 
19% of the 10.6 million deaths that occur each year. ALRI rates are not available for 
Kabul or at the national level for Afghanistan. However, under-5 mortality rates are 
reported as 176-250 and infant mortality as 128-170 per 1000 live births. As with other 
developing countries, ALRis are likely to be the leading cause of death and in the 
winter time one of the main causes of death of young children. Prevalence of acute 
respiratory infections (for upper and lower respiratory infection rates) for under 5 year 
old infants in the 2 weeks before a summer survey was reported at 18.5% in Kabul. 
Two case-control and other observational studies have linked immunological functions 
of vitamin D with an increased risk of pneumonia in <5-year olds (adjusted odds ratios: 
13.4 and 11.1) . In the recent years, numerous other immunological studies have 
highlighted the important role of vitamin D in regulating and enhancing immune 
functions during infection. 
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Vitamin D is commonly deficient in many developing countries with rates ranging from 
5-45%, even where abundant sun-shine is available -Afghanistan is one such country 
with >73% of high-risk <5-year olds below severe deficiency levels (8 ng/dl) in 
Chindawal area of Kabul (see appendix 1 in protocol document). Therefore, there is a 
possibility that giving vitamin D in such high risk populations be protective by reducing 
further cases of pneumonia (or even other infective illnesses). If this proves to be the 
case it is likely that child deaths due to pneumonia will be reduced. 
A single oral dose of 1 OO,OOOiu (2.5 mg) of vitamin D has been shown to be safe and 
effective in preventing vitamin D deficiency for a period of 3 months in infants as 
young as 1 week of age and for under 5 year olds. It is cheap and possible to use 
routinely during vaccination programmes. This makes the application of this 
supplementation practical and the use of our intervention sustainable at large scale 
nationally if proven to be effective. 
Study Purpose 
With the above considerations, the purpose of our study is as follows: 
1. To investigate whether vitamin D supplementation will reduce the incidence of 
pneumonia in children. 
3. To provide recommendations to clinicians and policy makers on the role of vitamin 
D in improving incidence of young children with pneumonia in Afghanistan, where 
pneumonia is one of the commonest causes of child death. 
4. To provide similar recommendations for international adaptation. 
5. Enumerate the objective(s) of the study. 
The specific objectives are to investigate the following study questions and then use 
these for policy making and clinical decision making: 
Primary study questions: 
Will 3-monthly supplementation of 100,000 IU of oral vitamin D reduce the incidence 
of pneumonia, among children aged 1 to 11 months living in a socio-economically 
deprived community of Kabul, Afghanistan? 
Secondary questions: 
Will 3-monthly supplementation of 100,000 IU of oral vitamin D to children aged 1 to 
11 months reduce vitamin D deficiency in the population during the 18 months of 
follow-up? 
Will 3-monthly supplementation of 1 OO,OOOiu of oral vitamin D to children aged 1 to 11 
months reduce the incidence of other infective illnesses during the period of 
supplementation (including diarrhea)? 
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6. Description of methods used in protocol. 
Overall design 
This wil~ be an individually randomised double blind placebo controlled trial, involving 
3~00 children aged 1 to 11 month old (the high risk age group for pneumonia), who 
will. be ra.ndomised to receive six doses of either 1 OO,OOOiu of vitamin 0 or placebo. 
Dosmg will take place at home, and children will be visited two weekly for 18 months 
by a team of 45 Fieldworkers, each visiting up to 10 children per day, 6 days per week. 
Data on illnesses, particularly pneumonia, will be ascertained though the two weekly 
home visits and from attendances and admissions at the trial clinic in the nearby 
Maywand Teaching Hospital with paediatric in-patient and out-patient facilities and 
equipped/trained x-ray department. 
Study Hospital and Population Base 
The trial will be based in selected residential areas around the Maywand Teaching 
Hospital. The paediatric hospital that serves this area is the Maywand Teaching 
Hospital. These are all areas included in a 2006-7 winter vitamin D trial being based at 
the Maywand Hospital which means that our research team is familiar with the setting 
and the authorities. Furthermore, all but a few areas have been mapped by Aga Khan 
Trust for Culture (AKTC) as part of their renovation and development work. We can 
use this information for clustering and random sampling will be made easier and more 
cost effective. 
The 2005 MOPHIUNICEF survey in Chindowal area of District 1 near the Maywand 
Hospital suggested a very high level of vitamin D deficiency amongst the under 5 year 
olds of Chindawal. District 1 is an old part of the city with narrow, shaded lanes, often 
with roofed tops, between high walled mud houses; the houses have small courtyards 
with high walls so that for much of the day sunshine does not reach the courtyard. Other 
areas we will cover share some of these building characteristics too. 
Our winter 2006-7 study has confirmed that dietary intake of vitamin 0 by the child 
population is poor because fish and liver are hard to get, and breast milk is a poor 
source of vitamin D (especially when mothers are rarely exposed to the sun due to a low 
level of out door activity and covering of most of the skin). The population is mostly 
socio-economically deprived with large families and high rates of all illnesses. 
The Maywand Teaching Hospital has a teaching unit for paediatrics and through 
previous collaborations we have established a close working relationship with the 
paediatric doctors. Since the population involved in the study is already part of the 
catchment area of the hospital, we will not be adding to the work load of the hospital. 
The study being conducted during the winter of 2006-7 (still not concluded in February 
2007) with these same populations and hospital involved, has so far progressed with 
satisfaction and the cooperation of the population and hospital staff. We expect the 
same level of success in the study being proposed here. 
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Community sensitization 
Community sensitization will be ongoing, but will start at about 6 weeks before the 
sub~e~t recruitment in order to facilitate agreement and cooperation of elders and 
dect~ton makers of the community. The elders approached will specially include the 
Vaktls of Gozar through the District Rais Nahiya, and the religious leaders in the areas 
covered. 
Recruitment 
Area mapping: A complete household mapping of the households exists through the 
work of Aga Khan Trust for Culture (a collaborating agency). For the areas where this 
is not available, during the preparation phase a mapping exercise will be conducted. 
Recruitment will proceed from randomly chosen streets and continue house to house 
along each of those streets until 3000 children are recruited; 45 female Fieldworkers, 
each accompanied by a chaperone to facilitate their entry into households, will recruit 
an average of 6 children per day over a 4-week period. 
Informed consent: At recruitment the Fieldworker will explain to the family the purpose 
of the study, the benefits offered and the procedures involved. An information sheet 
with the details of the study objectives, procedures, risk and benefits will also be given 
to the parents. Informed consent will then be obtained from both the mother and father 
of the child: finger prints and signature (literacy rate estimated at <50%) will be 
obtained in the presence of two witnesses, one a friend or family member and one the 
chaperone accompanying the Fieldworker. 
Initial Dosing: After consent the first dose of oil (placebo or vitamin D) will be given 
from a numbered syringe to the child. The number on the syringe will be recorded as 
that child's unique study id number. If a child has diarrhea/vomiting/pneumonia at the 
time of supplementation, the Fieldworker will return the next week or the week after in 
order to dose after symptoms have subsided. 
A study id card with study information (see sample of this id/information card) will be 
given to the child with this number on it for future reference by study staff and the 
recruitment questionnaire will be filled. 
Supplementation dosing for children 
One dose of lOO,OOOiu of vitamin D (in olive oil base), or placebo (olive oil alone), will 
be given by the recruiting Fieldworker to each child after consent on the first visit and 
then quarterly (6 doses during the 18 months). 
Randomisation and intervention/placebo packaging: The children will be individually 
randomized into intervention or placebo group. An independent statistician from the 
LSHTM will produce the randomization list allocating individual study numbers to 
vitamin D or placebo within variable blocks of study numbers. The placebo and vitamin 
D doses will be individually packaged into sealed 1 ml syringes at LSHTM and labeled 
with one of the numbers generated by the central office at LSHTM. After consent, the 
recruiting Fieldworker will give the oral dose of oil in pre-packed syringes, with the 
next consecutive number, to the child. The number on the syringe will be the child's 
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unique study number and will be recorded for each child. (we have tested this method 
of dosing successfully during our RCT of this winter at Maywand Hospital. 
The placebo and vitamin D syringes will look the same and the taste of the fluid will be 
th~ same. Ther~fore, the families and all project personnel, including clinicians, will be 
blmd to the chtld~en's group allocations. Oil from the syringes will be dropped in the 
mouth of each chtld at dosing. During the dosing weeks, Fieldworkers will receive 10 
syringes each day with consecutive study numbers to be used that day and checks will 
be conducted in the evening. Thus Fieldworkers will only ever have 10 single doses in 
their possession, minimizing the possibility of mis-dosing. 
Follow-up for 18 months 
Two weekly home visits (active case finding follow-up): For 18 months and two 
weekly, Fieldworkers will collect information on signs and symptoms of acute 
respiratory infections and diarrhoea in the last 14 days and current breastfeeding status. 
1. After each visit, the Fieldworker will leave a graphic chart with the mother. This is 
simply to aid the mother's memory for the next visit and will not act as an illness diary 
since many mothers will be illiterate. The mother will be asked to mark each picture if 
the child has one of the illnesses shown during the 2 weeks between Fieldworker visits. 
We have successfully used these diaries during our RCT in this winter at Maywand 
Hospital. 
2. Every 2 week, Fieldworkers will visit the child's residence and conduct a verbal 
recall interview from mother or primary caregiver (usually the mother) about illnesses 
in the last weeks, diet, sun-exposure and some other factors. They will also be trained to 
take the child's temperature, count the respiratory rate twice using a stop watch, 
examine for sub-costal recession, and refer to the study clinic if appropriate. 
3. The families will be given details of the research staff in Maywand Hospital and 
told to go to this clinic and see our study staff if their child becomes ill. If a study child 
(coming with study id card and other proof of identity) is diagnosed with pneumonia 
again in the Maywand Hospital outpatient clinic, first-line antibiotics will be given free 
by the project. 
4. The families will also be told to call the Fieldworker or hospital clinic doctors if the 
child is diagnosed as having pneumonia by another doctor. 
45 female Fieldworkers will be recruited. These will be divided into 4 teams each with 
a team leader in order to ensure that the visits are made on time and questionnaires 
collected daily. The team leaders will also check the quality of the questionnaires and 
will also make unscheduled visits to the homes of families visited by one other team in 
order to monitor the quality of the data collection by other Fieldworkers. These 
Fieldworkers and their team leaders will receive one month training on IMCI and 
clinical measurements and usage of study tools that they are required to do. 
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Outpatient clinic and hospital admissions of pneumonias (passive case finding follow-
up): 
For 18 months, the first port of call will be a trial outpatient clinic set up within the 
Maywand Teaching Hospital located in the study area and within easy reach for all 
recruited families. 
This will be run by 4 paediatricians with at least 3 years experience, who will receive 
refresher training in the diagnosis of pneumonia (according to the WHO/UNICEF 
Integrated Management of Childhood Illness [IMCI] criteria); they will work a shift 
system covering 24 hours, 7 days a week. They will be supervised by 1 senior 
paediatricians working 8am to 3pm who will also examine children with signs of 
pneumonia and a random sample of other children seen at the clinic. 
The paediatricians will fill out a detailed clinical assessment form for each child, 
conduct pulse oximetry, request X-rays and treat (according to standard IMCI) and/or 
refer for admission if there is severe pneumonia. In the Maywand Hospital, the protocol 
for admission is that, simple pneumonias will be sent home with treatment, while severe 
or very severe cases (pure IMCI criteria) will be admitted. Therefore, since we follow 
the same protocol, this study should not increase the inpatient load of the hospital 
excessively. The recovery criteria and additional in-patient data on the progress of 
children admitted will be collected by the duty clinic paediatricians. That is, the 
admitted patients will be visited every 12 hours daily by the study doctors, important 
clinical and management changes recorded and their respiratory rate (using a stop watch 
and 2 times count for 1 minutes each), subcostal recession, fever and danger signs for 
pneumonia (see definitions section in summary project proposal) will be examined and 
recorded. 
The Fieldworkers and doctors will use a standardised patient diary questionnaire to 
collect data on all pneumonia criteria (cough, respiratory rate and the danger signs) as 
well as fever. Clinical management of pneumonia will follow standard WHO-
recommended guidelines. 
In order to encourage care-seeking for illness episodes, the trial will cover costs of all 
IMCI recommended or hospital inpatient related ALRI medications. 
All these doctors will attend a 3 week theory and practical training on the ARI and a 
few other components of IMCI (this is a refresher course since all have already been 
trained) and on the study design, requirements and questionnaires and including 
practicing the questionnaire with patients. 
Vitamin D blood measurement 
In order to ensure that the vitamin D supplements have been effective, a random sample 
of the children will be selected at 5 strategic times in order to measure their blood 
vitamin D status. The sample will include half of the vitamin D and half of the placebo 
group, but the children will be selected by the independent statistical methods of 
LSHTM. In order to reduce the number of children giving multiple blood tests, for each 
round of testing a new group of children will be randomly selected. In analysis, the rate 
of pooled sufficient or insufficient vitamin D results will be compared. Consent will be 
sought at the start of the project (see consent form). 
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A trained paediatric phlebotomist will be retrained to visit to the homes and conduct the 
blood sampling. The same procedure will be followed as the prevalence study in 
Chindawal during January 2005. This will be as follows: 
The blood samples will be carried between houses in a cooler containing ice packs and 
at the end of each working day or half a day (no longer than 5 hours) the blood samples 
will be taken to the German Diagnostic Clinic of Kabul where a trained and 
experienced lab technician, supervised by the senior staff of the German Clinic will 
centrifuge the clotted blood samples and extract the plasma. The samples will be 
immediately transferred in cool boxes to a nearby EPI centre where they will be frozen 
to below -20C. At the end of the survey the samples of plasma will be sent frozen to 
Aga Khan Laboratories in Karachi for analysis. High pressure liquid chromatography 
(HPLC) will be performed to establish vitamin D status in each child. 
The measurement of plasma 25-hydroxyvitamin D can be variable between 
laboratories. The Aga Khan University Micronutrient Research Laboratory has 
established internal and external quality control protocols in collaboration with the 
Nutrition Biochemistry laboratories at the International Center for Diarrheal Diseases 
Research (Dhaka, Bangladesh) and Bio-Rad (EQAS, UK) . For external quality control 
there is a regular (fortnightly) monitoring system established with Bio-Rad (EQAS) and 
the coefficient of variation (CV) of the analysis ranges from 2-4%. 
Baseline, confounders and other data collection 
At recruitment and the next visit the study staff will collect data on a range of socio-
economic and demographic variables, as well as known risk factors for pneumonia or 
vitamin D deficiency, including exposure to cigarette smoke, type of fuel and heating 
used at home, vaccination, supplementation, diet, and sun exposure habits/practices. 
Some of this information will be collected again at appropriate intervals in the study. 
Trial management and monitoring: 
• The trial director will be based in Kabul responsible for overall aspects of the day to 
day conduct of the trial. 
• The trial directors will be assisted in this by a trial manager, a data manager and 1 of 
the 3 senior paediatricians, meeting weekly as the Trial Management Team (TMT). 
• She will be in regular email and telephone contact with the other international 
collaborators. 
• An independent data monitoring and ethics committee (DMEC) will be set up in 
accordance with the UK Medical Research Council criteria; they will receive weekly 
reports concerning any deaths or hospitalisations among study children. 
• They will be advisory to the Trial Steering Committee (TSC), which will comprise 
the TMT, representatives from the collaborating institutions in Kabul (MOPH, 
UNICEF, Save the Children US, Maywand Teaching Hospital, German Diagnostic 
Centre, and District 1 Municipality) and the applicants. 
• The Trial Director will provide 3 monthly progress reports for the TSC that will 




12 data entry staff will be trained and will enter the questionnaires into an ACCESS 
database. A data manager will monitor their work and manage the quality of the 
database, co.nduct consistency checks weakly and interface with the computer 
programmer m order to ensure an optimal data base. 
Data analysis 
The study groups will be compared for the range of baseline variables, and regression 
techniques will be used to control for their effect if any important differences are found. 
The main analysis will consist of a comparison of pneumonia incidence rates between 
the vitamin D and placebo groups on an intention to treat basis, using a multilevel 
regression model to account for repeated pneumonia episodes. All time series data will 
be analyzed using the Cox proportional hazards model, controlling for age and other 
covariates. 
The impact of the intervention on vitamin D status in plasma will be confirmed using t-
tests to compare mean serum concentrations, and chi-squared tests to compare the 
proportions severely deficient between the two treatment groups. 
All time series data will be analyzed using the Cox proportional hazards model, 
controlling for age and other covariates, and will be plotted on Kaplan-Meier survival 
curves. Vitamin D and placebo groups will be compared for the range of baseline 
variables, and regression techniques used to control for their effect if any important 
differences are found. 
There will not be an interim analysis since this a safe intervention study. 
Data management and quality control: 
High data quality will be achieved through several means: 
1. All staff will be trained: 
Clinical staff will all be retrained in technical skills such as IMCI criteria of 
pneumonia in order to standardize procedures and definitions - this will reduce 
examination/diagnostic bias. 
We will minimise inter-observer variation through standardisation exercises for all 
clinical personnel prior to the study. This has been considerably successful in previous 
pneumonia studies. 
With the details of how to fill the questionnaires in order to reduce recording errors 
and biases. 
2. Questionnaires are translated into Dari, the main local language in the area of study, 
and pre-tested for appropriateness and quality. Most of the questionnaires are identical 
to the questionnaires used for the vitamin D trial in Maywand Hospital during the 
winter of 2006-7 and thus adapted for Kabul use. 
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3. The Fieldworkers will be organized into 4 teams of 10 Fieldworkers each 
supervised by a team-leader who will collect and check all questionnaires daily 'before 
submitting them to the trial manager. 
4. The clinical reports will similarly be checked and submitted on a daily basis by one 
of the senior paediatricians. The trial manager will make further checks before passing 
to the data manager. 
5. Any unclear entries at the time of data entry will be checked with the field staff. 
6. Double entry of all data within a week of collection and built-in range and 
consistency checks will minimise data entry and field errors. 
7. Team-leaders will make unscheduled visits to Fieldworkers' families to check on 
the quality of their data collection. 
8. Senior Paediatricians will make unscheduled checks of the clinical assessment of 
patients by study doctors every 3 days, in order to check on the quality of their clinical 
assessment. 
9. Patients are frequently absent during home follow-up in community-based studies. 
This is factored into the sample size calculations. The Fieldworker will try to minimise 
absenteeism by reminding families at the time of each visit about the following week 
when the Fieldworker would come for visit. The time of the next visit will be reminded 
to the families. Questions will be asked about possible move of the family to another 
address at the time of the next visit. Furthermore, several addresses and phone numbers 
of friends and relatives will be obtained to help locate a family if they move 
unexpectedly. This method was very successful dfuring the 3 month follow-up of the 
witnerwinter of 2006-7 study - only 5% of the families were lost to follow-up in 3 
months. 
10. Children will have more than one episode of pneumonia during the observation 
period. We are interested in these second episodes and will encourage families to tell 
the study about these episodes. However, in order not to enroll the same child more 
than once as having a first episode, we will give them study ID cards, and we will 
maintain patient records notes and a list of all participants (basic identification details 
only with study id number) on site in the outpatient and inpatient clinicss of Mayan war 
Maywand Hospital. Those identified as coming in for a second episode will the 
excluded from being recruiting again. 
Reporting 
Interim reports for the steering committee (TSC) are described in the above section. 
Once the fieldwork is complete, the study manager and director, with the advice of 
statisticians at LSHTM will analyse the data and report upon it through the compilation 
of a final report and a paper for peer review publication. 
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It is hop~d that some of the staff will be recruited from the university of Kabul students 
or staff. m order to strengthen the rigorous epidemiological experience gained by these 
professiOnals. 
At least 3 open ~ectures will be held about the scientific aspects of the study, one at the 
Maywand Hospttal for the staff, and two at the Medical University for the lecturers and 
students. Other scientific lectures can be held on request. 
7. Study duration 
a. Expected duration of study period to be completed: 20 months 
b. Expected duration of study on each individual subject: 18 Months 
8. Description and justification of sample size. 
Sample size for the rate and severity of pneumonia as the result of supplementation 
We estimate that the incidence of pneumonia in the placebo group will be 0.008/ 
child/month during the six month study period. This is calculated as follows: 
In Rudan et al's global estimates, for South-East Asia low or non-Malaria populations 
studies, the incidence of acute lower respiratory infections ranges from 0.18 - 0. 75 
episodes/child year(cy) (these are mostly rural studies). Since our population is 
socioeconomically deprived, crowded urban population, with known high prevalence of 
diseases and micronutrient deficiencies, we assume that conservatively, a mid-point of 
these rates would apply to our population, i.e. 0.65 episodes/child year. Rudan et al, found 
that globally 6 - 12% of these incidences were severe pneumonia (defined mostly by 
hospitalization). Given the circumstances of our population, harsh winters of Kabul, and 
that we would use clinical criteria for definition of severe pneumonia which may not lead to 
hospitalization in all cases, we took 12% as being applicable to our study. Assuming 25% 
of pneumonia will be repeat episodes during 18 months of follow up, we estimate that the 
incidence of pneumonia in the placebo group will be 0.0585 episodes/child (0.65 
x0.12x0.75) during the 18 months study period. 
We expect a 35% reduction in the incidence of pneumonia in the vitamin D group given 
that 73% of children have vitamin D deficiency in the study area and that the incidence of 
pneumonia is 10 times higher in vitamin D deficient children than in normal children. A 
study with 80% power and 95% significance to detect a 35% reduction in the incidence of 
pneumonia compared to the placebo group will require 22079 child months per group. 
Since each child will be followed for 18 months and assuming a 20% loss to follow up, the 
the study will require 14 72 child per group. In order to facilitate randomization and 
allocation of staff we have rounded this figure to 1500 child per group. 
Therefore in total we aim to recruit 3000 1 to 11 month infants. 
Sample size for vitamin D blood test as process measure: 
50 children per group will give 80% power of detecting a 50% reduction in the proportion 
of children with 1,25(0H)zD <8ng/ml (50% being conservative compared to the published 
literature), assuming that this deficiency is about 70% in the placebo group (the level 
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observed in the prevalence study). The sub-samples of children for this outcome will be 
selected by the independent statistician. 
All calculations assume the probability of a Type I error of 5% and a Type II error of 10% 
(power of90%). Epi-Info sample size programme was used for sample calculations. 
a. Subject information. 
1. Age range: 1-11 months infants 
11. Sex: D Male D Female L8J Both 
9. If subjects are children, pregnant woman, people with disabilities or mental illness, 
prisoners, or if it includes fetal research, give brief explanation of need to use these 
particular individuals. 
The subjects are children. This is important because we intend to investigate the effect 
of vitamin D supplementation on reducing infant and child pneumonia. The background 
that led to the plan of this project is based on children and pneumonia and therefore it is 
only by researching in children that this research question can be answered. 
10. Criteria for inclusion and exclusion of study subjects (type separately) 
Inclusion criteria 
Any child, living in the study areas aged 1 to 11 months. 
Exclusion criteria 
Children will not be eligible if: 
(1) The family is expecting to move within the next 6 months; 
(2) The child has been diagnosed with rickets or known to have received a course of 
vitamin D treatment in the past 3 months. 
(3) Child has Kwashiorkor or Marasmus. Delayed entry for those with diarrhea, vomiting, 
or pneumonia by up to 2 weeks until symptoms are minimized. 
( 4) Caretakers do not give consent. 
11. Compensation/Incentives (to research subject): 
a. Monetary: r8J No DYes Amount: 
Please describe rational for monetary amount: 
b. Other: D No r8J Yes 
Please describe compensation/incentive: 
Benefits and incentive for families and children 
1. Free antibiotics for pneumonia illness of the child for 18 months of follow-
up; 
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~· . Two weekly visit of a trained female research staff at home which could 
tdenttfy unreported illness; 
3 · Extended access to well trained paediatricians for 18 months in their own 
area; 
4. Treatment with vitamin D for all (placebo group receiving at the end of 18 
months); 
5. Box of biscuits after each blood-taking visit. 
c. Reimbursement of expenses: 0 No I2SJ Yes 
Please describe types of expenses covered and amounts: 
1. Me?ical reimbursement- For all episodes of respiratory infections will be given 
accordmg to IMCI and protocol guidelines. 
2. Easier access to pediatric assessment (especially for pneumonia) at Maywand 
hospital will be provided for the 18 months after recruitment. This is not for 
payment and the clinic is specially set up for the study with well trained, 
experienced and supervised pediatricians. 
12. Adverse events 
a. What adverse events are expected to the subjects involved in the investigation 
during the study and; 
1. Participation is anticipated to cause NO HARM to the children; in fact children will 
benefit through the provision of free medication and vitamin supplementation. 
2. Although vitamin D overload is a theoretical possibility, this is unlikely. 1 OO,OOOiu 
of vitamin D has been shown to provide the best protection against vitamin D 
deficiency and no overload in high-risk 0-9 month infants with normal baseline ranges 
of vitamin D. There are no known noticeable side effects from this supplementation .. 
Furthermore single intramuscular injection of 3 times this dose (300,000iu) was safe 
and effective in treating nutritional rickets in 6-30 month old children residing in lower 
socioeconomic regions of sunny Istanbul24. In addition higher than recommended 
doses of daily supplementation of vitamin D (500-1 OOOiu/day, adding-up to 120,000iu 
over 3 months) plus additional vitamin D fortified milk, has been shown not to induce 
an overload; this was the case in infants starting with normal ranges of vitamin D, even 
when supplementation continued during the summer (in France) and mothers had 
antenatal vitamin D supplementation. Both in the published literature and in one of the 
collaborator's clinical experience (ZM), clinical and biochemical features of vitamin D 
toxicity occur in plasma 25-hydroxyvitamin D concentrations > 1 OOng/ml due to 
inadvertent vitamin D poisoning, e.g. 600,000iu administered orally several times a 
week or month. Thus the evidence suggests that the proposed dosing regime should be 
safe and effective. Nevertheless, close monitoring of any unusual sysmptoms will be 
established in the 10 days following dosing. 
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3. There is no routine screening for vitamin D deficiency in Kabul which the trial 
would interfere with; children known to have rickets, or prescribed vitamin 0 
supplements .by a ~octor on clinical grounds, will be excluded. Due to the known high 
r~te o! deficiency m the area, the placebo group will be given one dose of 1 OO,OOOiu 
vttamm D at the end of the trial. 
b. What is the provision for managing these events? 
N/A 
c. Who will pay for them? 
N/A 
13. What are the actual potential benefits if any to be obtained by participating or society as 
a result of this study? 
For benefits to families please see above question number 9. 
Capacity building 
One of the main objectives of this project will be epidemiological research capacity 
building in Afghanistan. All staff or collaborators of the project will benefit through 
formal training and involvement in the project. All staff will be trained in team work, 
research disciplines and data integrity. Furthermore, each will have training specific to 
their work which will be of benefit in their career development. A randomised 
controlled trial is the highest level of medical research which looks to prove hypothesis 
in an indisputable way by eliminating biases which can affect the results. Experienced 
gained through participation in such an academic study will be of value to those 
individuals and Afghanistan. 
It is hoped that some of the staff will be recruited from the university of Kabul students 
or staff in order to strengthen the rigorous epidemiological experience gained by these 
proessionals. It is also hoped that one or more Afghan staff can register and start a PhD 
based on their work in this study. 
At least 3 open lectures will be held about the scientific aspects of the study, one at the 
Maywand Hospital for the staff, and two at the Medical University for the lecturers and 
students. Other scientific lectures can be held on request. 
Benefits for MOPH 
Evidence will be provided for policy development which may impact Millennium 
Development Goals of infant and child mortality: For Afghanistan this study can lead to 
policy applications with reduced deaths of pneumonia in young children. This is one of 
the 2 health MDGs which is high on MOPH's priorities. 
Furthermore, if incidene of pneumonia is improved, and less children get repeat 
pneumonias, the hospital/health service costs, will be reduced. 
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Publications and global profile for Afghanistan: Whatever the findings of this study the 
~esults ~ill ~e of interest internationally; WHO headquarters have already show~ an 
mter.est t.n thts stud~. The findings will no doubt be published in major peer reviewed 
medtcal J~urnals (wtth Afghan collaborators as co-authors) and this will help to outline 
the capactty of Afghan professionals and the positive road to development taken here 
which can impact the lives of others globally. 
Global benefits 
At the present, the evidence available in support of an association between vitamin D 
and pneumonia is limited, but compelling. If indeed supplementation will reduce the 
incidence of pneumonia, lives may be saved. Global literature indicates that vitamin D 
deficiency is prevalent in many sun-rich developing countries. Whatever the cause of 
this, it is clear that given the high rates child death from pneumonia in these countries, 
if a relationship is found with this common illness and this common vitamin deficiency 
the results of this proposed study will be of major clinical importance in all such 
countries. The impact could potentially be as important as those resulting from the trials 
demonstrating that zinc given at the time of illness reduces treatment response and child 
mortality in developing countries, leading to its incorporation in WHO/UNICEF child 
survival strategies. If effective, oral vitamin D supplementation could feasibly be 
implemented in developing countries since it is cheap and easy to administer since a 
once only dose for 3 monthly administration is safe and effective. 
14. How is confidentiality going to be maintained? 
1. The staff will be trained about the principles of confidentiality in order to prevent 
use or communication of families' information for other means. Their contracts will 
make them legally responsible in this regard. 
2. Strict confidentiality and security of data will be maintained at all times through 
safe keeping of paper forms and coding of computer entries so that individual identity 
will not be apparent without access to the paper forms and decoding of the entries: 
All participants will have a study ID number. For data entry, the computer 
programming in ACCESS will hide all personal details except this number after entry. 
Access to the data will be limited to the study number for each child by those staff with 
a code. 
The paper copies of questionnaires will be kept in a safe and secure place (locked) in 
order to keep the information confidential and out of public access. Access to these will 
be by authorized staff only. 
3. Address and family identification details of the participants and address of one 
friend/family member is needed so that after recruitment the children can be found 
again, visited at home, examined and questionnaires filled. Sometimes families move 
home and by having family member details we can find the family again (We have 
successfully used this method during this winter's RCT at Maywand Hospital.)This will 
be explained at the time of consent and these details will be kept secure as above. 
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15. Location of study: 
rgJ Out~atient ~linic. l2$J Inpatient units [8J Other (specify): 
The. subJec~s ":ll~ be.t~enttfied through household recruitment and followed up at home 
and dunng thetr chmc vtstts or inpatient treatment for 18 months. 
16. Laboratory studies: 
a. Will any test be per~ormed which are not routinely included as part of the workup 
for these types of patients? b) Who or what agency wi 11 pay for these tests? 
Yes -a blood test for vitamin D level in a sub-sample of the children. The project 
grant will pay and conduct these tests. 
17. Explain any ETHICAL ISSUES or CONSIDERATIONS of this study. Discuss 
obtaining informed consent in this section. 
1. Strict confidentiality and security of data will be maintained at all times through 
safe keeping of paper forms and coding of computer entries so that individual identity will 
not be apparent without access to the paper forms and decoding of the entries. 
2. Address of the participants and one friend/family member is needed so that after 
recruitment the children can be visited at home, examined and questionnaires filled. 
3. Participation is anticipated to cause NO HARM to the children; in fact children will 
benefit through the provision of free medication and vitamin supplementation. 
4. Although vitamin D overload is a theoretical possibility, this is unlikely. 1 OO,OOOiu 
of vitamin D has been shown to provide the best protection against vitamin D deficiency 
and no overload in high-risk 0-9 month infants with normal baseline ranges of vitamin D26. 
There are no known noticeable side effects from this supplementation. Furthermore single 
intramuscular injection of 3 times this dose (300,000iu) was safe and effective in treating 
nutritional rickets in 6-30 month old children residing in lower socioeconomic regions of 
sunny Istanbul24. In addition higher than recommended doses of daily supplementation of 
vitamin D (500-1 OOOiu/day, adding-up to 120,000iu over 3 months) plus additional vitamin 
D fortified milk, has been shown not to induce an overload25; this was the case in infants 
starting with normal ranges of vitamin D, even when supplementation continued during the 
summer (in France) and mothers had antenatal vitamin D supplementation27. Both in the 
published literature40 and in one of the collaborator's clinical experience (ZM), clinical 
and biochemical features of vitamin D toxicity occur in plasma 25-hydroxyvitamin D 
concentrations > 1 OOng/ml due to inadvertent vitamin D poisoning, e.g. 600,000iu 
administered orally several times a week or month. Thus the evidence suggests that the 
proposed dosing regime should be safe and effective. Nevertheless, close monitoring of any 
unusual sysmptomssymptoms will be established in the 10 days following dosing. 
5. There is no routine screening or supplementation for vitamin D deficiency which 
the trial would interfere with; children known to have rickets, or prescribed vitamin D 
supplements by a doctor on clinical grounds, will be excluded. 
6. Due to the known high rate of deficiency, the placebo group will be given one dose 
of 1 OO,OOOiu vitamin D at the end of the trial. 
7. Some discomfort will be experienced by the children selected for the vitamin D 
blood sub-samples; the small volume of venous blood will be taken by carefully trained and 
experienced staff. 
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Other considera~ion~: Calcium deficiency is a possibility in these deprived populations 
and may speed vttamm ~ metabolism. This population has access to dairy products, eggs 
and nu~s. To reduce cal~tum deficiency, all families will be given dietary advice to improve 
th~ cht.ld or breastfeedmg mother's calcium intake. Introduction of calcium supplements 
wtll dtvert f~om the. pro~rammat~c approach of this trial: that is testing 3 monthly 
supplementation of vttamm D whtch for programmatic approaches will be much more 
useful than daily supplementation. Furthermore, there is no evidence that the 
immunological function of vitamin Dis related to calcium. 
Informed consent: At recruitment the Fieldworker will explain to the family the purpose 
of the study, the benefits offered and the procedures involved. An information sheet with 
the details of the study objectives, procedures, risk and benefits will also be given to the 
parents. Informed consent will then be obtained from both the mother and father of the 
child: finger prints and signature (literacy rate estimated at <50%) will be obtained in the 
presence of two witnesses, one a friend or family member and one the chaperone 
accompanying the Fieldworker. (See consent form) 
18. Any other information relevant to the study in the context to Afghanistan? 
Feasibility of the study and pilot performed in 2005 
During the pilot study mentioned above, as well as investigating the prevalence of vitamin 
D deficiency in the proposed study population, several caretakers of infants who were 
visited for sampling were informally interviewed. The aim was to investigate their possible 
acceptance to take part in a larger study with the set-up described in this proposal. All but 
one said that they would agree to participate. Even 4 out of 5 caretakers who did not 
consent to have blood taken from their infants (all mothers with children less than 1 year of 
age) declared that they would consent to be involvement in a larger study if consent was 
obtained from the father, and if there seemed to be a direct benefit to their infant from 
giving blood (such as free treatment or free visit to trained doctors). 
The population proposed for study live near the Maywand Hospital and it is practical that 
the staff can visit up to 6 families per day with the help of project transport. Community 
sensitisation will be conducted at the start of the project where the Area Hakim and District 
Governor and authorities and Mullahs and other known representatives of the community 
will be informed ofthe project. 
Given the range of health problems facing the children of Afghanistan, vitamin D's effects 
upon skeletal development is not important enough for a national priority. However, should 
clinical management of a common disease such as pneumonia be improved through 
supplementation, this may have major implications for children's health and public health 
in Afghanistan. 
19. Has this type of study been conducted elsewhere earlier? If yes please give details. 
Similar study designs were used to show the effectiveness of zinc and vitamin A for 
improving the rate and severity of infections and pneumonias. This particular study 
involving vitamin D has not been done before- for this reason the findings of this study 
will be of great international interest. 
20. Who is the funding agency for this study? 
We have applied to the Wellcome Trust for funding and will know in May. 
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21. What is the total budget of the study? 
US$300,000 although this may change depending on donor limits or requirments. 
Email Note: 
To the Chairman 
Ethics Review Board of the Ministry of Public Health 
Ministry of Public Health of the Islamic Republic of Afghanistan 
Kabul 
Dear Esteemed Chairman and Members of the Ethics Review Board 
I am writing to request that you would kindly review the submitted Check-list with attached 
summary protocol (which contains pertinent technical appendixes), consent form (English 
and Dari), and questionnaires A to F (English and Dari). The questionnaires are very 
similar to those used during our 2006-2007 vitamin D study at Maywand Hospital approved 
by your committee in November. Therefore they have been pre-tested and piloted for that 
study and improved. 
You will know from your records, that this project follows a vitamin D survey that was 
conducted by this same investigating team together with the MOPH (Nutrition Dpt) and 
UNICEF in 2005 (appendix 1 of the protocol document) and the present 2006-2007 vitamin 
D study at Maywand Hospital which was approved by your Ethics Board. This present 
proposal was discussed at the Board meetings as early as in 2005. We can continue this 
important line of work still in collaboration with the MOPH, Kabul University Medical 
School and its Teaching Hospital, Maywand Hospital. 
We would be grateful if you could kindly review this proposal in the October meeting. 
We look forward to your comments. 
Yours sincerely 
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Annex 3 Study approval letter by Ethics Committee, LSHTM 
LONDON SCHOOL OF HYGIENE 
& TROPICAL MEDICINE 
ETHICS COMMITTEE 
APPROVAL FORM 
Application number: 5117 
Name of Pnnctpal 1nvest1gator Daniel Chandramohan 
Department Infectious and Tropical Diseases 
Head of Department Professor Simon Croft 
Title: The effect of Vitamin 0 supplementation on the Incidence of 
pneumonia in Afghanistan: a randomized controlled trial 
Amendments to this application have been approved by the Ethics Comm1ttee. 
Chair 
Professor Tom Meade 
Date .... ... ._ ...... 29 July 2008 .. 
Approval Is dependent on local ethical approval having been received. 
Any subsequent changes to the application must be re·submltted to the 
Committee. 
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Annex 4 Consent form 
Ministry of Public Health of Afghanistan 
Vitamin D supplementation trail in children in Afghanistan 
1. Who is doing the study? What is the aim of the study? 
The Ministry of Public Health, Maywand Hospital, Kabul Medical School, London University and 
the Aga Khan Health Services are doing a study in children in your area of Kabul. We want to find 
out whether giving vitamin D to children will help to reduce chest infection (pneumonia), diarrhea 
and other microbial diseases. 
2. Why are we doing this study? 
We already know that ( 1) Vitamin D helps to make bones and teeth of children and to keep them 
healthy; (2) Vitamin D may help our body's ability to fight infections; (3) children who have 
pneumonia may have less vitamin D than children who did not have pneumonia ( 4) 
Supplementation dose of vitamin Dis safe in children. But we do not know whether vitamin D 
can prevent or reduce the severity of pneumonia in children. 
In Afghanistan many children have less vitamin D in their blood and pneumonia is a common cause 
of illness and death in young children. If we find out that giving vitamin D can prevent incidence of 
pneumonia and diarrhea or can reduce the severity of these diseases, we can help many children. 
3. What will happen to your child if you agree to take part in the study? 
1. Our Survey is for 18 months. 
2. First we will examine your child to find out whether he/she has any illness that will disqualify 
from the study. 
3. We will ask you questions about your child's health, and your living conditions. 
4. At the start of our project, and every 3 months during 18 months (totally 6 doses), the children 
will receive a few drops of olive oil in their mouth. With these drops of oil, by chance, half of 
the children will get vitamin D at the beginning and 3 month basis, and the other half will get 
vitamin D at the end of the survey. 
5. Our female health worker will visit and examine your child at horne for chest infection, 
diarrheal disease and other microbial diseases every two week for 18 months 
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6. During each house visit if our staff suspect that you child has a chest infection or other 
mentioned diseases they will request you to bring your child to the Maywand hospital. 
7. We will also request you to bring your child to the Maywand hospital ifyour child has any 
illness during the 18 months of the survey. 
8. If they suspect pneumonia, the doctors at the Maywand hospital will do a X-Ray examination 
and other testes needed to confirm and treat pneumonia 
9. All treatment, tests and visit to Maywand hospital by our doctors for your will be free. 
10. All you and your child's information will remain confidential and safe in our store place. We 
will never tell anyone about your information c,tnd only use this information grouped together 
with other children's information (for example we will not tell anyone that Ali was 13 months 
old, but we will count that 10% of study children were 13 months old). 
4. Will we collect blood from your child? 
Totally we are selecting 3000 children and only 600 of these will be selected by lottery for taking 
one teaspoon full of blood. The reason for this is that we need to know the amount of vitamin Din 
the blood after we have given this vitamin. If your child is selected, you will be told later and can 
discuss this separately with our staff. Your child can still be part ofthis study if you do not want 
blood to be taken and this will not make any difference to your child's participation in the study. 
This means that by lottery we will select only 120 children at the start of the survey, 120 children 1 
month after the start ofthe survey, 120 children 3 months after, another 120 children in the summer, 
and 120 in the spring next year (2009). 
We will not collect blood from any child more than once. 
Blood collection will be carried out by an experienced phlebotomist (nurse) and we will follow 
strict safety procedures. 
5. What are the benefits for your child? 
1. Your child will get free vitamin D, 
2. In the next 18 months you can get good free advice from specialist doctors if your child 
gets ill and get free medicine for your child if he/she gets a chest infection and diarrhoea. 
6. What if you refuse to take part in the study? 
There are no penalties if you refuse to take part in the study. Your child will continue to receive all 
routine health services. Taking part in the study is entirely your choice. 
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7. Can you withdraw your child after agreeing to take part in the study? 
Yes. You can withdraw your child from the study at anytime. If you decide to withdraw from the 
study your child will continue to receive the routine health care. 
8. Who has approved the study? 
The Head of your District (Rais Nahiyah) and the trustee of your street (Vakils ofGozar) agree with 
our work and support us. The ethical research committees of the Ministry of Public Health of 
Afghanistan and London School of Hygiene and Tropical Medicine, London have approved this 
study. 
9. Whom should you contact if there is any problem or question? 
If during the study you have any questions or worries or your address changes you can talk to the 
lady health worker who visits your home, to the Maywand Hospital doctors listed below or contact 
Dr-------------------- on the phone number--------------------
If God forbid, your child gets ill in the next 18 months, you should come to the Paediatric 
Department of the Maywand Hospital, bring the child's study card, and see our well trained doctors 
for treatment. The name of our doctors are: -----------,-----------------------,--------------------,-----------
11. Do you have any questions? 
12. If you agree that your child participates in this study, please sign this form: 
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Full name of the child--------------------------sex-------study number of the child----------
Birth date of the child (or if not exactly known the rough age) 
Month Year ----------------------
Full name of the consenting person-------------------------------------------------------------
The relation of the consenting person to the child (please specify your relationship with the child) 
Address of the consenting person (district, street, number of house, etc) 
I have read the above information (or was read to me), I understood it and asked my questions from 
the visiting staff (name )---------------------------and I am happy with all the explanations. 
I agree that my child has the drops of oil, that my child be examined at home weekly for 18 months 
by a female health worker and examine the child and ask me questions for the survey. I understand 
that at anytime I can stop taking part in this study without giving a reason and without any effect on 
medical care or treatment to my child. 
I understand that if my child is selected, one teaspoon full of blood will be taken from the arm of 
my child to measure the amount of vitamin D in the blood and I agree with that. 
I am happy to take part in this survey 
Yes No _______ _ 
Signature (or thumb print) from parents or legal carer---------------------------------------
Witness' name-------------------------------------- signature/thumb print-------------------------------------
Witness' relation to the child------------------------
N arne of the interviewing staff------------------------------ signature --------------------------
Contact number of interviewing staff-------------------------------------
Name of the interviewer's mahram--------------------------- signature --------------------------
Date-------dd-----mm ----yy 
Time (24 hour clock) ------hr------min 
We are very grateful for your cooperation. 
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Annex 5 Recruitment questionnaires (Form A and F) 
Questions about family members 
Questions about the mother 
.. ~~ ... --«---........ 
10. first and middle name of the mother _] Surname/Family name of the mother 
12. what is your date of birth? Day [. Month: Year ' • Do no know 0 11. Nickname of the motehr 
13. What is your age in complete years (please choose one)? 0 2- Estimated 0 1- Confirmed 
0 40-44(7 0 35-39(6 0 30<34(5 0 25-29(4 () 20-24(3 0 16-19(2 0 1)15.andbelow 
0 99) Don't know 0 12) 65 or older 0 60- 64 (11 () 55- 59 (10 0 50- 54 (9 0 45- 49 (8 
14. What is your current marital status (please choose one)? 
0 1) Only Wife of the husband 0 2) Husband has other wives 0 3)Widow 0 4) Separated not divorced 0 5) Divorced 0 99) Don't know 
15. Do you attend any formal education (if not, then refer to quesiton number 17) 0 99- Don't know () 2- No 0 1- Yes 
16. What was the highest level of education you attended (Pieasae choose one)? 
Primary completed 1-6 years 
Secondary completed 7-9 years 
Hlgh schooll 0-12 years 





Years completed;' College or university completed (please specify) 0 ; ,. .. __ ......... . .......... . 
17. What other education did you attend? (please choose one or more) 
1) Not attended school or Madrasa, but can read and write 
2)Religious study at Madrasa 
3) Religious study at home or Mosque 
4) Can not read and write 
5) Can read, but can not write 
6) Vital education 
0 1- Yes 2- No 
1- Yes 02-No 
0 1- Ves ()2-No 
01- Ves ()2-No 
01- Yes ()2-No 
0 1- Yes 02-No 
18) Have you ever worked? () 1- Ves O 2- No (If No1 refer to question number 22) () 99- Don't Know 






0 99- Don't know 
0 99- Don't know 
0 99· Don't know 
() 99- Don't Know 
C 99- Don't Know 
:"'"'> 99- Don't Know 
"-' 
Q1-Yes 02-No .19a Do you work now? 
.19b If yes please specify I C'! 6) Farmer 
'·' 
0 5) Huckster O 4)Servant 
() 99) Don't mow Ci 10) Other (please specify 
0 3) Government employee 0 2) Tailor () 1) Teacher 
0 9) Job in NGO 0 8) Rug mal<.er O 7) SeWing 
zo. What was your previous job? 0 6) Farmer () 5) Huckster C) 4) Servant 0 3) Government employee () 2) Tailor 
0 99) Don't know () 10) Other (please_!ecify) 0 9) Job in NGOs () 8) Rug mal<.er 0 7) Sewing 0 ~ (1 
······-·-···-J 
Zl.Who takes care of your child (study child) if you go to work? (Please choose 1 or maximum 3) 
1) Husband 0 1- Yes 
2) Brother or Sister of the child 0 1- Yes 
3) Child's Grandparents C1 1- Yes 
4) Uncle or aunt (maternal or paternal) 0 1- Yes 
5) Other family members of the child O 1- Yes 
6)Frlend/Neighbor 0 1- Yes 
7) Private child caregiver 0 1- Yes 
8) Kindergarten 0 1- Yes 
9} Other (Please specify) 0 1- Yes 
[ 
Questions from the father: 









() 2- No 
02-No 
0 99- Don't know 
0 99· Don't know 
0 99- Don't know 
0 99· Don't know 
() 99- Don't !<now 
C· 99- Don't !<now 
0 99- Don't !<now 
0 99- Don't !<now 
0 99- Don't !<now 
-~ 
23. first and middle name of father Surname/Family name 1_ _ __ , __ _ 24. Nickname of father 
25. Age of father in complete years (please choose one) () 2- Estimated 1· Confirmed 
0 40.44 (7 0 35- 39 (6 () 30-34 (5 0 25. 29 (4 0 20-24 (3 
0 99) Don't mow C· 12) 65 or older 0 6o- 64 (11 0 5s • s9 (1o 
16- 19 (2 0 1) 15 or below 
0 50 - 54 (9 0 45 • 49 (8 
.___ _____ ; 
=ather's ethnicity (please choose one} () 99) Don't know 5) Other (Please specify) 0 4) Hazara 0 3) Uzbak 0 2) Pashtoon 0 1)Tajik 
, Did you attend any formal education () 1- Yes 2- No () 99- Don't know 
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28. What was the highest level of education you attended (please choose one)? 
Primary education 1-6 years 0 
Secondary education 7-9 years 0 
High schooll0-12 years 0 
vocational education completed 0 
coHege or University completed (please specify) 0 ... 
29. What other education you completed (please choose one or more) 
1) Not attended school or Madrasa, but can read and write. 
2) Religious study in Madrasa 
3) Religious study at home or Mosque 
4) Can not read and write 
5) Can read, but can not write 
6) Vital education 
30. Are you working now? 






I) 1-Yes '-· 
0 1-Yes 





() 2- No 
2-No 
() 2- No 
Years completed 
Years completed 
Years completed '-~~-=.J 
Years completed ~-~ 
L_--~--..-J 
Years completed i 
0 99- Don't know 
0 99- Don't know 
0 99- Don't know 
C· 99- Don't know 
0 99- Don't know 
0 99- Don't know 
0 99- Don't know 
31. What was your previous job? Cl 7) Military officer () 6) ~1\ason 0 5) Carpenter C· 4) Engineer 0 3) Nurse 0 2) Doctor 0 1) Teacher 
(1 99) Don't know 0 9) None 0 8) Other (please specify) L ______________ =:J 
32. What was your main current occupation? 
0 8) Rug Maker 0 7) Freighter C; 6) Farmer 
0 99) Don't know 0 13) Other (please specify) 
'·······--·-··--····-·"·····----·-···-··· ........ ,,_, 
33. Field workers observation: 
0 3) Government Employee O 2)Tailor 0 1) Teacher 
() 12) Labour 0 11) Driver 0 1 0) Shopkeeper 0 9) Businessman 
1) Repiratory rate per minute first Respiratory rate per minute Second Respiratory rate per minute 
Z) At the time of taking the respiratory rate was the child awake or sleep? 0 2· Sleep 0 1· Awake 
3) Sub costal recession (chest in drawing) C 99- Don't Know 0 2-No 0 l·Ves 
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Questionnaire for Recriutn1ent to program(Form A) 
1. Date or flRing the questionnaire in solar (Shamsi) 
day L !month [ year time according 12 hour Hour c:~Jminute L J 0 AM QPM 
2. Name of the field worker filled the questionnaire -·--· .. ·-·-~-· v 
; 
4. complete name and last name of the child 3. Code of the study Child __________ ZJ 
6. Gender------------------------------- 0 1-male 0 2- Female 5. f /name of the child ---~ _____ _j 
Details about sickness of today and yesterday 
1.0oes your child has had the following sickness today or yesterday~ 
field worker please re.MI the folowing symtom and S'ickrle!i's, (PieaS'e. tick one of the option what mother says below 
1. Cough ---------------------------------------------------------------------------------- () 1-yes ()Z-No 0 99-0 Know 
2. Difficulty in breathing-------------------------------------------------------------- 0 1-Yes 02-No 0 99-0Know 
3. Fever-------------------------------------------------------------- 0 1- Yes 02-No 0 990Know 
4. Nazal construction and Flue ------------------------------------------------------------- 0 1-Yes 02-No 099-DKnow 
5. soar throat and Rooph Sounds------------------------------------------------------------ 0 1-yes 02-No 099· DKnow 
6. ear discharge and eat pain-------------------------------------------------------------- 0 1-yes 02-No 0 99- DKnow 
7. child Eritation and more crying-------------------------------------------------------------- 0 1-yes ()2-No ()99- DKnow 
8. Unconscious-------------------------------------------------------------- 0 1- yes 02-No 0 99- DKnow 
9. no breast sucking-------------------------------------------------------------- () 1- yes 02-No 0 99-DKnow 
10. no eating and drinking -------------------------------------------------------------- 0 1- yes 02-No 0 99- DKnow 
11. eyepro~ems -------------------------------------------------------------- 0 1- yes ()2-No 0 99- DKnow 
12. skin problems -------------------------------------------------------------- 0 1- yes 02-No 0 99- DKnow 
13. Diahrrea --------------------------- ---------------------- ------------- 0 1· 'y"es 02-No 0 99· DKnow 
14. Vomiting -------------------------------------------------------------- 0 1- yes 02-No 0 99- DKnow 
15. convalsion -------------------------------------------------------------- 0 1- yes 02-No 0 99- DKnow 
16. other clinical signs and symptoms(pl«:~se clear it) --===~-~-~~==·=·===----·-·-·· __ -·-··--·---· 0 1-yes ()Z-No 0 99- OKnow 
·---------··-·· 
11. None of signs and symptoms (If yes follow question 11) --------------- ()1-yes ()2-No ()99-DKnow 
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8• If you have visited the doctor what was the main sickness of the child. (please select one of the following, if multiple 
select the last one 
Have visit the doctor(if No follow question9) 
1. Pneumonia)-------------------------------------------------------------
2. cold and nu) --------------------------------------------------------------
3. Bone trama and skin burns ) ------------------------------------------------------------
4. )Soar throad and difficult sound)-------------------------------------------------------
5. ) Minigitis ) --------------------------------------------------------------
6, ) Other sicknesses (please dear it))------------------------------------------------------ ,,____....,. 
i ·-----------·- ------------1:)r1~al;·) --------------------------------------------------------------
8.} Oiaheria and vimating deasis) ------------------------------------------------------
9. Anemia)--------------------------------------------------------------
10. Rikets) -------------------------------------------------------------
11. Skin deasis ) -------------------------------------------------------------
12. others(please dear it}-----------------------------------------------------------
[ 
9. When it started?'i please select only one 
Day I month: . year [ ___ _ 
1. ) Idon't know precisely-more than a week and less than a month) 
2. ) 1 don't know precisely-more than a month and less than three months ) 
3. ) 1 don't know predsely- from new born more than three months ) 
4. ) 1 don't know precisely- from new born till now ) 
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0[1:::>'6.5 
0 1- yes 
0 1- yes 
0 1- yes 
0 1· yes 
0 1· yes 
0 1- yes 
. "-
0 1· yes 
0 1- yes 
0 1- yes 
0 1· yes 
0 1- yes 




















0 99- DKnow 
0 99- DKnow 
0 99- DKnow 
0 99- DKnow 
0 99-DKnow 
Q 99- DKnow 
0 99-DKnow 
l 
0 99- DKnow 
0 99- DKnow 
Q99· DKnow 
0 99· DKnow 
Q99- DKnow 
0 99- DKnow 
--, 
' __j
10. During i~;t4a~hour .if.chtld hav~-gi;~;; some plti;, ~y;~ or ~~~ti~ (~;k i~~~ mother to br-i~g the d~gs and it~ ~overs)-
please read each of them for mother and select one or more 
I. ethical treatment (Please clarify it)-------------------------------::-:---------------- 0 1- yes 0 2- No 0 ~~ DKnow 
L. 
2. Some pills or syrop like drug (name it if possible) --------------------------------- 0 1- yes ,-
1 
3• Injection - (name it if possible)------------------------------------------------------ 0 1- yes c- -. --. . .. . . - . ~-=-.:__ __________ . -. - ----·-- -- ..... . 
4,) other actions out of above (name it if possible)------------------------------------ 0 1- yes 
r ·--····--"·-- -~~~~===-~:::·-----
5. ) No Drugs)-------------------------------------------------------- 0 1- yes 
Chronic heart diseases 
11. Does your child during last three months has given any serious or chronic diseases 
(special medical past story) 
1. Heart diseases (name it if possible)--------------------------------------------------- 0 1- yes 
r 
2. Measals ------------------------------------------------------------ 0 1· yes 
3. Pneumonia -------------------------------------------------------------- 0 1· yes 
4. Chronic diaheria (more than 14 days) or vomitive diseases-------------------------- 0 1- yes 
5. Animia -------------------------------------------------------------- O 1- yes 
6. Rikets -------------------------------------------------------------- 0 1- yes 
1. others (name it if possible) --------------------------------------------------------------0 1- yes 
c~ 
12. Child weight/Kg :ftrst 0. :second ...... -o ... 
0 2- No C: 99- DKnow 
_ _j 
0 2· No C 99- DKnow 
0 2- No 0 99- DKnow 
() 2- No 0 99- DKnow 
0 99- DKnow C· 2- No 
() 2· No () 99· DKnow 
0 2- No 0 99- DKnow 
0 2· No 0 99· DKnow 
0 2- No 0 99- DKnow 
0 2· No 0 99- DKnow 
0 2- No 0 99- DKnow 
12. a 12. Did child wore anything else During child's weighting out of thin underwear if No Follow Q13 -2 (:: 1- yes 
12. b 12. If yes how much was the weight this dothes 0 mother didn't take out the clothes 0 
12. c 12.if she didn't what clothes remained 
•.... '::::c:c::"":c:::o::::::::::·:::::::::··:: .. 
13. Child's height/CM 
Address 
first: ·-= 
15.Is this house your own properties 
r---: 0 Second:, 0 0. 
If yes hove you planned to sell or rent this house in coming 18 mont 0 1-yes ()99- Dl<now 0 2- No r-- ~fMonths before) ()1- yes 
0 2- No(Name of house owner) 
when wiH your house Agreement complete? month year :Don't know 0 
Do you live in the same area of kabul when your aggrement complete 0 l- yes 0 2- No 0 99- DKnow 
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Annex 6 Child's 10 card 
Ministry of Public Health of Afghanistan 
ID Card and Information for Families 
Study of the effect of vitamin D supplementation upon incidence of pneumonia in 
children 
(Note- this form was first made in Dart and translated to English- therefore, some of the phrases make better sense in 
Dari) 
The Ministry of Public Health, Maywand Hospital, Kabul Medical University, London 
University and the Aga Khan Health Services are doing an 18months survey of children in 
some parts of Kabul. 
Vitamin D helps to make bones and teeth of children and to keep them healthy. Some 
doctors think that as well as strengthening bones and teeth, giving vitamin 0 may help 
reduce chest infection. This study will help the Ministry of Public Health and doctors 
decide if for reducing chest infection, they should give all children vitamin 0 or not. 
The Head of your District (Rais Nahiyah) and the trustee of your street (Vakils ofGozar) 
are aware of our work and support us. The ethical research committees of the Ministry of 
Public Health and London University have approved this project too. 
In addition to your support, pleases keep in mind the following benefit of the project 
to you and your child during the study period: 
1. Free Vitamin D: At the start, and every 3 months during 18 months of the project your 
child will receive a few drops of olive oil in their mouth (totally 6 doses of Vitamin D). 
With these drops of oil, by chance, half of the children will get vitamin 0 at the beginning 
and middles and the other half will get vitamin D at the end of the survey. This way we can 
compare if giving vitamin D at the start or the end of the cold seasons as well as warm 
seasons is better for chest infections and diarrhoeal disease or not. The vitamin 0 has no 
side effects and tastes like the oil itself. 
2. Experienced doctors and easy access to them in Maiwand Hospital: If God forbid, 
your child gets ill in the next 18 months, you should come to the Paediatric Department of 
the Maywand Hospital, bring this child's study card, and see our well trained doctors for 
treatment. The names of our doctors are: Rashid, Wali, Mujahid, and Khesraw. 
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3. Free good quality medicine: If your child needs medicines for chest infection and 
diarrhoea, our doctors will give you this medicine for free. 
4. Free Chest X-Rays: 
5. Free examination of the child at home: Our female health worker will visit and 
examine your child at home for chest infection and diarrhoea every two weeks for 18 
months. She will also ask some questions from you and all your information will remain 
confidential and safe in our store place. We will never tell anyone about your information 
and only use this information grouped together with other children's information (for 
example we will not tell anyone that Ali was 13 months old, but we will count that 10% of 
study children were 13 months old.) 
6. Measuring Weight and Height: 
7. Please give you children aged less than 6 months old foods rich in calcium for better growth 
and better absorption of vitamin D. These foods are: Dairy such as milk, butter, yoghurt, 
cheese, beans, peas, lentils, vegetables such as spinach, clover, cabbage, lettuce etc. 
With all mentioned services, please contact our doctors whenever you child get any diseases 
and use our free and quality medicines 
We hope you and your child may get benefited. If you face any problem, please contact our 
field workers, our clinical doctors whose names are mentioned above or contact the project 
We are very happy that your child is part of this study. Thanks for your cooperation 
StudJ! Child's Photo Study Child's Photo Study Child's Photo 
I>ate: ------/------/------ I> ate: ------/------1------ Date: ------1------1---
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Full name of the child-------------------------------------------------
0 
sex: Male o Female 
Age of child at recruitment in month: ------------ Month 
Child's Study Number: -------------- Date of recruitment: -------/ ----1 ------
Full name of the father (or head of family) --------------------------------------------
Address of the child at recruitment (district, street, number of house, etc)---------------------
------------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------------------
Name ofthe field workers fill this card: signature--------------
Name of the Project in charge: signature ---------------------
This table is for field workers to record the dates and visit numbers when they go for home 
visits 
Visit Date Signature 
# 
Visit# Date Signature 
1. ------1------1------ 2 3 ------1------1------
2. ------1------1------ 2 4 ------1------1------
3. ------1------1------ 2 5 ------1------1------
4. ------1------1------ 26 ------1------1------
5. ------1------1------ 2 7 ------1------1------
6. ------1------1------ 2 8 ------1------1------
7. ------1------1------ 2 9 ------1------1------
8. ------1------1------ 3 0 ------1------1------
9. ------1------1------ 31 ------1------1------
1 0. ------1------1------ 3 2 ------1------1------
11. ------1------1------ 3 3 ------1------1------
12. ------1---~--1------ 34 ------1------1------
13. ------1------1------ 3 5 ------1------1------
14. ------1------1------ 36 ------1------1------
15. ------1------1------ 3 7 ------1------1------
16. ------1------1------ 3 8 ------1------1------
17. ------1------1------ 3 9 ------1------1------
18. ------1------1------ 4 0 ------1------1------
19. ------1------1------ 41 ------1------1------
20. ------1------1------ 4~ ------1------1------
21. ------1------1------ 43 ------1------1------
22. ------1------1------ 44 ------1------1------
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This table is for clinicians to record the dates if a child comes to the hospital frequently 



























Annex 7 Pictorial signs and symptoms card 
Pictorial Signs and Symptoms Card for Mothers 
Child's name: ------------------------ Study number: _____ _ Date given to Family: I I __ _ 
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I Diarrhea I Fever 

















Annex 8 Standard Operating Procedure (SOP) for vitamin D administration 
Standard Operating Procedure 5: 
Vitamin D/Piacebo Administration; and 
Observing and Managing Serious Adverse Events administration of Vitamin 
D/placebo 
1. Once you have obtained consent from the mother and father of the child ask if the 
child has vomiting on that day. If the child HAS vomiting on the day, ask for a 
clean spoon and water and test by giving a spoon of water. Ifthis is vomited after 10 
minutes tell the mother that you will return in a week and try to give the drug and 
complete recruitment then. Arrange with the mother to be home when you think you 
wi II be back. 
2. If child has NO vomiting on the day give the contents of the syringe (containing 
Vitamin D/placebo) you choose for this child. 
3. To give the syringe contents, remove the syringe cap. Lay the baby almost flat in 
the mother's arms, put the syringe in the child's mouth and slowly push the plunger 
so that the fluid goes in and is swallowed by the child. 
4. Do not do this in a rush. If the baby seems to have spitted the oil or it has dribbles 
out of the mouth -try to estimate how much is spitted out and record on the Drug 
administration form. 
5. After administration of Vitamin D/Placebo, ask that they keep the baby in the same 
room as you. Watch the child during the next few activities and for at least 30 
minutes to see if he/she vomits or develops any new symptoms. 
6. Fill the drug administration form immediately and make sure you put the syringe 
number in the space for study number for the child. 
7. Put the study number written on the syringe on questionnaire A, the child study tag 
and ID card. 
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8. Proceed to fill Questionnaire A, ID form and anthropometric measures, and during 
this time ask that the child be kept in the same room as you. Observe the child to 
make sure he/she does not vomit the syringe oil. 
9. If the child develops other symptoms before you leave the house make a note of this 
on the Drug Administration form and tell your supervisor at the end of the day. 
1 0. Ask the mother (or main caretakers of the child) to watch out for any unusual/new 
symptoms in the child and write them in the "Pictorial symptoms card for mothers". 
11. There is very little likelihood of a drug reaction, but what to do if there is an 
apparent drug reaction will depend on the nature of the reaction. You should inform 
your supervisor urgently and the action to be taken will be decided by the 
management team and you will be informed about this. 
12. Submit the drug admin form to your supervisor at the end of the day (Form M). 
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Annex 9 Vitamin D administration form 
uestionaire for administration ofVitD/Placebo 
t. Date of filling the questionaire: 
oay [ I Month ] Year [" Time (12 Hours): Hour OPM 
2. Name of the fteldworker filling the questionaire: r· v 
3. Child's study number ..;'1 4. first, middle and last name of the child 
5. First and middle name of the child's father ··--·····-------·- _____ ] 
6. Sex of the study child 0 2- Female C 1- Male 
1. Code number of syringe containing VitO/Placebo administered to the child: [_ 
8. Did the child vomit the oil within 20 minutes after administration? C· 2- No 
If Yes, 
9. How many minutes after the administration of the oil the child vomited? 
0 1) 10 ·5 minutes after dose 
0 2) 11-15 minutes after dose 
0 3) 16-20 minutes after dose 
0 4) others (please specify it) 
10. Did the child have any other symptopm within 20 minutes after administration of oil? 
1) Rash 
2) Difficulty in breathing 
3) 5weling of the body 
4) Other (please specify) 
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0 99- Don't !<no() 2- No 
0 99- Don't knoO 2- No 
0 99- Don't knoC 2- No 
0 99- Don't l<noC· 2- No 
0 1- Yes 
Q 1- Yes 
0 1- Yes 
0 1- Yes 
O 1- Yes 
Annex 10 Two-weekly home visit form 
Two-'\veelv Home \isit uestionnaire 
t. Date of filing the questionnaire 
QPM 
,~ ,- I 




Hour (according to 12 hours) Tilm! 
2. Name of the field worker filling tl\e questionnaire v'~ 3. Visit Number -
_, -~~ u'-> '"-"">"~"• ·~ ,.,_,.,_..,_..,.,...~ """"''•,v••~· ·----,-« '-" -·--• ··~~·-·•-•' 
4. Child's study nun1ber v-;, S. First, middle and surname of the child 
'"""#~--~--~~-~··- -- -··· --~····-·-·- ----·-···- -----· 
G. Complete name of child's father l 7. Sew of the child 0 2, Fem~le 0 1, ~1ale 
e. Who were tl\e main caretaker of your child In the last z weeks ( 14 days)? Ask three main caretaker 
1) Child's mother 
2) Chitd•s ratehr 
3) Brother or Sister 
4) Grand father or mother of the child 
5) Uncle or Aunt of the Child 
6) Uncle or Aunt of the Child 
7) Other relative~ 
8) Friends or neighboors-
9) Child caretaker 
10) ICindergarden 
11) Others (please specify) 
Ask remaining from one of three rna in people 
9. Relation of person to the child? 
0 1- f'llOther 0 2- Father () 3- Brother or ~ister of the child 0 4- Qand father or Grand mother of the chUd 
i'"'-""="'v_"'*"_""'*"''VA'>'W'>'-·"""""'-"'...,"'""._"""""'_~, "'"'~ 
0 5- Others (pleas specify) 
194 
13. From which of the following did you get advice about any of the above symptoms in the last 2 weeks (including last 24 hours)? 
0 99- Oont know 0 Z· No 0 1· Yes 1) Mother's own experience 
0 99- Oont know 0 2- No 0 1- Yes 2) Grandparents of the child/ Child's other family members 
0 99- Dont know C 2- No 0 1- Yes 3) Friends/neighbours 
0 99- Dont know 0 2- No 1- Ye~ 4) Study hospital doctor 1 clinic 
0 99· Dont know 0 2- No () 1- Yes 5) Doctor from another hospital/other doctors 
Q99-Dontl<now Q2·No 0 !·Yes 6)Nurse 
0 99· Dont know 0 2- No 0 1- Yes 7) Pharmacist 
0 99· Dont know 0 2- No 1- Yes 6) Dio or old ladies/ Fortune teller I Hoim Shops/ Greek herbs doctor 
0 99· Dont mow 0 2- No 0 1- Yes 9) Mullah 
0 99- Dont mow 0 2- No Q 1- Ves 10) Other (specify _________ __s c ......... --- ·-·-·---
14. Which of the following treatments did you give for any of the above aysmtoms in the lost 2 weeks 
(induding lost 24 hours)? 
O 99- Dont know 0 2- No 
0 99· Dont'k,ow 0 2- No l) Gave some medicine tablets or syrup (please specify _____ __, 
, . ,··-·"-"" - -·--· 0 99- Dont know O 2- No () 1- Ves 3) Gave some injection (please specify _____ __. 
----------·~·------------------·--------------------------
99- Dont know 0 2· No 
0 99- Dont know O 2- No 
0 99- Dont know 2· No 
0 99- Dont know Q 2· No 
0 99· Dont know Q 2· No 
0 99· Dont know 0 2- No 
r-... 1· Yes 
"'' 0 1· Yes 
-"-·""'" .. o-W'~-- '''"-·~·~ ---·~"•"•--4)6;~dage/c~ol with cloth/ cold compress (plea~e specify -----..J 
5)-------------------------------·--------------------------------------------·-----------0.R.S 
6) other extra Huid treatment (water, tea milk, herbal drinks etc) 
7) Drought to Hospital or doctor 
8) Advice from another person 
9) oid nothing 
0 99· Dont know O 2- No O 1· Yes 10) other (please speciry _____ -.~ 
[_ __ 
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15. Field worker observation 
1) Respiratory rate per min 2nd per min L_ t st 
0 2- Sleep 0 1- Awake 2) At the time of taking respiratory rate was the child awake or sleep (W or S)? 
0 99- Dont Know 0 2· No 0 1· Yes 3) Sub costal recession (chest in drawing) 
0 99· Dont know C 2- No () 1· Yes 4} Fever oc 
c--J 2nd r ·~=] 1st 
0 99- Dont know 0 2· No 0 1· Yes 5) Nasal flaring 
0 99- Dont know 0 2· No 0 1· Yes 6) Not eating or drinking (observe by giving some drink or breastfeed) ____ _ 
0 99- Dont know 0 2- No () 1· Yes 7) loose motion 
[- ·· J How many times fro last 12 hours 
0 99- Dont know 0 2- No () 1- Yes 8) Vomits everything (Observe by giving some drink or breastfeed) 
0 99· Dont !<row 0 2- No 0 1- Yes 9) Lost skin turgor (Observe by pinching) 
0 2- More than 2 sec 0 1· less than 2 sec 
0 99- Dont know 0 2· No 0 1· Yes 10) lethargic 
0 99- Dont know 0 2- No 0 1· Yes 11) others (please specify ______ _, 
c ·~·-=-~~---~---·--------- ·-----···--····-- --··········· 0 99- Dont know 0 2· No 0 1· Yes 16. Do you know if you wilt stay at this same address for my next 2 weekly visit? 
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Annex 11 Absent form 
en Child is Absent 
Name of the child Code of study child v 
Name and surname of father . i Name of the field worker who fill this form 
1 When did the field worker visit you for the last time ? ( Before you moved or if she could not find you) Day c= I Month Year 
Name of field worker visited you last time? v 
2. Date family was visited again (After return or if the lost family was found again)? 
Period family has not been mited (Ab•eru:e periold till before put two weeks) 
Day ll Month _, Year CJ 
3. Where was the child in the period where has was not visited by feild worker ? 
A) in the city or other provinces (Specify it) 
B) in other parts of kabul (Specify it) 
C) in other cities (Specify it) 
4. During abasence, did your child had any of the following conditions? 
v. 01- yes 
02-No 
0 99- D Know 
If ye$ how many times admited 
Due to D iffernt health 





Annex 12 Outpatient (OPD) form 
Ou 
1. Date of filling the questionnaire 
Year· _Month L .. -~ Day l. Time (12 hour clock) Hour ' r·······-···· _Minute L__j 0 PM ()AM 
2. Name of doctor Oiling the questionnaire 
3. Child's study number 
5. Name of Child's father'-;::::::::::==:.::::::.: 
4. Child's full name and surname 
G. Sex of the child () 2- Girl 0 1- Boy 
1. Age of child in months L. 
0 First visit For this disease 
Seond visit for this disease 0 More than 48 hours and less than 14 days 0 48 hours O 24 hours 
0 Less than 24 hours 
Illness Detail 
Clinical notes from Mother 
8. Signs and symptoms that mother says about this disease 
l)Fever 
2) Getting cold 
3)Skin rash 
4) Cough 
5) Difficulty breathing 
6)Wheeze 
7) Blocked or runny nose 
8) Sore throat/hoarse voice 
9) Ear ache I pussy 
10) loose motion 0 99- Dont l<now () 2- No 
11) Dysentry 
12) Mucous diarrhea 
13) Vomiting 0 99- Dont l<now 0 2- No 
14) Projectile vomiting 
15) Drinking eagerly /thirsty 
16) Not able to drink or eat food/not take breast 
17) Excessive crying/restless 
18) sunken eyes 
19) Eye problem/eye discharge 
20) Sever Palmar poltar 
21) Unconscious 
22) Convulsion in last 2 4 hours 
() 1· YeS 
0 1· Yes 
0 99- Dont l<now 02-No 
0 99- Dont l<now 02-No 
0 99- Dont know 02-No 
99- Dont know 02-No 
() 99- Dont know 02-No 
0 99- Dont know 02-No 
0 99- Dent know 02-No 
0 99- Dont know 02-No 
0 99- Dont l<now 02-No 
How many times in how many hours 
0 99- Dont l<now 0 2- No 
0 99- Dont know 02-No 
How many time in how many hours 
() 99- Dont know 0 2- No 
0 99- Dont know O 2· No 
0 99- Dont ~.now O 2- No 
() 99- Dent know O 2- No 
0 99- Dent know 0 2- No 
0 99- Dont know 0 2· No 
0 99- Dont know 0 2- No 
99- Dent l<now 0 2 • No 
0 99- Dont know 0 2- No 
23) Other clinical signs or symptoms (SpeciFy it -----------' 
() 99- Dont know 0 2- No 
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01- Yes 
0 1- Yes 
01- Yes 
0 1- Yes 
0 1- Yes 
0 1- Yes 
01- Yes 
0 1- Yes 




. 01- Yes 
C 1· Yes 
0 1- Yes 
01- Yes 
() 1- Yes 
0 1· Yes 
01- Yes 
0 1- Yes 
0 1- Yes 
0 1- Yes 
9. For this illness or symptoms of your child that you said about, did you or other family members do anything or get advice from anyone! 
nf99~oont.ki10\7': 2- No 0 1- Ves 
\.~-. ~ ............ »••." ·•·•• .... ,. ... ".;t 
10) From which of the following did you get advice about any fo the above symptoms? 
1) Mother's own eMperience 
2) Grandparents of the child/child's other family members 
3) Friends/neighbours 
4) Study Hospital doctor /Clinic 
5) Doctor from another hospital/other doctors 
6) Nurse 
7) Pharmacist 
6) Dai or old ladies/fortune seller /Hakim shops/Greek Herbs doctor 
9)Muftahs 
10) Others (please specify __________ --J 
0 99- Dont knO'() 2- No 
0 99- Dont kno<:: 2- No 
() 99- Dont kno•/) 2- No 
0 99- Dont knot() 2- No 
0 99- Dont knol() 2- No 
0 99- Dont knol() 2- No 
0 99- Dont knol() 2- No 
0 99- Dont knol() 2- No 
0 99- Dont knol() 2- No 
0 99- Dont knell() 2- No 
11. Which of the following treatments did you give for any of the symptoms in question # 8? 
1) Traditional medicine or treatment (please specify 0 99- Dont kncC· 2- No 
2) Gave some medicine tablets or syrup {please specify ______ __; 
["' --~- -·-· .. ... . ,. ..... -....... 
3) Gave some injection {please specify _______ _, 
4) Bandage/cool with cloth/ cold compress (please specify _____ __, 
5) O.R.S----------------------------------------------------------------------------
6) Other eMtra fluid treatment (water, tea milk, herbal drinks etc) 
7) Brought to Hospital or doctor 
8) Advice from anothers 
9) Did nothing 
10) Other {please specify ______ __, 
0 99- Dont kno\A(~\ 2- No 
0 99- Dont knov() 2- No 
0 99- Dont knol(:: 2- No 
0 99- Dont knctt(:> 2- No 
0 99- Dont knc•v:) 2- No 
0 99- Dont l<nov::.· 2- No 
0 99- Dont kno•l'> 2- No 
0 99- Dont knov .. ·· 2· No 
0 99· Dont kno<:: 2- No 
l2. Did you see the doctor in this MaywandStudy dlnic for this illness ofyour child? . () 2- No (j 1- Ves 
13. If yes, why did you come back to the clinic today? 
1) Symptoms did not improve 
2) Symptoms got worse 
3) Another illness seems to have appeared 
4) other {please specify _________ __. 
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0 99- Dont knol(:: 2- No 
() 99- Dont knO\() 2- No 
0 99- Dont knoo.() 2- No 
() 99- Dont kno•[: 2- No 
0 1- Yes 
0 1- Yes 
0 1- Yes 
0 1-Yes 
0 1- Yes 
0 1- Yes 
0 1· Yes 
0 1- Yes 
0 1- Yes 
0 1· Yes 
O 1- Yes 
0 1- Ves 
J 
l 
0 1- Yes 
-- J 
0 1- Yes 
0 1-Ves 
0 1· Yes 
()1-Ves 
0 1· Ves 
0 1· Yes 
0 1· Yes 
0 1· Ves 
0 1- Ves 
0 1- Ves 
O 1- Yes 
Qther points about mother's! caretaker's visit to the clinic 
Signs and symptgms that the doctor observed through examination 
14. After eMamination, are the following signs and symptoms present in child? 
1) Strider 
Z) Sub-costal recession (chest in drawing) 
3) Raised Respiratory rate according to the age of child 
O 2· Sleep 0 1· Awake b/min 2nd O 2- Sleep 0 1-Awake 
4) Fever OC [" "] 2nd 
5) Diarrhea with signs of mild, moderate, or severe dehydration 
6) Other reasons for admission to hospital {Please specify ____ _. 
[--
15. Is one or more of the above present in child? 
16. Write your diagnosis and go to the end to question number 26. 
1) Common cold and cough 
Z) Viral URTI 
3) Mild watery diarrhea with no dehydration 
4) Mild Ear Infection 
S) Mild Eye Infection 
6) Others (please specify) 
L 
17. further clinical notes from doctor oberved through examination. 
1) Cough 




6) Sub-costal recession (chest drawing) 
7) Blocked or runny nose 
8) Convulsion 
9) Sunken Eye 
10) Ear ache or pussy 
11) Neck regidity 
12) Watery Diarrhea 
13) Drinks eagerly {by offering some water) 
14) Vomits aU drinks 
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:" .. , 99- Don't ~no(: ~: 2- No .. _. :.... . ...... :-~ 
0 99- Don't knoC 2- No 
01- Yes 





() 99- Don't krro\ : 2- No 
0 99- Don't krro( 2- No 
0 1· Yes 
0 1- Yes 
02-No 
0 99- Don't knoC· 2- No 
0 99- Don't knoC:- 2· No 
0 99- Don't krroC 2- No 
0 99- Don't kno\) 2- No 
0 99- Don't kno\. · 2- No 
0 99- Don't l<no(· 2- No 
0 99- Don't knoC· 2· No 
0 99- Don't knot::- 2- No 
0 99- Don't knoC: 2- No 
0 99- Don't kno<> 2- No 
0 99· Don't r-!io() 2- No 
0 99- Don't kno() 2- No 
0 99- Don't l<.no(~ 2- No 
() 99· Don't krro(·· 2· No 
(\ 99- Don't kno\· 2- No 
.j 
0 99· Don't kno("· 2· No 
0 99- Don't kno(:· 2- No 
..-·,, 99· Don't kna{··, 2· No 
,.._,..' ·-· 
() 99· Don't knoO 2· No 
0 99- Don't kno() 2- No 
....., 
__ __j 
0 1· Yes 
01- Yes 
()1-Yes 
0 1- Yes 
0 1· Yes 
0 1- Yes 
0 1· Yes 
"'"_j 
Q 1- Yes 
0 1· Yes 
01- Yes 
0 1· Yes 
() 1· Yes 
0 1· Yes 
C 1- Yes 
O 1· Yes 
0 1· Yes 
0 1· Yes 
O 1- Yes 
C 1· Yes 
01- Yes 
C 1- Yes 
15) Projectile vomiting o·?9= ~on\~·r;,;c::· 2- No 
16) Not taking Breast/food/Drinks 
17) Lost skin turgor (Be skin pinching) 
0 99- Don't Kno( · 2- No 
() 99- Don't Kno( 2- No 
02- >2 sec C> 1- <2 sec 
111 Abdominal distension 
19) Coated tongue 
20) Thrush in Mouth 
21) Sever Palmer pallor 
22) Moderate Palmer paUor 




27) Other things and symptoms (please specify) r-· ,,,, ..... ,,,,_.,_._ ..... ,.,,,, ... ,,,,,,.,, 
L-- -
18. Doctor's clinical diagnosis 
1) Pneumonia 
2) Sever Pneumonia 
3) Yery sever Pneumonia 
4) Congestive heart failure 
5) Septicemia 
6) Laryngitis or sore throat 
7) Acute Watery Diarrhea with some dehydration 
8) Acute Watery Diarrhea with moderate dehydration 
9) Acute Watery Diarrhea with sever dehydratin 
10) Presistent Diarrhea 
11) Sever presistent Diarrhea 
12) Otitis media 
13) Measeles 
14) Typhoid fever 
15) Malaria 
16) Simple ferbile Convulsion 
17} Meningitis 
18) Sever anemia 
1 9} Sever malnutrition 
20) Hepatitis 
21) Tuberculosis 
22) Other please specify 
201 
0 1- Yes 
C 1- Yes 
() 1- Yes 
0 99- Don't KnoO 2- No 
0 99- Don't Kno(:> 2- No 
0 99- Don't Kno( 2- No 
0 99- Don't KnoC 2- No 
0 99- Don't Kno() 2- No 
0 99- Don't Kno<: 2- No 
0 99- Don't KnoQ 2· No 
0 99- Don't Kno(> 2- No 
0 99- Don't Kno( 2- No 
0 99- Don't KnoC: 2- No 
0 99- Don't kno(_:. 2- No 
0 99- Don't r..no\_ 2- No 
0 99- Don't knoC> 2- No 
0 99- Don't l<no( 2- No 
0 99- Don't kno() 2- No 
(\ 99- Don't kno\ ·, 2- No ·-- .. / 
0 99- Don't kno(.· 2- No 
0 99- Don't l<no(• 2- No 
0 99- Don't kno(: 2- No 
0 99- Don't kno() 2- No 
0 99- Don't knoO 2- No 
0 99- Don't knoC• 2- No 
0 99- Don't kno(i 2- No 
0 99- Don't knoO 2- No 
0 99- Don't l<no() 2- No 
() 99- Don't kno(i 2- No 
0 99· Don't \<no(: 2- No 
() 99- Don't kno(; 2- No 
0 99- Don't k.no\ . · 2- No 
() 99- Don't kno(; 2- No 
0 99- Don't kno() 2- No 
99- Don't knoO 2- No 
0 1- Yes 
() 1- Yes 
0 1- Yes 
01- Yes 
0 1- Yes 
0 1- Yes 
(> 1- Yes 
0 1- Yes 
0 1- Yes 
0 1- Yes 
I 
___J 
0 1- Yes 
0 1- Yes 
0 1- Yes 
() 1- Yes 
0 1- Yes 
C· 1- Yes 
01- Yes 
0 1· Yes 
01- Yes 






() 1- Yes 
0 1- Yes 
() 1- Yes 
0 1- Yes 
() 1- Yes 
0 1- Yes 
O 1- Yes 
19. Have you sent htls child for chest X-Ray? 
o ~)~ r· 
~0. Doctor admitted the child for hospitalization? 
Result Date 0 1- Yes 
0 3- No 0 2- Yes C 1-Yes 
z1. Is the child already on antibiotic? () 99- Don't know 0 3- No 0 2- Yes, but no more talo:ing 0 1-Yes still ta!Qng 
z2. If yes what anitbiotic si the child taking now? 
first anitbiotic name 0 99- Don't Kno(! 3- IM 
second anltbiotic name 0 99- Don't Kno() 3- Hvl 
Q 2-IV 
0 2- IV 
01- Oral 
0 1- Oral 
23. Did you (Doctor) give treatment to the child that was same or different from before? 0 2- No 0 1- Yes 
24. If yes, Is the anitbiotic a continuation of previous one? 0 99- Don't kno(> 2- No 0 1- Yes 
25. If No, What is the new antibiotic's name? 
First antibiotic name ~:~+~ ~~ ~0 
Second antibiotic name 
26. Name of the advised medicine: (Choose one or more) 
() 3-IM 
0 3-H·tl 
0 2· IV 
Q 2-IV 
1) Drug for cough (Specify _________________ --J 
L--~------ ···----·-·-·----·----····~-
2) Pain killer and antipyretic (Specify ______________ __, 
r· 
3)0RS 
4) Other medicine (please specify _______________ -... -.... -.. -. - ... -... -.... -.----~-----' c _·_ ..... "' 
202 
() 1- Oral 
0 99- Don't l<n01() 2- No 
0 99- Don't !<no<: 2- No 
0 99- Don't knov:·.~ 2- No 
,., 99- Don't ~..floC:· 2- No \../. . . - ... . . - .. 
,-. 1- Yes 
C 1- Yes 
O 1- Yes 
(':1-Yes -' J 
Annex 13 Study protocol (1) 
Clinical Protocol (1) 
DEFINITIONS 
Pneumonia: Is defined as age specific rapid breathing and cough associated with fever or 
not without wheezing. 
Rapid breathing is defined as respiratory rate 60 or more in children< 2 months, 50 or 
more in children 2 months up to< 1 year, and 40 or more in children one year to 3 years 
old. 
Severe Pneumonia: Is defined as rapid breathing with cough and chest in-drawing. 
Very Severe pneumonia: Is defined as having signs and symptoms of severe pneumonia 
plus danger sings (central cyanosis, severe respiratory distress, nasal flaring, grunting, 
convulsion, vomiting and not being able to drink) 
Fever: Axillary temperature> 37.5 oC (age 1 week- 3 months) and >38 oc (age 2-24 
months) 
• Rectal Temperature of'2: 38 oC (definition of fever in childhood by American 
College of Emergency Physicians) 
Wheezing: Long high- pitched whistling or musical sound on expiration that can be heard 
from mouth. 
Recovery criteria for in-patients (severe or very severe pneumonia)- 3 following 
criteria have to be met for two successive days: 
1) Normal respiratory rate of <60/minute in children <2 months, <50 breaths/minute in 
children aged <12 months and <40/minute in those aged 12 months or more. 
2) No danger signs 11 or sub-costal recession (chest in drawing). 
3) No fever (axillary temperature <37.5°C in <2 month-olds and <38°C in 2-24 months age 
children). 
* Discharge after one day or more in presence of above criteria 
11 Not drinking/breastfeeding, convulsion, vomiting everything, lethargic/unconscious, 
stridor in a calm child 
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Failure to respond to treatment: Failure to improve refers to no change in the resting 
respiratory rate over the respiratory rate detected at baseline during diagnosis in clinic (or 
fever if present) over a 72-hour period. This will allow for a rate of± 5 breaths/minute of 
the baseline value. For example, if the baseline rate was 55 breaths/minute, the condition 
would be viewed as failure to improve if the sustained rate at 72 hours ranged between 50-
60 breaths/minute at rest. 
Worsening condition: 
1. Worsening condition refers to a sustained increase of greater than 5 breaths/minute 
over baseline in respiratory rate. 
2. The new emergence of sub-costal recession (chest in drawing) or one of the danger 
signs suggestive of severe pneumonia. In this case there may be a progression of 
severity definition, which will either be from 'pneumonia' to 'severe pneumonia' or 
'very severe pneumonia'. 
Relapse: Diagnosis of pneumonia again within 14 days after the last day of illness of the 
previous episode of pneumonia. 
Duration of illness: Date of clinical diagnosis and treatment onset to the last date of illness 
with any of the following criteria: 
1. Normal respiratory rate according to age 
2. No danger signs or sub-costal recession (chest in drawing) 
3. No fever (temperature< 38.0°C or< 37.5 oc if< 2 months old) 
Episode: A minimum of 14 days(JO, 124) (equal to 2 home visits) free of raised respiratory 
rate or sub-costal recession will be required to define a new (rather than continuing) 
episode of pneumonia. 
Respiratory rate measurement: To be reported using a stop watch and after 2 repeated 
counts for 1 minute and while infant/child is calm 
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DIAGNOSIS AND TREATMENT GUIDELINES: 
Children aged 2 months to 5 years: 
Sign and symptoms Classification Treatment 
RR/min: Oral Amoxicillin 12 • 
- ~60 ( <2 months age) After second referral oral 
- ~50 (2-12 months age) Pneumonia Cephalexine13 
- >40 ( 12-59 months age) 
IV I IM 
Chest in drawing Severe Penicillin crystal
14 
Pneumonia If not improving 
add Gentomicin15 
IV I IM 
Cyanosis, Very sever Penicillin crystal + 
Inability to feed pneumoma gentamicin or 
Ceftriaxon 16 
Children aged 7 days to 2 months: 
Sign & symptoms Classification Therapy 
• RR~ 601min IM I IV 




• RR~ 601min 
• Sever chest in 
IM or IV 
drawing 
Ampicillin + 
• Cyanosis Very sever gentamicin 
• Inability to feed pneumonia 
Respiratory 
or, 
• Ceftriaxon + 
distress 
( grunting , nasal 
A 'k . 18 m1 acm 
flaring) 
12 Amoxicillin: 25-50 mg/kg/day thrice daily for 5 days 
13 Cephalexine: 25-50 mg/kg four times daily for 5 days 
14 Penicillin Crystal : 50,000-100,000 IU/Kg /day every 6 hours for 5 days 
15 Gentamicin: 5-7mg/kg/day every 8 hours for 5 days 
16 Ceftriaxon: 50-75mg/kg/day 12 hourly for 5 days 
17 Ampicillin: 1 00-200mg/kg/day 6 hourly for 5 days 
18 Amikacin: 15-20mg/kg/day 12 hourly for 5 days 
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Where to treat 
Hospital 
Hospital 
Annex 14 Inpatient (IPD) form 
Inp~tient Questionnaire (IPD Form) 
-· 
1. Date of filling the form in Hejri Shamsi 
-··-~ '" 
Day 'month year time According to 12 hour hour ____ j minute QAM ()PM 
2. Name of the doctor who admite the child v 
3. Code of the study child v 4. Complete Name,surname of the child 
= .. ~c::··-:::··::· 
s.complete f /name of the child 
6.Gender Cl 1· Male 0 2· Female 
1. Age of child 
Dear Doctors: Please record the admission information from guest ion 19 I 
This section should be filled when the child gets discharged by doctor 
r·---·-.. -· 
8. Date of Admission L .... 
9. Date of Discharge 
10. Name of the doctor who discharge the Child 
11. final diagnosis (Underlying Cause} 
~---- v.J 
1. Idiopathic 
2. Severe pneumonia 
3. acute Wattery diarrhea 
0 1· Yes 02-No 0 99· D know 
01- Yes () 2- No 0 99- D know 
0 1- Yes () 2- No 0 99- Dknow 
0 1· yes 02-No 0 99- Dknow 
4. Dysentry 
5. Severe Persistent Diarrhea) 
6. Urinary Track infection 
7. Very severe mafnutration 
8. Mealses 
9. Severe Animia 
10. Congestive heart failure 
11. Congenital heart diseases (Please dear it) 
L~_-_ ... --------=:.-.~==-
12. Other congenital disorders 
0 1· Yes ()2-No 0 99- Dknow 
0 1· Yes 02-No 0 99· Dknow 
0 1· yes Q2-No 0 99· Dknow 
() 1- yes ()2-No Q99- Dknow 
0 1- yes Q2-No 0 99- D know 
0 1· yes Q2-No C 99- D know 
0 1- yes 02-No 0 99- D know 
·-~~~-~~~ -~ c-··-~--·-• •o ·-••-·• •-n -·---·--- ... ----
,.. ("' 2 No \.) 1· yes J - 0 99· D know 
r· ----------------· 
()99- Dknow 
Others (please describe it) .13 • '"""" .. ~·•·•··•·•·• ·-···~, .. ~····~•"-"'""~'·w••••" ····-•·•••••• , .. , ..• _,._ ·~ """'""""" ••••••• •••••••••• •• ·••--~--~''"""'"•··~ .... ····•••·•·····- •• ····-~········•-··----"""""""" 
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12. final diagnosis(Immediate Cause)Select more than one 
1. Severe numonia 
z. Very severe pneumonia 
3. wattery diarrhea with severe Dehydration 
4, Oisentry without Dehydration 
s. Oisentry with Dehydration 
&. (Server Persistent Diarrhea) 
1. Diarrhea with moderate Dehydration but treatment with ORS Failed 
a. Severe Mulnutration 
9. Measles 
10. Severe animia 
11 . Congestive heart failure 




0 1- yes 
0 1- yes 
0 1- yes 
C) 1- yes 
0 1- Yes 
0 1· yes 
0 1- yes 
O 1· yes 
0 1- yes 
O 1· yes 
0 1· Yes 
O 1· Yes 
0 1- Yes 
15. U.T.I) ----------------------------------------------------------------------------------- 0 1- Yes 
16. Others (Please describe it) 
admision result of patient 
O 1. Chl1d is compilately cured and return home 
O 2. Some sympumt remained but the child could be fallow up it at home 
O 3. The child was sick but due to some reasons, dk:harge from hospital (Clear it) 
0 4. He refered to other hospital 
O 5. the pateint with no notice to the doctor1 left the hospital 
0 6. Deid 
0 1- yes 
Where 
Cause of that 
()2-No 
C· 2- No 
(> 2- No 
02-No 












14. Whether all the treatment with its answer noted or not ? 0 1- yes 0 2- No 
Treatement recommended during dicharge 
15. Dear Doctor: Have you recommended any equal or different treatement to the 
previous one to the child that could continue at home? 
16. What is the name of Antibotic that the child could take it at home? 
Name of first Antibotic 
Name of second Antibotic 
0 4- Antipyr atic () 5- ORS 
L _______ _ 




C 1- Yes 0 2· No 
C 99- D know 
C 99· D know 
C 99- D l<now 
0 99- D know 
0 99- D know 
0 99· D know 
C) 99- D know 
0 99- D know 
0 99- D know 
Q99- Dknow 
0 99- D know 
0 99- D know 
0 99· D know 
0 99· D know 
Q99- D know 
0 99- Dknow 
1. If any special com~~t i~re?-~.d to Admission and Discharge of the Child please note that? 
A 
vl 
8. Please ask mother incase they shift or change their address in comming two weeks so 0 1- yes 0 2- No 0 99- o Know 
1at the fseld worker don't face any problem for searching the child. Will your address 
1ange or not? 
~tails of the child diseases during Admission: 
~nlcal signs and symptoms that mother says for her child during the Admission: 
g, Clinical signs and symptoms that mother states (Please note all the signs and symptoms what mother says? 
1. Fever 0 1- yes 0 2- No 0 99- D Know 
z. Cold C1 1- Yes Q 2- No 0 99- D Know 
3, Skin Problem 0 1- Yes 0 2- No 0 99· D Know 
4. Cough 0 1- yes 0 2- No 0 99- D Know 
s. Oiffteulty in Breathing 0 1- yes 0 2- No 0 99- D Know 
6. Extra sound during breathing 
1. Nazal Discharge 
B. Soar throat (Not other sounds) 
9. Ear Discharge 
0 1- Yes 0 2- No () 99- D Know 
0 1- yes 0 2· No 0 99- D Know 
0 1- yes 0 2- No (i 99- D Know 
0 1- yes 0 2- No Q 99- D K10w 
10. Wattery Diarrhea 0 1- yes (1 2- No 0 99- 0 Know how many time in last few minutes 
11. Bloody Diarrhea 
12. Mucous Diarrhea 
13. Yomatting () 1- yes 0 2- No 0 99- D Know 
14. Projectile vomatting 
15. Very thirsty 
16. Not eating, drinking, or taking mother's breast and weakly drinking 
17. Crying 
18. Sunken Eye 
19. Eye problem 
20. litargk 
21. Unconscious 
22. Convulsion in last 24 hourse 
23. Other clinical signs and symtoms (Describe it) c--
208 
0 1- yes 0 2- No 0 99- D Know 
0 1- Yes 0 2- No 0 99- D Know ~ 
How many time in last few minuts 
01-Yes QZ-No Q99- DKnow 
Q1-Yes 02-No 099- DKnow 
0 1- Yes 0 2- No 0 99- D Know 
0 1- Yes 0 2- No 0 99- D Know 
0 1- Yes () 2· No 0 99- D Know 
0 1- Yes 0 2- No 0 99· D Know 
01-Yes Q2-No 099- DKnow 
0 1- Yes C· 2- No 0 99- D Know 
0 1- Yes C: 2- No 0 99- D Know 
0 1- Yes 0 2- No 0 99- D Know 
). For the same sign and symptoms that you said, Has you or any member of your , · ....... , 
1mdy (before now have you taken any treatement from anyone for your child? OJ..~ .. Y.:~] 0 2- No 0 99- D know 
1. which one of the following people did recommendationjtreatement the above signs and symptoms to the mother (Please ~led more than one) 
1. Mother's Experience C 1- yes 02-No 0 99- D know 
2. Grandmother/Grandfather of the child or other member offamily 
3. Friends and Neighbores 
4. Doctor of maidwand hospital related to the project 
01- yes 02-No () 99- Dknow 
0 1- yes ()2-No 0 99- D know 
0 1- yes Q2-No 0 99- D know 
5. Doctors from other hospitals or other doctors 0 1- yes 02-No 0 99· D know 
6. Nurse 0 1- yes 02-No .::; 99- D know 
7. Pharmacist 0 1- yes () 2- No C.· 99- D know 
s. Greek doctors, Astrologer 0 1- yes ()2-No 0 99- D know 
9. Mullah 0 1- yes 02-No (:;. 99- D know 
10. others (Please describe it) 0 1· yes C2-No 0 99- D know 
22. Whcik kind of the following treatment have given for the child for the above signs and symptoms (Question 19) 
1. Traditional treatement (Please dear it) 0 1- yes () 2- No 0 99- D know 
I .... ·-·----··----:~: ... ~.~~:~~=:~·-·-· J 
2. Some dragslike syrop and piUs {If possible name it) 
3. Injection (If possible name it} 
I --· 
4. Cold compress 
5. Using other exmination for treatment (using ORS water instead of boiled Milk) 
6. We brought the child to the doctor or Hospital 
7. We took suggestion from other people 
8. We did nothing 




0 1- yes 
01- yes 
01- yes 
0 1- yes 
C 1- yes 
C) 1- yes 
r' \)2-No 
Cz-No 






() 99- D l<now 
0 99- Dknow 
l 
0 99· Dknow 
C'l 99- D know 
0 99- D know 
0 99- D know 
0 99- D know 
0 99- Dknow 
Clinical findings of the doctor 
cough 
soar throat and difficulties in sound 
Stridor in breathing 
Wising in breathing 
granting during breathing 
chest in drawing 
Flue or nazel contruction 
Nazal flaring 
sunken eye 
ear pain or ear discharge 
neck regedity 
wattery diarrheria 
drinking with intereste (please give water for the child) 
(the child vomating everything) please give the child breast milk,water or ORS 
. projectal vomating 
No sacking,eating and drinking 
, losing of skin torgar (test Skin pinching) 
(1-less than two second 0 2· more than two second 
'· Abdomenal distintion 
1. loaded tongue 
l. Mouth trush 
1. severe palmer pale 
z. moderate palmer pale 
3. Irritation 
4. litergic (sleepy) 
5. Unconscious 
&. Convulsion 
ther symptoms and signs (please dear it) 
~ brea1bing r.rtt breathing/min 0 1-awake 0 2- sleep 'etond time 
Fever fiM Ume silses degrees second time . silses degrees 
4. Discription for treatment Givne to the child 
1- yes 02-No Q 99- D Know 
C 1- Yes Q2·No 0 99- D Know 
0 1- Yes 02-No 0 99- D Know 
0 1· Yes 02-No 0 99- D Know 
0 1- Yes () 2· No 0 99- D Know 
0 1- Yes 02-No 0 99- DKnow 
() 1- Yes c 2-No 0 99- D Know 
0 1- Yes 02-No 0 99- DKnow 
0 1- Yes 02-No 0 99- D Know 
() 1- Yes 02-No C 99- D Know 
0 1- Yes 02-No 0 99- DKnow 
0 1- Yes 02-No () 99- D Know 
0 1· Yes 02-No 0 99- DKnow 
0 1- Yes 02-No 0 99- D Know 
0 1· Yes 02-No 0 99- DKnow 
0 1- Yes () 2- No 0 99- DKnow 
0 1· Yes 02-No 0 99- DKnow 
0 1- yes 02-No 0 99- DKnow 
C 1· Yes () 2- No 099- D Know 
01- yes 02-No 0 99- D Know' 
() 1- yes 0 2-No 0 99- D Know 
0 1- Yes ()2-No 0 99- D Know 
01- Yes 02-No ()99- DKnow 
() 1- yes () 2- No 0 99- D Know 
0 1· yes 02-No 0 99- DKnow 
Cj 1- Yes 02-No 099- DKnow 
C) 1- Yes ()2-No 099- DKnow 
.J 
bruthinghnin 0 1- awake 0 2- sleep 
v 
25. Table of signs and symptoms to be filled 2 times (12 hourly) daily if the child is admitted in hospital 









































<::»yes - () 1- yes 












Skin Conscious Remark 
torgar status 
. N OflTial U 1· Alert 
0 Slowly 0 2· irnlic 
r> vem 0 . 
'v' 'J 3· fitefglC 
:;lov,•ly 
0 4 -unconsctous 
Annex 15: X-ray form 
Rad estionaire 
1. Date of filling the checklist Year r-- Mor loay 
r--· ~-· Time: 1 ,Min L.... Hour (12 Hours): O PM ()AM 
2. Name. of the Radiographer filling the checklist v 
3. Child's study number vj1 4. first, middle and last name of the child 
s. First and middle name of the child's mohter 
6. first and middle name of the child's father 
1. SeM of the study child () 2- Female 0 1- Male 
8. Name of the doctor who referred the child for X-Ray 
9:. Type of advised M-ray 0 1- Chest x-ray 0 2- Bone x-ray (Please specify it) 
10. Number of the films eliminated, becaues of their bad quality: (M-rays taken) 
0 5- Four 0 4- Three() 3- Two 0 2- One 0 1- Non (0) 
'--------
11. Child's IO and date of taken M-ray is written on the film: ()2-No 0 1- Yes 
12. The film(s) was sent/given to: O 4- kept in x-ray department 3- Parents () 2- OPD Doctor 0 1- Ward Doctor 
13. Date Received back the film(s) after use by doctors and stored for project in x-ray department 
C Year Month Day 
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Annex 16 Breastfeeding and living status form 
Inforrna~tiori',lbout Breastfeeingand LiYing Status 
1. Date of filling the Questionnaire 
Yea.;- Monthfl Day· .lime OPM 
..• .1 
2. Name of ftetdwoker filling the quesionnaire 
3. Visit Number 
4. Child's study number 
5. first, middle and surname of child 
6. Name of Child's father 
7. Sex of the child 1- Male 0 
QAM 
2- Female 0 
Questions about breastfeeding the child 
B. Have you ever breastfed your child? (If yes, go to question 10) 
9. If you never breastfed your baby, please explain why? 
1) Baby ill/weak/doesnt take breast 01- Yes 
2) Mother ill/weak 0 1· Yes 
3) Breast disease or cracked nipples 0 1· Yes 
4) Mother didnt have milk at all () 1· Yes 
5) Baby doesnt take breast 0 1- Yes 
6) Mother needed to work 01- Yes 
7) Mother used contraceptive drugs 01- Yes 
B) Mother became pregnant 0 1- Yes 
9) Other (please specify 0 1-Yes -----
10. when did you first breastfeed your baby after delivery? 
Minute Hour ( 12 hOU!'s clock) 
1- Yes 0 2- No 0 99-Dontl<row 
02-No 0 99- Dont I<Jlow 
02-No 0 99· Dont I<Jlow 
02-No 0 99· Dent I<Jlow 
02-No 0 99- Dent know 
02-No 0 99· Dont know 
02-No 0 99· Dont I<Jlow 
02-No 0 99- Dent know 
02-No 0 99· Dont know 
02-No 0 99- Dont know 
0 
0 1· Within few minutes (in first half an hour) 0 2- Within first 3 hours (after first half an hour) 0 3- During 24 hours 
0 4- During 2 or more days 0 99- Dont know 
11. Are _you still breastfeeding? (If yes got'? question number 14) ~ 0 1- Yes 0 2· No 0 99- Dont know 
12. If No, When did you stop breastfeeding'? (if stopped from last month, then write days, if not then months) 
Days Month 0 99- Dont !<now 
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13. Why did you stop breastfeeding? Please choose one or more of following 
1) Child iU/weak 0 99· Dont know 0 2- No 
2) Mother ill/ weak 0 99- Dont know 0 2- No 
3) Breast disease or cracked nipples 0 99- Dont know 0 2- No 
4) No milk () 99- Dont know 0 2- No 
5) Child does not take breast 0 99- Dont know 0 2- No 
6) Mother needed to work 0 99· Dont know O 2- No 
7) Mother used contraceptive drugs 99- Dont know C 2- No 
B) Mother became pregnant () 99- Dont know 0 2- No 
9) Child reached age of supplementary feeding 0 99- Dont know 0 2- No 
10) Child was elder to be breastfed 0 99- Dont know 0 z- No 
11) other reasons (Please specify 0 99- Dont know 0 2- No 
0 1- Yes 
0 1- Yes 
01- Yes 
0 1- Yes 
() 1- Yes 
O 1- Yes 
0 1- Yes 
0 1- Yes 
C 1- Yes 
O 1- Yes 
01- Yes 
14) At any time since yesterday morning till this morning (24 hrs) was your child given any food or drink other 
than breast milk? (PI~~.se (:hoose .one or more) 
13) lentil soap 
0 99- Dont know 0 2- No 0 1- Yes 
14) Vegetable soap 0 '*' Dont know 0 2- No 0 1· Yes 
15) Boiled usual herbs 
99- Dont know 0 2- No 0 1- Yes 
() 99- Dont know 0 2- No 0 1- Yes 
16) Vegetable oil 0 99- Dont know 0 2- No 0 1- Yes 
17) Honey 
18) FrUit 
19) Fruit Juice 
20) Sweet tea 
21) Simple tea 
22) Plain water 
() 99- Dont know 0 2- No 0 1- Yes 
C· 99- Dont know 0 2- No 0 1- Yes 
C· 99- Dont know 
G 99- Dont know 
0 99- Dont know 
2- No 0 1- Yes 
0 2- No 0 1- Yes 
02-No ()1-Yes 
23) Medicine in tablet or syrup 
99- Dont know 2- No 0 1- Yes 
24) other food (please specify) _ 
99- Dont know 0 2- No 0 1- Yes 
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1) Meat 0 99- Dont know 0 2- No 01- Yes 
2) Milk products like butter 
0 99· Dont know 0 2- No 0 1- Yes 
3) Vogurt 0 99- Dont know 0 2- No 01- Yes 
4) Cheese 0 99- Dont know 0 2- No C 1- Yes 
5) cow's milk 0 99· Dont know 0 2- No 0 1- Yes 
6) Dried milk 0 99- Dont know () 2- No 0 1· Yes 
7) Egg 0 99- Dont know () 2- No 0 1- Yes 
8) Seriluck 0 99- Dont know 0 2- No () 1- Yes 
9) Mashed/porridge/Uti or halwa (Please specify) 
() 99- Dont know 0 2- No 0 1- Yes 
10) Potato O 99- Dont know rJ 2- No 0 1- Yes 
11) Rice 0 99- Dont know 0 2- No 0 1- Yes 
12) Meat soap 
() 99- Dont know 0 2- No 0 1- Yes 
Jn other days during last week except yesterday h.ld · 
st milk? (Please choose one or more) (Please read ~a~~~~~r) 1 gaven any other food or drink other than 
cereal soap 
I· Dont know 0 2- No 0 1· Yes 
regetable Soap 0 99- Dont know C· 2· No 0 1- Yes 
Boded usual herbs (Please specify) 
1- Dont know 0 2- No 0 1- Yes 
----·······---··· 
-·"'"'""'M• ~. 
/egetable Oil 0 99· Dont know C) 2- No 0 1· Yes 
~oney 0 99- Dont know 02-No 0 1- Yes 
=ruits 0 99- Dont know 02-No 1- Yes 
Fruit JUice 0 99· Dont know () 2- No 0 1· Yes 
sweet tea 0 99- Dont know 02-No 1- Yes 
Simple tea 0 99- Dent know C: 2· No () 1· Yes 
Plain water 0 99· Dent know 0 2- No 0 1· Yes 
Medicine in tablets or syrup 
0 99- Dent know 0 2- No 0 1- Yes 
Other food (Please specify) __ _ 
~9- Dont know 0 2- No 0 1- Yes 
1) Meat 0 1- Yes 0 2- No ~-- 99- Dont mow 
2) Milk products like butter 
0 99- Dont mow Q 2- No Q 1- Yes 
3) Yogurt 0 99· Dont mow 0 2· No 0 1· Yes 
4) Cheese 0 99- Dont know O 2- No 0 1- Yes 
5) Cow's milk 0 99- Dont know 0 2- No O 1- Yes 
6) Dried milk 0 99- Dont know 0 2- No 0 1- Yes 
7) Egg 0 99- Dont know 0 2- No 0 1- Yes 
8) Serliluck 0 99- Dont know 0 2- No 0 1- Yes 
9) Mashed/porridge/ liti or halwa: Please specify_ 
0 99- Dont know 0 2- No C> 1· Yes 
[ 
10) Potato () 99· Dent know 0 2- No 
11) Rice 0 99- Dent know 0 2- No 
12) Meat Soap 
0 99- Dont know 0 2- No 
_j 
0 1- Yes 
0 1- Yes 
0 1- Yes 
What type of house is the family of child living in? (Please fill in this question based on your obseravation of the families house) 
1) Modern house with proper water and saltation system 
2) House with enough number of rooms but not having proper water and sanitation system 
3) Crowded house, lai<Jng proper doors and windows 
4) Others (Specifiy lt) ,--
. How many rooms do the family of the child live in? 
. How many people sleep in the same room as the child? {Do not count the child) 
lo. of children 0 - 5 yrs [_ 2) No. of people 6 - 15 yrs 3) No. of people more than 15 yrs or above 
How many people usually sleep with the baby in one bedding? (Do not count the child) 
~0. or children 0 - 5 yrs 2) No. of people 6 - 15 yrs 3) No. of people more than 15 yrs and above 
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Annex 17 Sun-exposure and Indoor air pollution form 
Sun Ex11osure •tndu~t.~ Air Pollution 
1. Date of filling teh questionnaire 
Year ··1 Month rl"' ·oay 1 . t 0 Hour [~=}ime (12 hours clock) 
J •. ~ Minu e 
2. Name of the field worker filling the questionnaire ···· ·--v 3. Vist Number 
4. Child's study number: ... ~~] 5. First, middle and surname of tt\e child: -·-'·-··-.. ---r-' 
6. Full name of child's father 7. 5eK () 2- Female 0 1- Male 
Questions about Child's Sun Exposure 
8. Ask the following questions for the child's sun eKposure 
Please ask all the below questions 
1) Was the child playing in the house yard/on the roof (on average during last two weeks time, during the day? 
0 99- Dont know 0 3- Rarely 0 2- At least twice in a week 0 1- Everyday 
2) Is the yard eKposedt~.enough daily sun shine? 0 99- Dont know 0 3- No () 2- Yes (Less) 0 1- Yes (more) 
3) Was the child going out with his/hwer parents to hazar or when parents weat out for working (on averge during last 2 weeks? 
0 99- Dont know () 3- Rarely 0 2- At least twice in a week 0 1- Everyday 
4) If yes go to question 1 and 3, has the child's body been bare for sun exposure? 
() 1- No, the ch1ldhas been either swaddled or had many clothes, even his/her face was 
covered 
() 2- Yes, only hands and face 
0 3- Yes, hands includ1ng arms, face, head and legs including thighs 
0 4- Yes, parts of the body in addition to hands feet, face arms and thighs· 
0 5· Dont know 
5) Has the child been exposed to sun from 11am- 3pm (on average in the last two weeks)? 
0 99- Dont know 0 3· Rarely c) 2- At least twice in a week C· 1· Everyday 
6) Has.'the chlh~ beei1 exposed to sun at least 2 - 3 hours (on aYerage in the aast two weeks)? 
C· 99- Dont know O 3- Rarely 0 2- At least twice in a week C 1- Everyday 
9. Take the answers of question B into consideration and write your estimation regarding child's sun exposure 
(Fieldworker) _ . 
r\ 3- often ('\ 2 · '::>omet1mes 0 1 • Never '-,J ..._/ 
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\ Questions about Indoor Air Pollution 
\10. Does anybody in your home smoke cigarettes or chalam (bubblies)? 0 99- Dont know 0 2- No 0 1- Yes 
I 
jt1. If yes, how many people smoke cigarettes or chalam (bubblies )? 
1
.12. Among them, how many people smoke cigarettes or chalam (bubblies) inside the room the child lives? ==-=~---==~­
j13. On average how many cigarettes/chalam do all these people smoke in a day? 
!14. What do you use to cook your food? 
1
1) Oegdan (using wood) () 99- Dont know 0 2- No 
2) Degdan (using coal) O 99- Dont 1---now C· 2- No 
1- Yes 
1- Yes 
3) Picnic (Gas) 0 99- Dont know () 2- No 1- Ves 
4) Diesel Bokhari 0 99- Dont know Ci 2- No C> 1- Yes 
5) Others (please specify () 99- Dont know 2- No r·-, 1- Yes ~ ........ • 
15. What kind of heating did you use in your main living area during last 2 week? (Choose one or more) 





(A 0 2- No () 1- Yes 
""(B- 0 2- No 0 1- Yes 
(C- () 2- No 0 1- Yes 
(0- 02-No Q1-Yes 
!Electric Bokhari (E- 0 2- No 0 1- Yes 
t ··-· 
\Bori Araa B~i (F- 0 2- No () 1- Yes 
Sandalii 
Chaari 
;~~~zt~f<' (G- C: 2- No 0 1- Yes 
~-- . -
...,.(H-: 0 2- No C1 1- Yes 
Taba Khana (1- C) 2- No 0 1- Yes 
t.heater on (on average in the last 
L~-"="'~~~~:~:~~e~~k'=.,.,~E~·····.· ~ ._] 










Annex 18 Vaccination, economic status, and total birth form 
Questioiuulire About Cllild Vaccination, Ecouo1nic Status ruul Total 
Birtlls in a Family 
1. Date of filling the form (Solar /Shamsi) 
:year .. :month [ 1 :Day time :Hour :minute I 1 0 AM ()PM 
2. Name of Field worker of the study child. v 
3. Number of visite 
4. Code of the study child 
v 
6 F /name orthe study child 
S.Complete name and surname of child 
1. Gender----------------------------------------------------- () 2- Girl 0 1- Boy 
• Information about Vaccination Status 
0 1) He or she has the card and all the Vaccines are recorded) it must entered in the following table 
0 2) He or she has the card but some of the vacines are not recorded (it must be entered in the following table) 
Q4)Doesn't have card and hasn't vaccinated 0 3)( doesn't have the card but has vaccinated 
·- No Vacination Date of ,,,, usual timing for Note/Remark 




"""'~ ~~#- OPT2/HepB2 
f' - -5 .. Polio2 
6"' " , OJ!T3/HepB3 
Polio3 ......... -L ti 7 . . 
r· 8 t. Measles 
9 Other 
-~,, 
as soon as after born 
sixth weekly 




forth weekly B 





According to 1:::: hour 
Economic Status 
!9. Does your family own the following assets? 
I !.sewing machine I 2. wall dock 
2. cooking pressure 
\ 4. Radio. 
5. TV. 
6.Bicyde 




Field worker should read the foUowing items and tick yes or no for that 
0 ...N-~·1 0 ~-2 
o...,J..,-1 oy..;t.J-2 















12. How much is The average income of your family? 
(Husband,wife, Children, Charity help who are eating from the same table) This will be a secret 
II Estimation of Field worker about economic status of the family (From the current condition of the house that you can 
estimate) O 4· Very good 0 3· Good 0 2· medium 0 1- Poor 
Jl otal number of the child you have qiven born to {live and dead children) With the current child 
I live births Still birth {emberunic lives were more 
I still aren't alive still alive than seven months you shouldn't 
I .. _ ... ~-,~- ,,_________ involve whose .::~~~ss than seven 
'Boys· ~rls 
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